University of Mississippi

eGrove
Electronic Theses and Dissertations

Graduate School

1-1-2014

Cranberry metabolites with urinary anti-adhesion activity
Christina M. Coleman
University of Mississippi

Follow this and additional works at: https://egrove.olemiss.edu/etd
Part of the Pharmacy and Pharmaceutical Sciences Commons

Recommended Citation
Coleman, Christina M., "Cranberry metabolites with urinary anti-adhesion activity" (2014). Electronic
Theses and Dissertations. 1505.
https://egrove.olemiss.edu/etd/1505

This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been
accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more
information, please contact egrove@olemiss.edu.

CRANBERRY METABOLITES WITH
URINARY ANTI-ADHESION ACTIVITY

A Dissertation
presented in partial fulfillment of the requirements
for the degree of Doctorate of Philosophy
in the Department of BioMolecular Sciences
School of Pharmacy
The University of Mississippi

by
CHRISTINA M. COLEMAN
August 2014

Copyright © 2014 by Christina M. Coleman
All rights reserved.

ABSTRACT
The fruit of the American cranberry (Vaccinium macrocarpon Aiton, Ericaceae) is a
common food and a top selling dietary supplement in the U.S. Cranberry juice is traditionally
used for the prevention of urinary tract infections (UTIs), many of which are caused by Pfimbriated Escherichia coli. Human urine produced after cranberry juice consumption can
prevent E. coli adhesion, but the urinary metabolites responsible for this activity are currently
not known. High-molecular weight components of cranberry juice, specifically
proanthocyanidin oligomers (PACs), are currently believed to be responsible for the ability of
cranberry juice to prevent UTIs. Cranberry PACs can prevent the adherence of P-fimbriated E.
coli to uroepithelial cells in vitro and are hypothesized to act by a similar mechanism of action
in vivo. Many questions exist, however, regarding the potential for PACs to be absorbed,
metabolized, and excreted into urine. Adult female sows were therefore fed spray-dried
cranberry juice powder (5 g/kg/d) and urine was collected via catheter. Urine fractions were
tested for anti-adhesion activity using a human red blood cell (HRBC) anti-agglutination assay
with uropathogenic P-fimbriated E. coli. Active urine fractions but not control urine or inactive
fractions were found to contain complex mixtures of oligosaccharides but not PACs. An
octasaccharide, consisting of a tetrameric, β-(1→4)-linked D-glucose backbone and possessing
two D-xylose-L-arabinose side chains, was purified from the oligosaccharide mixture of active
urine fractions in sufficient quantity to assign the full structure. Oligosaccharide mixtures of
similar character were subsequently identified in cranberry products using methods adapted
from those applied to urine samples. Cranberry oligosaccharides were enriched in large scale
ii

from three sources of cranberry material and were shown to have activity in both the antiagglutination assay and a second anti-adhesion assay that used uropathogenic E. coli and
uroepithelial cells. The results of these studies indicate that the compounds responsible for the
anti-adhesion properties of urine after cranberry juice consumption are oligosaccharides that
are structurally related to those found in cranberry. These findings overturn the current
paradigm regarding the active components of cranberry juice that prevent UTIs and provide
many new directions for future research.
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CHAPTER 1: CRANBERRY JUICE & URINARY TRACT INFECTIONS

A. The American Cranberry
The American cranberry (Vaccinium macrocarpon Ait., Ericaceae) is a perennial,
evergreen, low-growing, shrub-like plant that is native to North America (Roper & Vorsa 1997,
McCaleb et al. 2000, Neto & Vinson 2011) (Appendix A color plates: Figure 94). The
American cranberry is closely related to the European cranberry, or lingonberry (V. vitisidaea), to blueberries (V. corymbosum), and to myrtlberries, or bilberries (V. myrtillus). Many
Vaccinium species have received attention regarding their chemistry and biological properties
and all are known for their flavonoid composition, acidic or tannic taste, and distinctive flavors.
As with other plants in the Vaccinium genus, cranberry prefers acidic, bog-type soils. It is
cultivated in northern areas of the U. S., with different agricultural varieties suited to different
geographic regions. The oldest cranberry cultivars include ‘Early Black’, ‘Howes,’ ‘McFarlin,’
and ‘Searles’, and many other varieties are actively being developed to improve disease
resistance, fruit production, and suitability to different growing environments. Fruits are hollow
with a waxy cuticle, ripen in the fall, and are typically harvested through a unique method that
involves flooding bogs and knocking the fruit from plants with specialized mechanical beaters.
Cranberry fruit has long been part of the American diet, and cranberry products are
familiar to most people as common food items including cranberry juice, sweetened-dried
cranberries, and cranberry sauce (McCaleb et al. 2000, Neto & Vinson 2011). Cranberry juice
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is industrially prepared by pressing fresh berries, and the resulting liquid is filtered and
concentrated via spray drying or reverse osmosis to yield juice powder or a concentrated syrup,
respectively. Powder and syrup are used as ingredients for the preparation of many different
cranberry-based products, especially juices and sweetened juice blends. The pressed berries
may be re-infused with a sugar solution and dried to yield sweetened-dried cranberries which
may be sold and consumed directly or used as an ingredient in other commercial food products.
Cranberry fruit products are prominent in the U. S. dietary supplement market due to
their purported medicinal properties, and cranberry was the number one top selling herbal
dietary supplement in 2011, with sales of just over $40 million (Blumenthal et al. 2012).
Cranberry dietary supplements are typically composed of fruit or juice powder in capsule form
with additional inert ingredients that act as binders (gelatin), fillers (cellulose), or stabilizing
agents (ascorbic acid). Fruit and juice materials may be concentrated or extracted using
methods that are not disclosed by manufacturers to yield products that are marketed as “extrastrength” or “concentrates.”
Cranberry fruit and juice products have been the focus of many studies regarding
chemical composition and biological properties and these materials will also be a focus of this
report.

B. Cranberry Chemical Composition
The majority of compound isolation and characterization has been done with the ‘Early
Black’ cultivar, in part because of its prominence in the food industry, and studies that compare
the known chemistry of multiple varieties of cranberry typically do so with a food industry
perspective (Justesen et al. 1998, Vvedenskaya & Vorsa 2004). The known compounds of
2

cranberry have been reviewed (Hong & Wrolstad 1986, Pappas & Schaich 2009, Neto &
Vinson 2011) and highlights relevant to the present studies are included below. Investigation of
cranberries using metabolomics-type methods have indicated that many thousands of
compounds are additionally present that remain uncharacterized (Brown et al. 2012a,b).
Flavonoids were the first compounds isolated and identified from cranberry (Grove &
Robinson 1931) and are consequentially the best studied group of compounds. Flavonoids such
as anthocyanins are the main pigments in the berries, and the first of these identified included
cyanidin-3-arabinoside, peonidin-3-arabinoside, cyanidin-3-galactoside, and peonidin-3galactoside (Sakamura & Francis 1960, Zapsalis & Francis 1965). Many early studies involving
cranberry flavonoid pigments followed common themes of improving color quality or color
stability in commercial cranberry products (Fuleki & Francis 1968a–d, Fuleki & Francis 1967).
Work on cranberry anthocyanins has also involved quantification using Matrix-Assisted LaserDesorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF-MS) and other
methods (Wang & Sporns 1999, Krueger et al. 2004).
Carotenoids and volatile aroma constituents were the next two groups of compounds
investigated in cranberry. Compound identifications were based on comparisons of retentions
times, fragmentation patterns by GC-MS, and UV spectra to those of standard compounds, and
led to the identification of 23 carotenoids and about 45 volatile constituents (Curl et al. 1963,
Anjou & Von Sydow 1967, Anjou & Von Sydow 1968, Croteau & Fagerson 1968).
Studies have also examined varietal differences in relative quantities of glucose,
fructose, sucrose, pectins, ascorbic acid, benzoic acid, and 6-benzoyl-D-glucose (Schmid 1977,
Marwan & Nagle 1986a, Marwan & Nagle 1982), and of the flavonoid monomers catechin,
epicatechin, myricetin, and quercetin (Wang et al. 1978, Justesen et al. 1998).
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The identification of various cranberry bioactivities and the availability of improved
technology and resources led additional researchers to investigate cranberry chemistry. These
researchers examined differences in the profiles of known aromatic acids and flavonoids
present in fresh and canned cranberry juice before and after acid hydrolysis (Chen et al. 2001),
identified two new iridoid glucosides and several organic acids (Jensen et al. 2002), and
reported several additional volatile constituents as part of a controlled atmosphere study
examining the stability of berries during storage (Gunes et al. 2002). The presence of both cisand trans-resveratrol in fresh cranberry juice was initially reported as part of a study to
determine the presence and relative quantity of resveratrol in fruit juices and wines (Wang et al.
2002), and was later confirmed independently (Rimando et al. 2004). Resveratrol was also later
identified from other Vaccinium species (Rimando & Barney 2005, Rimando & Cody 2005). A
series of flavonoid glycosides has been isolated from spray dried cranberry juice powder
(Vvedenskaya et al. 2004), and several complex organic and aromatic acids, additional
glycosylated flavonoids, plant sterols, terpenoids, a peroxypyran, two additional iridoid
glucosides, and a depside have also been reported (Turner et al. 2007).
Interest in the anti-adhesive properties of cranberry led to the identification of
proanthocyanidins (PACs) as compounds of interest. Plant PACs are complex, oligomeric
flavonoids, commonly referred to as condensed tannins. They typically occur as a complex,
heterogeneous pools of polymers, with both A- and B-type linkages between units, and
decoration with galloyl groups and sugars (Foo & Porter 1980, Foo & Porter 1981, Foo et al.
2000b, Porter et al. 2001). Proanthocyanidin-enriched fractions of cranberry are typically
prepared via extraction with EtOAc and the use of dialysis membranes and gel filtration resins
such as Sephadex LH-20 or Sephadex G-10 (Foo & Porter 1980, Portor 1988). More soluble,
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dialyzable, lower molecular weight (MW) polymers are typically fractionated by gel filtration
into groups containing dimers and trimers or tetramers through octamers, while higher MW,
non-dialyzable material (NDM) can be retained by dialysis membranes of different MW cutoffs (Delehanty et al. 2007). Enriched fractions may then be further purified using highperformance liquid chromatography (HPLC) combined with ultraviolet (UV) spectroscopy and
various types of mass spectrometry (MS) to detect and isolate pure compounds (Mabry et al.
1970, Prior et al. 2001, Berhow 2002). Using methods such as these, epicatechin dimers and
trimers with A- and B-type linkages (Figure 1) have been isolated from fresh-pressed
cranberries (Foo et al. 2000a,b) and from fresh cranberry juice (Vorsa et al. 2003). The NDM
fraction of cranberry juice has been partially characterized, is reported to lack sugars, proteins,
and other low MW compounds, and is believed to consist of PACs with MWs of greater than
14,000 or 6,000 depending on the dialysis membrane and method used (Bodet et al. 2007b).
The structural characteristics and complexities of purified cranberry PACs have been
investigated using MALDI-TOF-MS with the aid of calculations to determine the number of
polymeric units based on mass fragments (Neto et al. 2006, Howell et al. 2005, Krueger et al.
2004, Reed et al. 2005), and MALDI-TOF-MS has been combined with ESI-MS, 13C NMR
spectroscopy, and acid catalyzed degradation with phloroglucinol for comprehensive structural
assignments (Foo et al. 2000b). Additional chemical analysis methods may also be used to aid
in structural characterization (Mabry et al. 1970, Foo & Porter 1981, Berhow 2002, Gu et al.
2003). Proanthocyanidin bioactivities are typically reported for crude PAC subfractions due to
the structural complexity of these polymeric compounds and the difficulties of isolating pure
entities. Proanthocyanidin-enriched extracts are typically prepared by the research group
conducting a given biological study and are often presumed to be free of lower MW, non-PAC

5

molecules. Proanthocyanidin-enriched fractions are typically characterized by MS alone or in
conjunction with UV spectroscopy, TLC, and other methods (Mabry et al. 1970, Porter et al.
2001, Howell et al. 2005). Methods typically used cannot, however, assess sample purity or
provide information about all other compounds that may be present, and the use of MS-based
methods alone for the characterization of PAC-enriched fractions may cause minor constituents
to be overlooked or masses to be incorrectly assigned to isobaric compounds.
Proanthocyanidin-enriched fractions that are known to contain other flavonoid molecules with
potential bioactivity have even been used in some assays (Kandil et al. 2002), making it
difficult to determine if PACs or other compounds are responsible for a reported bioactivity.

Figure 1. Structure of an oligomeric PAC with indicated A- and B-type linkages.
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C. Cranberry Bioactivity
Cranberry juice has been reported to possess numerous bioactivities, many of which
have been attributed to PACs, other flavonoids, and other compounds known to be present
(Cook & Samman 1996, Beecher 2004, Pappas & Schaich 2009, Neto & Vinson 2011). For
many studies assessing biological properties, purified compounds with confirmed biological
activity are not obtained.

1. Anti-oxidant Activity
Anti-oxidant properties of cranberry have been recognized in numerous studies and are
typically attributed primarily to flavonoids such as PACs, flavonols, flavonol glycosides, and
anthocyanins. Other compounds also likely contribute to the anti-oxidant properties of
cranberry materials, may of which still have yet to be identified. Anti-oxidant assays examining
cranberry materials have assessed the oxidation of low density lipoproteins (Porter et al. 2001,
Wilson et al. 1998), free radical scavenging ability (Neto et al. 2003), and TPA-induced
ornithine decarboxylase activity (Kandil et al. 2002), among others (Gunes et al. 2002). The
anti-oxidant properties of cranberry phytochemicals are thought to be a mechanism by which
cranberry possesses antitumor activity (Gao et al. 1994, Yan et al. 2002), and promotes
cardiovascular health (McKay & Blumberg 2007, Porter et al. 2001, Wilson et al. 1998).

2. Antitumor Activity
The potential antitumor activity of cranberry has been assessed primarily using in vitro
antiproliferation assays with various tumor cell lines (Neto 2007, Neto et al. 2008, Singh et al.
2012, Vu et al. 2012, Kresty et al. 2008). Fractions and individual compounds from cranberry
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have been found to inhibit the growth of a range of tumor cell lines and are proposed to act by a
variety of mechanisms (Kandil et al. 2002; Neto et al. 2003; Neto et al. 2006). Studies
examining the antiproliferative properties of PACs have typically used crude PAC-enriched
materials with minimal, if any, structural elucidation of the presumed bioactive components
(Ferguson et al. 2004, Ferguson et al. 2006; Bomser et al. 1996; Seeram et al. 2004, Seeram et
al. 2006). Cranberry PACs may be able to prevent the proliferation of several tumor cell lines,
but further studies are needed to identify and confirm the structures of the components
responsible and to determine the in vivo relevance of cranberry as a cancer chemopreventative.

3. Antimicrobial & Anti-adhesion Activity
The reported antimicrobial properties of cranberry juice may be due, in part, to
numerous mechanisms that work synergistically to prevent microbial growth (Leitão et al.
2005, Shmuely et al. 2012, Lee et al. 2000). Historically, cranberry juice antimicrobial
properties were attributed to the high benzoic acid content (Marwan & Nagel 1986). More
recent studies examining cranberry anthocyanins and PAC-enriched fractions (Leitão et al.
2005, Hui et al. 2004) have suggested that PACs may possess antimicrobial properties against
certain select organisms under specific growth conditions. Decreased growth rates were
observed for Staphylococcus aureus, while P-fimbriated Escherichia coli growth was
unaffected in the presence of cranberry PACs (Hui et al. 2004). Cranberry juice and high-MW
cranberry PACs are also reported to possess antiviral activity, hypothesized to be the result of
the inhibition of viral particle binding to target cell surface receptors (Weiss et al. 2005, Lipson
et al. 2007, Su et al. 2010).
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Observed antimicrobial effects of cranberry juice may be due in part to indirect effects
resulting from the inhibition of microbial adhesion to substrates. The prevention of adhesion
can slow growth rates by preventing the binding of microbes to food sources and can prevent
biofilm formation (Hui et al. 2004). High-MW cranberry PACs have been reported to prevent
the formation of biofilms and subsequent oral disease and tooth decay caused by human mouth
bacteria, including Streptococcus sp. (Duarte et al. 2006, Steinberg et al. 2004, Gregori et al.
2007, Yamanaka et al. 2004), and Porphyromonas sp. (Labrecque et al. 2006). Cranberry juice
has also been found to interfere with the co-aggregation of different species of oral plaque
bacteria (Weiss et al. 1998). Cranberry juice and high-MW PACs have been shown to interfere
with the adhesion of Helicobacter pylori to gastric mucous (Shmuely et al. 2004, Burger et al.
2000). Studies have also shown that high-MW NDM cranberry PACs bind to the Lipid A
moiety of lipopolysaccharides (LPS) from Gram negative bacteria, preventing the association
of LPS with epithelial cell surface receptors and the subsequent release of signal-transduction
components involved in inflammation (Delehanty et al. 2007, Bodet et al. 2007a,b, Johnson et
al. 2008). Lipopolysaccharide-induced inflammation plays a role in periodontitis and inhibition
of this process may contribute to the ability of cranberry to promote oral health (Bodet et al.
2007a,b). Many of these studies have established that the ability of cranberry juice to prevent
the adhesion of various bacteria is not due to cytotoxic or antimicrobial effects (Allison et al.
2000, Steinberg et al. 2004, Yamanaka et al. 2004) or to direct interference with host cell
surface receptors such as those on epithelial cells or mucous (Burger et al. 2000), but rather to
direct interactions between cranberry components and microbial cells (Ofek et al. 1996, Liu et
al. 2006, Liu et al. 2008).
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Cranberry juice has been shown in vitro to prevent the adhesion of P-fimbriated
uropathogenic E. coli to the receptors found on epithelial cells. Atomic force microscopy
(AFM) studies indicate that this inhibition of E. coli adhesion is due to molecular-scale changes
in the conformation of E. coli surface macromolecules resulting from contact with cranberry
juice (Liu et al. 2006, Liu et al. 2008). Bioassay-guided fractionation using an in vitro human
red blood cell (HRBC) anti-agglutination assay has led to the identification of A-type PACs
with a degree of polymerization of 3–6 as compounds that could be responsible for the E. coli
anti-adhesion properties of cranberry juice (Foo et al. 2000a,b). Anti-adhesion studies
comparing PAC-enriched fractions to whole cranberry juice indicate, however, that additional
anti-adhesion compounds may be present in the juice (Turner et al. 2005, Pinzón-Arango et al.
2009, Holguin et al. 2008, Tao et al. 2011, Ermel et al. 2012, Kimble et al. 2014).
Bacteria are known to bind to carbohydrate receptors on the surfaces of human
epithelial cells using protein adhesins. These adhesins, such as the P-type and Type-1 fimbriae
of E. coli, are differentially expressed by various strains of a given pathogen (Ofek & Beachey
1978, Enerbäck et al. 1987, Dodson et al. 2001, Hull et al. 2002, Lane & Mobley 2007), and
many pathogens have the ability to simultaneously express multiple types of adhesins (De Man
et al. 1987, Sharon 2006, Pieters 2007). Different adhesins selectively bind to carbohydrate
ligands with different structures, thereby resulting in cell and tissue tropism (Abraham et al.
2002, Pieters 2007, Dodson et al. 2001, Strömberg et al. 1991). Compounds that mimic the
natural binding ligands of microbial adhesins or that interfere with adhesin-ligand binding
would be able to interfere with microbial adhesion to cell surfaces, thereby preventing
subsequent infection (Beachey 1981, Sharon & Ofek 2000, Sharon 2006, Pieters 2007). The
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identification of the anti-adhesive compounds present in cranberry is therefore of great medical
interest (Sobota 1984, Ofek et al. 1991, Howell et al. 1998, Shoaf-Sweeney & Hutkins 2008).
Several types of assays have been used to assess the E. coli anti-adhesion properties of
cranberry. These typically measure the ability of the study organism to bind to (a) a purified
receptor bound to an artificial substrate, (b) human red blood cells (HRBCs), or to (c) the target
epithelial cells. Purified receptor assays are highly specific and are typically used to help
identify the binding epitope of specific microbial adhesins (De Man et al. 1987, Zafriri et al.
1989). Results of these assays are informative regarding adhesin binding sites and the
mechanisms of microbial binding, but cannot be reliably extrapolated to in vivo systems. The
PapG adhesin of P-fimbriated E. coli binds to the α-Gal-(1→4)-β-Gal disaccharide epitope
found on the surfaces of (A1, Rh+) HRBCs causing agglutination (Leffler & Svanborg-Edén
1980, Kallenius et al. 1980, Leffler & Svanborg-Edén 1981, Winberg 1984, Enerbäck et al.
1987, Lane & Mobley 2007). In vitro assays that measure HRBC agglutination have been
generally accepted as a suitable, indirect measure for bacterial adherence to eukaryotic
epithelial cells. They typically measure hemagglutination visually, however, and may therefore
be susceptible to inter-experiment and inter-observer variations that can make it difficult to
quantify results (Johnson et al. 1997). Bacterial-epithelial cell adhesion assays are superior to
bacterial-HRBC anti-agglutination assays as they more closely simulate in vivo systems. These
assays are logistically more difficult to perform and maintain, but can provide quantifiable,
direct measures of bacterial-epithelial cell adhesion (Turner et al. 2005, Mathison et al. 2013,
Kimble et al. 2014). The studies discussed in this report used both bacterial-HRBC antiagglutination and bacterial-epithelial cell anti-adhesion assays (Howell et al. 2010, Mathison et
al. 2013, Kimble et al. 2014) to assess fraction anti-adhesion properties.
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D. Urinary Tract Infections & Cranberry
Cranberry juice is commonly used as a traditional American folk remedy for the
prevention of urinary tract infections (UTIs) and there is increasing use of cranberry dietary
supplements for the same application (Zafriri et al. 1989, Ofek et al. 1991, Blumenthal et al.
2012, Smith 2013).

1. Urinary Tract Infections
Types of UTIs include cystitis (bladder infection) and the more severe pyelonephritis
(kidney infection) which can lead to permanent kidney damage, bloodstream infections, sepsis
and death (Winberg 1984, Scholes et al. 2005). Nearly half of all women are believed to
experience a UTI at some point in their lives, and recurrent UTIs are common (Kunin 1994b,
Foxman 2010). Uropathogenic P-fimbriated E. coli (UPEC) cause up to 80% of uncomplicated,
community-acquired UTIs (Kunin 1994b, Dowling et al. 1987, Enerbäck et al. 1987). Bacteria
are typically inoculated into the urinary tract from the gastrointestinal (GI) tract or are
introduced by medical devices during hospitalization (Scholes et al. 2005, Foxman 2010).
Bacteria adhere to and then infect the cells lining the urinary tract, known as uroepithelial cells
(UECs), causing inflammation and pain associated with uroepithelial cell shedding (Beachey
1981, Justice et al. 2004, Mulvey et al. 1998, Hull et al. 2002). A variety of antimicrobial
agents are used to treat UTIs, but drug resistant infections are a common problem (Kunin
1994a, Foxman 2010). This is partly due to the formation of dormant E. coli reservoirs that are
protected from antimicrobial agents and partly due to the presence of resistant E. coli strains in
the GI tract that serves as the infection source (Mulvey et al. 2001, Justice et al. 2004, Howell
& Foxman 2002).
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The high incidence of UTIs results in an estimated $2.3 billion in annual (2010) direct
health care costs and other societal costs (Foxman 2010). As the initiation of a UTI requires
bacterial adhesion to uroepithelial membranes, compounds or products that interfere with such
adhesion are of great clinical interest (Sobota 1984, Sharon & Ofek 2000, Howell & Foxman
2002). Women who have recurrent UTIs may be given low doses of antimicrobial agents as
prophylaxis, but such prophylactic treatments can eventually lead to increased drug resistance
for the strains of uropathogenic E. coli that infect these women (Gupta et al. 2001, Kunin
1994a, Howell & Foxman 2002). Prevention of UTIs is generally preferable to treatment with
antimicrobial agents, as the use of preventive strategies would not provide a selective pressure
for the development of antibacterial drug resistance (Kunin 1994a, Signoretto et al. 2012, Reid
et al. 2003). Preventative therapies are also generally equally effective against both drugsusceptible and drug-resistant strains of bacteria (Howell & Foxman 2002, Shoaf-Sweeney &
Hutkins 2008).

2. Clinical Use of Cranberry for UTIs
Anecdotal and clinical evidence supports the ability of cranberry juice to help prevent
UTIs (Zafriri et al. 1989, Avorn et al. 1994, Ofek et al. 1991, Ofek et al. 1996, Reid et al.
2003, Howell et al. 2010). These reports often employ cranberry juice, cranberry juice
concentrate, or cranberry juice powder, and the use of native cranberry juice material rather
than extracts or “enriched” fractions may have contributed to the success of these studies (Reid
et al. 2001, Howell et al. 2010, Wang et al. 2012a, Jepson et al. 2012). In contrast, other
reports are inconclusive or do not directly support the effectiveness of cranberry as a
preventative agent, and these studies often used extracts or cranberry dietary supplements with
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unknown chemical composition (Beerepoot et al. 2011, Jepson et al. 2012). Studies that have
used meta-analyses to evaluate available clinical trials concerning the use of cranberry for the
prevention of UTIs have reached differing conclusions as to whether cranberry should be
recommended as a UTI preventative (Wang et al. 2012a, Jepson et al. 2012, Smith 2013).
These conflicting reports highlight the current mix of results that exists regarding the efficacy
of cranberry products and prompt questions regarding which cranberry products are the most
effective. Many of these studies may be assessing the efficacy of specific preparations or
products rather than the efficacy of actual cranberry constituents, and a better understanding of
cranberry bioactive constituents is necessary to resolve these questions and conflicts.

3. Cranberry Mechanism of Action Hypotheses for UTI Prevention
It was once hypothesized that cranberry juice acidified the urine, dropping the pH
through the action of hippuric acid and thereby creating an unfavorable environment for
bacterial growth in the bladder and the rest of the urinary tract (Bodel et al. 1959). This
hypothesis was later disproven (Papas et al. 1968, Ofek et al. 1991) and has since been
replaced by the hypothesis that certain high-MW constituents of cranberry prevent infections
by inhibiting the adherence of uropathogenic bacteria to UECs (Sobota 1984, Zafriri et al.
1989, Avorn et al. 1994, Ofek et al. 1996, Howell et al. 1998). Studies using AFM have shown
that cranberry juice constituents have direct effects on the conformation E. coli P-fimbriae (Liu
et al. 2006, Liu et al. 2008). The results of UPEC-UEC anti-adhesion assays validated with
galabiose and globotriose provide strong evidence that cranberry constituents bind to microbial
cells rather than to epithelial cells (Turner et al 2005). Cranberry juice and human urine
produced after cranberry consumption both possess anti-adhesion activity (Howell et al. 2010,
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Tao et al. 2011) and it has therefore been assumed that the compounds responsible for the
activity of both materials are structurally related and present in both juice and urine. The active
compounds present in urine are currently believed to be PACs or PAC-derived metabolites due
to the reported in vitro anti-adhesion properties of A-type PACs isolated from cranberry
(Howell et al. 1998, Foo et al. 2000a,b), and to the anti-adhesion activity of human urine
produced after the consumption of cranberry powder standardized for PAC content (Howell et
al. 2010), but PAC-related anti-adhesive metabolites have yet to be identified in mammalian
urine.

E. Anti-adhesive Urinary Metabolites of Cranberry Juice
Many different digestive processes may apply to generate the anti-adhesive urinary
metabolites of cranberry. Urinary metabolites are water soluble and chemical components are
typically of medium to low MW. Many types of compounds are excreted into human urine, and
urine metabolomics studies indicate that thousands of individual compounds are present in a
given urine sample, many of which are unknown (Saude et al. 2007, Bouatra et al. 2013).
Compounds with high polarity may be absorbed directly into the bloodstream and
filtered through the kidneys into the urine within a relatively short period of time without
metabolic modification (Brunton 2011, Rowland & Tozer 2011). Compounds with low polarity
may be modified via enzymatic and nonenzymatic metabolic and catabolic pathways to yield
more polar or lower MW metabolites, and may therefore take a longer period of time to reach
the urine. Processes may include oxidation, hydroxylation, hydrolysis, and the addition of
sulfate, glucose, glucuronic acid, or other polar groups via Phase I and Phase II metabolic
pathways (Brunton 2011, Rowland & Tozer 2011). Phase I enzymes involved in these
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processes typically include cytochrome P450 oxidases and reductases, and various esterases
and hydrolases, among others. Phase II enzymes that conjugate low-polarity ingested
compounds to more polar groups include glutathione S-transferases, glycosyl transferases, and
acetyl transferases, among others. In general, lower-polarity and higher-MW compounds are
more likely to be excreted through the fecal route. In the lower digestive tract, microbial
enzymatic biotransformations can then occur to modify ingested compounds, yielding higherpolarity and lower-MW metabolites that are then absorbed into the bloodstream and possibly
excreted via urine.
Little is currently known regarding in vivo PAC absorption and metabolism, but the
chemical nature of PACs suggests that these compounds are unlikely to be directly excreted
into urine. Many flavonoids are excreted into the feces, and may be derivatized or degraded by
gut microflora before re-entering the bloodstream to be later excreted in the urine (Schneider &
Blaut 2000, Braune et al. 2001, Rios et al. 2003, Blaut et al. 2003, Goldin 1986). A PAC-type
drug has recently been approved by the U.S. FDA for the treatment of non-infectious diarrhea
in HIV patients (Frampton 2013), further suggesting fecal elimination of PACs and similar
compounds. It is also likely that ingested PACs bind to other food molecules and protein
receptors along the digestive tract due to the tendency of PACs to form non-specific, covalent
bonds with proteins (Zhu et al. 1997). Such protein binding may prohibit or delay absorption
into the bloodstream.
Flavonoids that have been identified in urine are typically glucuronated, sulfated, or
glycosylated derivatives of ingested compounds with relatively low concentrations of free
phenolic forms (Hollman et al. 1995, Hollman et al. 1999, Harada et al. 1999, Li et al. 2001,
McGhie et al. 2003, Shimoi et al. 2003, Daykin et al. 2005, Kumazawa et al. 2004). If PACs
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are excreted into urine, it would therefore likely be as either conjugated or derivatized forms of
the known anti-adhesive PAC oligomers (Rechner et al. 2002). However, analytical studies that
have specifically searched for the presence of flavonoids and related metabolites in urine after
cranberry consumption have been unsuccessful at identifying PACs (Wang et al. 2012b,
Iswaldi et al. 2013). Many urinary metabolite studies depend upon comparisons of unknown
metabolites to reference compounds to confirm compound identifications, and the relative lack
of PAC standards makes the identification of these structurally complex, high-MW compounds
in urine impractical using typical, standards-based methods.

F. Objectives
The primary objectives of these studies were therefore (1) to isolate and identify the
urinary metabolites of cranberry juice that are responsible for the prevention of UPEC
adherence, and (2) to identify the compounds present in cranberry that are related to the antiadhesive urinary metabolites.
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CHAPTER 2: PORCINE URINARY METABOLITES OF CRANBERRY

A. Introduction
Human volunteers who consume cranberry juice produce urine that has anti-adhesive
properties (Howell et al. 2005, Howell et al. 2010, Tao et al. 2011). Anti-adhesion bioactivity
appears shortly after consumption of the juice until about eight hours later, and maximum antiadhesion effects are observed within four to six hours after ingestion (Howell et al. 2010, Tao
et al. 2011). This suggests rapid absorption and excretion of anti-adhesive cranberry
metabolites into the urine.
The identification of the anti-adhesive urinary compounds produced after cranberry
consumption is essential for further studies regarding the efficacy and bioactive constituents of
cranberry, but questions exist regarding whether PACs are the rapidly excreted urinary
metabolites with anti-adhesion properties (Chapter 1, Section E). The primary objective of this
study was therefore to isolate and identify the compounds responsible for the anti-adhesion
properties of urine after the consumption of cranberry products. This objective was based on
the hypothesis that the anti-adhesive urinary metabolites of interest were either PACs or
metabolically derived from PACs (Howell et al. 1998, Howell et al. 2005). These hypothesized
anti-adhesive metabolites were expected to be structurally related to the PACs previously
identified from cranberry that have been shown to have in vitro UPEC-HRBC antiagglutination activity (Foo et al. 2000a,b).
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Methods used for this study included the collection of urine after cranberry
consumption, bioassay testing using a UPEC-HRBC anti-agglutination assay, and bioassayguided isolation of active fractions and metabolites, followed by structural characterization of
putative active compounds using various methods. Sows were chosen to generate cranberryderived urinary metabolites due to their similar physiology and dietary adaptations to those of
humans (Pond 1986, Tumbleson 1986, Tumbleson & Schook 1986), and because they can be
fed a consistent diet supplemented with relatively large quantities of cranberry powder per day.
Sows also generate the volumes of urine (~1–2 L/d) necessary to provide sufficient material for
bioassay-guided fractionation and metabolite purification.

B. Materials & Methods

1. General Experimental Equipment
Lyophilization was performed using a variety of Labconco FreeZone Systems housed in
the NCNPR and Faser Hall at the University of Mississippi. All sample materials were stored at
–20 or –60 oC. The centrifuge used was a Thermo IEC Centra CL3R instrument with
exchangeable holders for different sizes of Falcon tubes. Early analytical and preparative
HPLC separations of FA urine fractions were performed on a Waters Delta Prep 4000 system
with #5 pump heads and a Prep LC Controller connected to a 2487 dual-wavelength UV
detector. Analytical HPLC separations were later primarily performed on a Waters Alliance
2695 Separations Module with a 996 photodiode array (PDA) UV detector connected in series
to a Polymer Laboratories PL-ELS2100 analytical scale evaporative light scattering detector
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(ELSD). Preparative HPLC separations for H and I urine fractions were performed on a Waters
Delta Prep 4000 system with #5 pump heads and a Prep LC Controller connected in series to a
2487 dual-wavelength UV detector and a Polymer Laboratories PL-ELS1000 ELSD. A Bruker
MicroTOF-Agilent LC 1100 series instrument was used to acquire LC-MS data with a
Phenomenex Luna C8 column (4.6 x 150 mm) at 27 oC, with a flow rate of 0.4 mL/min and a
20 min gradient from 20–100% MeCN or MeOH with 0.1% formic acid. Additional equipment
used by the CCRC is discussed in each respective section.
Regular solvents, TLC plates, HPLC solvents, and most reagent chemicals were
obtained from Fisher Scientific, Inc. Additional reagents, Sephadex LH-20, and Diaion and
XAD resins were obtained from Sigma-Aldrich, Inc., and SPE sorbents were obtained from
Phenomenex Inc. and Waters, Inc. Columns for HPLC were obtained from Waters, Inc., and
HPLC sample filters were obtained from Millipore, Inc. Water used for all experiments was
obtained from ultrafiltration systems located in Faser Hall or NCNPR. Water for HPLC was
additionally filtered within two days prior to use.

2. NMR Spectroscopy
Two different Bruker Avance III 400 MHz NMR instruments were used to acquire
NMR data. These instruments were housed in Faser Hall at the University of Mississippi,
School of Pharmacy, and were equipped with UltrashieldTM and UltrashieldTM Plus magnets
and 5 mm probes. Additional spectra were recorded on a Bruker Avance 700 MHz instrument
equipped with a 5 mm CPTCI cryoprobe, housed in the Bruker facilities in Billerica, MD.
Samples for NMR analysis were prepared by dissolving 2–10 mg of material in a
minimal amount of high purity DMSO-d6 or D2O (Cambridge Isotope Laboratories, Inc.).
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Selected samples were repeatedly lyophilized with D2O to avoid interference from the water
resonance. Either DMSO-d6 (99.99%) or D2O (99.99%) was used for most sample preparations,
and selected samples in NMR tubes were topped with argon gas to delay the absorption of
atmospheric water prior to data acquisition. The use of pulse programs for water suppression
during data acquisition was minimized to avoid resonance loss in this region. Spectra for most
fractions were recorded at 400 MHz and additional high-resolution spectra were obtained at
700 MHz for use in assigning the structure of 1.

3. Source Material
Research-grade, spray-dried cranberry (Vaccinium macrocarpon Ait., Ericaceae) juice
powder (Ocean Spray Cranberries, Inc.) was supplied through NIH grant no. 1R21AT00207601 to both the University of Wisconsin, Madison, WI, (UWM) for the feeding of swine, and to
the University of Mississippi, Oxford, MS, (UM) for preliminary separations and analytical
studies.
Five separate feedings produced the urine samples used for these studies, four of which
(Table 1) are discussed in this chapter. Animal protocols were approved by the UWM Review
Committee (approval number A3368-01, 04/25/2002). Adult female sows (~160 kg each, 1–2
yrs of age) used in this study were housed in gestation crates at the Livestock Laboratory on the
UWM campus and were offered a maintenance amount of a basal diet consisting of corn and
soybean supplemented with tryptophan, methionine, lysine, and various vitamins and minerals
as necessary to meet the recommended maintenance requirements of the National Research
Council (National Research Council 1998).
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Research-grade cranberry juice powder as described above was mixed with basal diet
components at an administration rate of 800 g powder/d/sow (~5 g/kg body weight) for 3–5 d
prior to collection of treatment urine. Feeding was continued through a collection period of 3–4
d and urine was collected via Foley catheters (2–6.5 L per sow). Control urine (~2 L) was also
collected via catheter prior to initiating the third feeding of cranberry powder. Urine was
collected in containers placed over ice, containers were emptied at 4 h intervals, and collected
urine was frozen. Animals were monitored two times per day and Foley catheters checked
regularly by research staff during collection periods.
The D and E urine materials were lyophilized as whole urine by UWM prior to
shipment to UM for chemical analysis. The F, H and I urine samples were frozen at –20 oC
immediately after collection, and were shipped to UM as frozen liquid on dry ice. Aliquots of
each fresh urine (~5 mL each) were frozen and sent to the laboratory of Dr. Amy B. Howell at
the Philip E. Marucci Center for Blueberry and Cranberry Research, Rutgers University,
Chatsworth, NJ, (RU) for preliminary testing in the UPEC-HRBC anti-agglutination assay to
confirm anti-adhesion activity (not shown) prior to materials being shipped to UM.
Table 1. Details of swine urine collections used as source materials.
Feeding
Period

Urine Collection Dates

Received Animal
Urine
by UM Number Vol.a (L)

Solute
Conc.a
(g/L)
11
18

UM
Sample
Code
D
FC

2005/12/19b
2006/02
NAb
2.5
2006/10/27 (control, 1 day) 2006/12
5081
2.0
2006/10/31 – 2006/11/02
3
2006/12
5081
7.0
20
F
(3 days treatment)
2008/06/24 – 2008/06/27
4
2008/07
5023
3.5
17
H
(4 days treatment)
2008/06/24 – 2008/06/27
5
2008/07
8401
2.5
18
I
(4 days treatment)
a
Approximate values. b Incomplete information was provided for this material. c The second
feeding, designated sample E, was used for numerous studies, but this parent material was
ultimately found to have questionable UPEC-HRBC anti-agglutination activity.
1
3c
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4. Anti-agglutination Assay
The anti-agglutination assay used for this study was performed at RU using methods
described previously with minor modifications (Foo et al. 2000a,b). This assay has been used
to identify PACs as anti-adhesive constituents of cranberry samples (Foo et al. 2000a,b) and to
detect anti-adhesion properties of human urine samples after cranberry product consumption
(Howell et al. 2005, Howell et al. 2010). The results of this assay have been accepted as as
representative of the ability of UPEC to adhere to epithelial cells (see Chapter 1, Section C3).
a. Bacterial Strains
Clinical strains of uropathogenic P-fimbriated E. coli (UPEC) were isolated and
cultured as described previously (Foo et al. 2000a,b) with the modifications that P-fimbriated
bacteria were not washed to prevent fimbriae from breaking off and were suspended directly in
phosphate buffered saline (PBS, pH 7.0) at a concentration of 5 x 108 bacteria/mL PBS for
testing. Cultures were kept on agar slants at 4 oC for short-term use over several months and
strains were kept frozen at –70 oC in tryptose broth (30% glycerol) for long-term storage.
b. Hemagglutination Assessment
Test samples were dissolved in different volumes of PBS based on the amount of
sample provided (e.g. 150 μL for 10–30 mg, 200 μL for 40–70 mg, 400 μL for > 80 mg), and
adjusted to neutral, physiologic pH (between 5.5 and 7.0) with 1 N NaOH. Serial two-fold
dilutions of each test sample were prepared in PBS and were tested as described previously
(Foo et al. 2000a,b). For ease of reference these methods are reproduced as follows:
“A 30 µL drop of each dilution was incubated with 10 µL of bacterial
suspension on the lid of a 24-well polystyrene plate for 10 min at room
temperature on a rotary shaker. Freshly-drawn HRBCs (A1, Rh +) [donated
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by human volunteers] were suspended (3%) in PBS and added separately
(10 µL drops) to test suspensions. Suspensions were incubated for 20 min
on a rotary shaker at room temperature and evaluated microscopically for
the ability to prevent agglutination. The final dilution was recorded at
which agglutination suppression by the test fraction occurred. Controls
included wells containing bacteria + PBS, HRBC + PBS, bacteria + test
fraction, HRBC + test fraction, and bacteria + HRBC.” (Foo et al. 2000b)
This assay has been reported to detect PAC anti-adhesion activity at 25–50 µg/mL when
performing two-fold serial dilutions with a starting amount of 1 mg purified PAC material (A.
B. Howell 2006, personal communication).
The microscopic evaluation for agglutination involved a visual assessment using a 0–4
scale as established by RU (Table 2). For example, a visual agglutination score (VAS) of '0'
represented 90–100% HRBC agglutination (Figure 2a) and therefore no inhibition of E. coli
adhesion by the test sample, while a score of '4' represented 0–5% HRBC agglutination (Figure
2b) and total inhibition of E. coli adhesion by the test sample. Dilution endpoints were reported
as the lowest dilution concentration at which the sample received a VAS of ‘1’ or ‘2’ with the
next dilution receiving a VAS of ‘0’ and having no anti-agglutination activity. Lower
concentration dilution endpoints therefore indicated higher relative anti-agglutination activity.
Table 2. Assignment criteria for visual agglutination score (VAS) values associated with
UPEC-HRBC agglutination.
VAS
HRBC
Inhibition of E. coli Adhesion
Agglutination (%)
by Test Sample (%)
0
90–100
0
1
60–90
10–40
2
30–60
40–70
3
5–30
70–95
4
0–5
95–100
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Figure 2. Light microscope image of HRBC agglutination by E. coli in the presence of inactive
(a) and active (b) samples.
The VAS value assigned to panel (a) would be ‘0’ as clumps of HRBCs have formed, while the
VAS value assigned to panel (b) would be ‘4’ as no HRBC agglutination has occurred.
Photographs provided by A. B. Howell.
c. Test Samples
Samples were submitted to RU as dry powders (~10–400 mg per sample) and were
shipped overnight on cold packs or dry ice. Sample weights were provided, but sample
identities were coded and samples were randomized within a set to avoid possible evaluation
and test sequence biases. Duplicate or triplicate samples were submitted for parent materials
and some fractions, but sample quantity limitations and the labor-intensive nature of the assay
made it impractical to submit triplicate samples for every sample tested in every sample set. To
account for assay variations over time, selected urine fractions were repeatedly tested with each
set of samples submitted. These included control urine samples and fractions and the parent
fractions for each separation step.
d. Interpretations of Assay Raw Data
Assay results were interpreted by UM using a qualitative scoring system similar to one
previously published in association with this assay (Foo et al. 2000a). The scoring system used
for this study assigned one of five scores (UM Scores) to each sample tested, based on four
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different criteria (Table 3). The majority of UM Score assignments were made based primarily
on dilution endpoint values, with secondary consideration given to the number of two-fold
dilutions applied to each sample. The third and fourth criteria, involving the comparisons of
fractions to parent materials or replicates, respectively, were considered but were given lower
priority as they did not apply for all samples. The UM scores were used to determine whether a
sample was or was not considered to be active and possibly able to prevent UPEC-epithelial
cell adhesion.
Table 3. Description of the qualitative scoring system developed by UM to interpret the results
provided by the UPEC-HRBC anti-agglutination assay.
The dilution endpoint values and number of two-fold dilutions for individual samples can be
found in the tables of Appendix B-3. Samples were assessed within an individual sample set
test date and then across test dates. Scoring criteria were applied in the order shown to
determine the probable activity of individual samples and assign a UM Score. Replicates were
not available for most samples.
Scoring Criteria:
First
Second
Third
Fourth
UM Assessment
Dilution
No. of
Sample
UM
Replicates
of Sample
Endpoint
Two-fold
Compared to
Score
(if available):
Activity
Range
Dilutions Parent Fraction:
++
+
+/–
–
––

active
probably active
may or may not
be active
probably not
active
not active

< 10 mg/mL

5+

more active

show activity

10–30 mg/mL

4

more active

show activity

30–60 mg/mL

3

about the same

may or may not
show activity

60–100 mg/mL

2

less active

show no activity

> 100 mg/mL

0, 1

less active

show no activity

5. Initial Characterization & Method Development
The premise that the anti-adhesive metabolites of cranberry would be polyphenolic
compounds such as PACs or related flavonoids was used to guide initial method development
(Mabry et al. 1970, Porter 1988, Berhow 2002). Numerous methods were therefore applied in
attempts to enrich for putative PAC metabolites. These included solvent-solvent extraction, gel
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filtration with Sephadex LH-20 and G-10, column chromatography with silica or C18 packing,
hydrophobic extraction resins (Diaion, XAD-8 and XAD-16), and many types of solid phase
extraction (SPE) cartridges (Waters Oasis® and Phenomenx®) with sorbents including C8, C18,
WAX, WCX, MAX, MCX, HLB, phenyl and others. Numerous TLC sorbents and solvent
systems were also employed in efforts to visualize and characterize fraction components. The
details of these methods have been omitted because they did not yield usable results.

6. Enrichment for Active Urinary Components
a. Urine Processing & Extractions
Frozen liquid urine (F, H, & I) was thawed overnight at room temperature. The general
processing and purification protocols shown in Figure 3 were applied to four batches of urine
(FC, F, H, and I). Crude urine was centrifuged (5 min at 2500 RPM) or gravity filtered through
filter paper (Whatman #1) to remove casts and solids. A portion of each clarified urine was
removed and lyophilized to serve as pre-extraction control samples. Clarified urine aliquots (1
L each) were partitioned with EtOAc (2–4 x 250 mL) or EtOAc:MeOH (2–4 x 50:250
MeOH:EtOAc). After solvent partitioning, EtOAc and aqueous urine fractions were evaporated
under reduced pressure with a water bath temperature of ~40 oC to remove organic solvents and
decrease the total volume of aqueous samples. EtOAc fractions were re-dissolved in water,
aqueous samples were diluted as necessary, and all samples were frozen and lyophilized.
Repeated dilution and lyophilization was often necessary for highly hygroscopic samples. All
samples were stored as dry powders or concentrated syrups (hygroscopic samples) in airtight
containers at –20 oC. Selected samples were submitted to the anti-agglutination assay as dry
powders.
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Figure 3. General purification protocol used for isolation of active urine metabolites.
Control urine (FC) was partitioned using the procedures developed for the active urine
samples, but was processed only through to the stage of analytical reverse-phase HPLC
analysis due to the absence of oligosaccharide components. Approximately 1.5 L raw urine was
centrifuged and filtered and the clarified urine (1.5 L) was extracted with EtOAc (2 x 375 mL).
Both fractions were concentrated, diluted, and lyophilized as before. The aqueous fraction
could not be successfully dried by lyophilization and instead produced a concentrated, viscous,
gooey material with about 90–95% of the original water removed. A portion of this material
(FC1, 15–20 mL, resulting from 250 mL of the concentrated aqueous fraction) was separated
on a Sephadex LH-20 column (4 x 33 cm) using an isocratic 75% EtOH solvent system, a flow
rate of 0.8–1.2 mL/min, and a collection time of 5 min/tube (Appendix A color plates: Figure
95). Fraction composition was compared by TLC on silica (MeOH:EtOAc:water, 8:1:1,
sprayed with ninhydrin) and fractions were combined to give three fractions (FC1-1, 3.539 g;
FC1-2, 3.065 g; and FC1-3, 0.233 g). Even with enrichment, control urine fraction FC1-1
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lacked characteristic oligosaccharide components detectable by HPLC-ELSD or NMR
spectroscopy, and further HPLC separation was not pursued. Control urine fractions were
submitted to the anti-agglutination assay as negative controls.
A portion of the raw I urine sample (~250 mL) was used for a rudimentary form of
stability testing. This material was mixed with 60 mL MeOH and left covered in a 1 L
Erlenmeyer flask at room temperature with ambient lighting for a period of three months. After
three months, this solution (IZ) was centrifuged, filtered, extracted with EtOAc (150 x 4), and
the resulting fractions lyophilized to yield IZ-A (3.573 g) and IZ-E (0.048 g). A portion of the
IZ-A sample was submitted to the anti-agglutination assay to determine if activity remained in
the aqueous fraction after the stability treatment described.
b. Sephadex LH-20 Chromatography
Aqueous urine fractions (10–50 g per column; various loading concentrations in eluting
solvent) were loaded onto Sephadex LH-20 columns (various dimensions) and eluted with 50
or 70% EtOH (isocratic) with gravity fed solvent and various flow rates (Tables 4–6; Appendix
A color plates: Figures 96, 97). Fractions (5 to 25 mL each) were collected using an automated
fraction collector and tubes were combined based on appearance and relative elution volume.
Selected preliminary fractions and Sephadex LH-20 fractions were submitted to the antiagglutination assay for testing. Active and putatively active Sephadex LH-20 fractions were
recombined and further purified as described below using additional Sephadex LH-20 columns
(for the FA sample) and reverse and normal phase HPLC with UV and ELS detection.
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Table 4. Details of multiple Sephadex LH-20 separations for the F aqueous urine sample.
The total amount of active material (FA, 1.747 g) recovered from all five columns accounted
for 1.3% of the total loaded samples (133 g) and contained both active and inactive
components.
Column Designation F1
F2
F3
F4
F5
Amount of Loaded
10.0
14.0
10.0
50.4
48.5
Material (g)
Loaded Volume &
45 mL
36 mL
31.5 mL
120 mL
100 mL
Concentration
222 mg/mL 388 mg/mL 317 mg/mL 417 mg/mL 485 mg/mL
Column Dimensions
5.5 x 32
7.5 x 5
5.5 x 34.5
10 x 24
10 x 24
(cm; width x height)
Solvent Composition 50% EtOH 70% EtOH 50% EtOH 70% EtOH 70% EtOH
Solvent Flow Rate
1.8–2.0
1.0–1.2
1.2–1.4
2.0–4.0
3.0–5.0
(mL/min)
Active Material
Total Elution
150
50
114
456
572
Volume (mL)
F1-1
F2-1
F3-1
F4-1
F5-1
Active Fractions
F1-2
F2-2b
F3-2
F4-2
F5-2b
F1-7a
Total Active
Material per Column
0.239
0.287
0.138
0.356
0.727
(g)
Active % of Loaded
2.39%
2.05%
1.38%
0.71%
1.50%
Material
a
Activity in this sample was the result of contamination with part of fraction F1-2 during
material transfers.
b
These samples did not show activity but were included in recombined FA sample to ensure
full recovery of potentially active metabolites.
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Table 5. Details of Sephadex LH-20 separation for the recombined, activity-enriched FA
sample.
The total amount of active material recovered from this column (0.917 g) accounted for 54.5%
of the loaded FA sample contains primarily active components, and is equivalent to 0.7% of the
total amount of separated F samples (133 g).
Column Designation
FA
a
Amount of Loaded Material
1.683 g
Loaded Volume & Concentration
5 mL; 337 mg/mL
Column Dimensions (width x height)
2.5 x 40.5 cm
Solvent Composition
75% EtOH
Solvent Flow Rate
0.5–1.0 mL/min
Active Material Total Elution Volume
200 mL
FA1 (0.030 g)
Active Fraction
FA2 (0.887 g)
Total Active Material per Column
0.917 g
Active % of Loaded Material
54.5%
a
Approximately 0.06 g of FA was reserved as a bioassay testing control.

Table 6. Details of Sephadex LH-20 separations for the H and I urine samples.
Combined oligosaccharide-containing fractions (1.334 g) comprised approximately 1–2% of
the total amount of separated material (69 g) and contained oligosaccharides with putative
activity as well as other, unrelated compounds.
Column Designation
HF1
HF2
IF1
IF2
Amount of Loaded Material (g)
10
40
30
14
Loaded Volume &
30 mL
125 mL
50 mL
50 mL
Concentration
333 mg/mL 320 mg/mL 300 mg/mL 280 mg/mL
Column Dimensions
10 x 25
7 x 38
7 x 38
7 x 38
(cm; width x height)
Solvent Composition
70% EtOH
70% EtOH 70% EtOH 70% EtOH
Solvent Flow Rate (mL/min)
1.0–1.5
1.5–2.0
1.0–1.5
1.0–1.5
Total Elution Volume for
Oligosaccharide-containing
350
450
380
200
Fractionsa (mL)
HF1-1
HF2-1
IF1-1
IF2-1b
Oligosaccharide-containing
HF1-2
HF2-2
IF1-2
IF2-2b
Fractionsa
IF1-3
Oligosaccharide Material per
0.148
0.607
0.425
0.154
Column (g)
Activec % of Loaded Material
1.48%
1.52%
1.42%
1.10%
a
HF1 fractions were tested in the Rutgers assay. HF2, IF1, and IF2 fractions were compared by
HPLC to HF1, FA1, and FA2 fractions to direct isolation efforts while conserving material.
b
The IF2 fractions were combined with the respective IF1 fractions prior to later separations.
c
Putative activity based on composition comparisons using HPLC and NMR.
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7. Isolation of Oligosaccharides by HPLC
Analytical scale HPLC was performed on a Waters 2695 separations module equipped
with a Waters 996 PDA detector connected in series to a Polymer Laboratories PL-ELS2100
ELSD. Preparative HPLC separations were performed using a Waters Delta Prep 4000
chromatographic system equipped with an LC controller and a 2487 dual-wavelength UV
detector connected in series to a Polymer Laboratories PL-ELS1000 ELSD. Preparative scale
fractions were collected in parallel with ELSD monitoring through the use of a flow splitter
installed in the output line after the UV flow cell. This device directed approximately 0.5–3
mL/min of eluent to the ELSD, allowing the rest to be collected. For Polyamine semipreparative separations, the HPLC instrument was configured with analytical scale tubing, the
analytical-scale UV detector flow cell, and split detection-collection with ~0.5–1 mL/min of
eluent delivered to the ELSD and the remaining ~2–2.5 mL/min delivered to a collection
vessel. For AtldC18 preparative separations, the HPLC instrument was configured with
preparative scale tubing, the preparative-scale UV detector flow cell, and split detectioncollection with ~1–3 mL/min of eluent delivered to the ELSD and the remaining ~22–24
mL/min to a collection vessel. System pressure data was acquired for all separations to monitor
system and column performance.
Analytical columns used included a Waters Atlantis dC18 (AtldC18) column (4.6 x 150
mm, 5 µm particle size), a YMC Polyamine II (Polyamine) column (10 x 150 mm, 5 µm
particle size, 12 nm pore size), and a Waters XTerra MS C18 (XTMSC18) column (4.6 x 150
mm, 5 µm particle size). The AtldC18 and XTMSC18 analytical columns were both equipped
with appropriate guard columns (4.6 x 20 mm). Analytical flow rates of 1–3 mL/min were
typically used. The AtldC18 column was used with either water:MeCN or water:MeOH
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gradients and a flow rate of 1 mL/min with a commonly used solvent systems of 100% water
for 5 min, 100% water to 30% MeOH over 30 min, and 30 to 100% MeOH over 20 min. A
commonly used solvent system for the Polyamine column consisted of 5 min at 65% MeCN,
followed by a gradient from 65 to 45% MeCN over 25 min, with a flow rate of 2–3 mL/min for
analytical separations. All columns were equilibrated in a minimum of 10 column volumes of
the initial solvent for each separation. Reverse phase samples were dissolved in a minimum
volume of water, while normal phase samples were dissolved in a minimum amount of either
DMSO, water, or, at most, 60% MeOH. Samples were syringe filtered with 0.2 μm filters
(PTFE or Nylon, 13 or 33 mm diameter) unless otherwise indicated, and various amounts of
material were injected per separation depending on the nature of the sample, the column, and
chromatographic conditions used. Typical ELSD settings for analytical AtldC18 and
XTMSC18 separations were a gas flow rate of 0.8–1.2 SLM, an evaporator temperature of 100
o

C, and a nebulizer temperature of 50 oC, and those for the Polyamine column were a gas flow

rate of 1.2–1.4 SLM, an evaporator temperature of 90 oC, and a nebulizer temperature of 50 oC.
These values remained constant throughout each separation and the ELSD was allowed to
equilibrate for at least 30 min at the desired settings prior to initial data acquisition.
Columns used for preparative and semi-preparative separations included an AtldC18
column (19 x 250 mm, 10 µm particle size), and a YMC Polyamine II column (10 x 150 mm, 5
µm particle size, 12 nm pore size), respectively. Guard columns were not used. Instrument
parameters, solvent systems, and sample preparation methods used for semi-preparative and
preparative separations were based on analytical methods and were scaled appropriately to
maintain chromatographic resolution. Commonly used solvent flow rates for the preparative
AtldC18 and semi-preparative Polyamine columns were 20–25 and 4–6 mL/min, respectively,
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with ~0.5–1 mL/min directed to the ELSD. Various amounts of material were injected per
separation, depending on the nature of the sample, the column, and chromatographic conditions
used (Tables 16, 20). An example method for the preparative AtldC18 column used
MeOH:water, a flow rate of 25 mL/min, and 100% water for 5 min, 100% water to 20% MeOH
over 30 min, 20% MeOH to 100% MeOH over 10 min, 3 min at 100% MeOH, followed by a
17 min gradient from MeOH to 100% water with an equilibration of 10 min prior to the next
separation. An example method for the Polyamine column used MeCN:water, a flow rate 4
mL/min, and 65% MeCN for 5 min, 65–45% MeCN over 25 min, and a 3 min gradient to 65%
MeCN, followed by equilibration in 65% MeCN.
Typical ELSD settings for the AtldC18 preparative separations were a gas flow rate of
0.8–1.2 SLM, an evaporator temperature of 100 oC, and a nebulizer temperature of 50 oC, while
those for the Polyamine semi-preparative separations were a gas flow rate of 0.8–1.2 SLM, an
evaporator temperature of 90 oC, and a nebulizer temperature of 45 oC. These values remained
constant throughout each separation and the ELSD was allowed to equilibrate for at least 30
min at the appropriate settings prior to initial data acquisition.
Fractions collected by preparative or semi-preparative HPLC were recombined based on
retention time and chromatographic profiles and were concentrated under reduced pressure
with a water bath temperature of ~40 oC to remove solvent and decrease water content.
Resulting samples were dissolved in water, frozen, and lyophilized. Selected samples were
analyzed by NMR and LC-MS.
Residual material recovered after HPLC separations from putatively active H and I
Sephadex LH-20 fractions was recombined based on HPLC profiles to give three fractions,
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HI1, HI2 and HI3. These fractions were submitted to the anti-agglutination assay testing and
examined by 1H NMR spectroscopy.

8. Carbohydrate Derivatization Analyses
The methods described above yielded a single sample, compound 1, in sufficient purity
and quantity (~10 mg) for further structural characterization. This sample was determined to be
a complex carbohydrate using preliminary NMR data and was therefore submitted to the
Complex Carbohydrate Research Center (CCRC) at the University of Georgia, for specialized,
professional, fee-for-service analysis. The majority of the structural characteristics for 1 were
determined using a series of analyses that required derivatization of the sample and were
therefore destructive. The results of these analyses provided information on (a) glycosyl
composition, (b) glycosyl linkage positions, (c) high-resolution mass by MALDI-MS, (d)
monomer configuration, and (e) glycosyl sequence. Details of the methods used by the CCRC
are included below.
a. Glycosyl Composition
Glycosyl composition was determined using gas chromatography/mass spectrometry
(GC-MS) of per-O-trimethylsilyl (TMS) derivatives of the sample. Monosaccharide methyl
glycosides were produced by acidic methanolysis (1 M HCl in MeOH at 80 C, 18–22 h),
followed by re-N-acetylation with pyridine and acetic anhydride in MeOH for detection of
amino sugars. The sample was then per-O-trimethylsilylated by treatment with Tri-Sil (Pierce)
at 80 C (30 min) as previously described (Merkle & Poppe 1994, York et al. 1986). Inositol
was added to the sample before derivatization as an internal standard (20 μg per sample). GCMS analysis of the TMS methyl glycosides was performed on an HP 6890 GC interfaced to a
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5975b MSD, using an All Tech EC-1 fused silica capillary column (30 m  0.25 mm ID).
Monosaccharides were identified by comparisons of retention times to those of standards, and
mass spectra were used to authenticate the carbohydrate nature of the derivatives.
b. Glycosyl Linkage (NaOH method)
For glycosyl linkage analysis, the sample was permethylated, depolymerized, reduced,
and acetylated. The resulting partially methylated alditol acetates (PMAAs) were analyzed by
GC-MS (York et al. 1986). Initially, an aliquot of the sample after dialysis was suspended in
about 200 µL of DMSO. The sample was then permethylated using treatment with NaOH and
CH3I in dry DMSO (Ciucanu & Kerek 1984). The sample was subjected to NaOH base for 10
min and CH3I was added and left for 20 min. This process was repeated to ensure complete
methylation. Following sample workup, the permethylated material was reduced by
superdeuteride to the methyl ester of uronic acid, hydrolyzed using 2 M TFA (2 h in a sealed
tube at 121 C), reduced with NaBD4, and acetylated using Ac2O/TFA. The resulting PMAAs
were analyzed on a Hewlett Packard 5890 GC interfaced to a 5970 MSD (mass selective
detector, electron impact ionization mode). Separation was performed on a Supelco 2330
bonded phase fused silica capillary column (30 m).
c. MALDI-MS
The sample was dissolved in deionized water (1 mg/mL) and 1 µL of the solution was
deposited on a spot of 2,5-dihydroxybenzoic acid matrix dried from MeCN:water (1:1). This
material was subjected to MALDI-MS on a Bruker MicroFlex Mass Spectrometer (+ mode).
All masses were calibrated to malto-oligosaccharide controls separated immediately before the
sample.
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d. Monomer Configuration
The absolute configuration of monomeric glycosyl units was determined by
comparisons between derivatized compound substituents and derivatized standards. The sample
was hydrolyzed in 2M TFA (500 μL) at 120 ºC for 1.5 h, the hydrolysate was dissolved in 200
μL (S)-(+)-2-BuOH (Fluka 19025), 15 μL acetyl chloride (Aldrich 236691) was added, and N2
was bubbled through the solution for 30 s. The mixture was capped tightly and incubated at 80
ºC for 16 h. The mixture was dried under N2, and absolute MeOH was added to ensure sample
dryness. To the dry sample, 250 μL TMS was added and derivatization was carried out at 121
ºC for 20 min. The same procedure was applied to authentic standards D-Glc, L-Ara, and DXyl; two sets of standards were derivatized to which either (S)-(+)-2-BuOH or (R)-(-)-2-BuOH
was added separately. The sample and standard derivatives were analyzed on an Agilent 5975C
GC interfaced with a 7890A MS detector.
e. Glycosyl Sequence
Glycosyl sequence was determined using per-O-methylated glycans analyzed by
Nanospray Ionization-Linear Ion Trap Mass Spectrometry (NSI-MSn) (Anumula & Taylor
1992). The sample was dissolved in DMSO, permethylated as described above (Anumula &
Taylor 1992), extracted with DCM, and dried under N2. The resulting per-O-methylated glycan
was dissolved in 1 mM NaOH in 50% MeOH and directly infused with a syringe flow rate of
0.5 L/min into an LTQ Orbitrap Discoverer mass spectrometer (Thermo Scientific) equipped
with a nanospray ion source. The capillary temperature was set to 210 C, and MS analysis was
performed in positive ion mode with fragmentation by CID (25% collision energy) in MS/MS
and MSn modes. Indicative partial-fragmentation patterns from NSI-MSn analysis of the per-O-
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methylated derivative of 1 were used to confirm side chain linkage positions and establish
monomer connectivity.
Compound 1: β-D-glucopyranosyl-(1→4)-[α-L-arabinofuranosyl-(1→2)-α-Dxylopyranosyl-(1→6)]-β-D-glucopyranosyl-(1→4)-[α-L-arabinofuranosyl-(1→2)-α-Dxylopyranosyl-(1→6)]-β-D-glucopyranosyl-(1→4)-β-D-glucopyranose (1); White amorphous
powder; 1H NMR and 13C NMR data: Figure 4, Figures 59–68, Table 28; MALDI-MS (Figure
42) (positive ion mode) [M+Na]+ at m/z 1218.117, to give a calculated molecular formula of
C44H74NaO37+ for 1.

Figure 4. Structure of the urinary octasaccharide (1) showing monosaccharide identities and
absolute configuration.
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C. Results & Discussion

1. Anti-agglutination Properties of Urine Fractions
a. Overview of Anti-agglutination Assay Results
Cumulative results across test dates for selected urine samples and fractions are shown
below (Tables 7–15). The raw assay data provided by RU (dilution endpoints) were interpreted
by UM using a qualitative scoring system (Table 3) as discussed above (Section B4d). The raw
data for these samples, organized by test date, are included in Appendix B-3 with some
additional discussion points regarding assay limitations in Appendix B-2. Raw data include the
same sample descriptions as shown below, the dilution endpoint values (mg/mL) provided by
RU, the number of two-fold dilutions applied to each sample before loss of detectable antiagglutination activity, the amount of sample submitted by UM, the amount of PBS used to
dilute each sample (dilution volume), and the starting concentration at which anti-agglutination
properties were first assessed. The VAS values were reported by RU to UM for only some of
the samples submitted and these scores are included in the raw data where available (Appendix
B-3: Tables 46, 48, 50, 52).
Although numerical dilution endpoint values were provided as the result for each
sample, these values were, at best, qualitative assessments of sample activity due to the
qualitative nature of the visual agglutination scoring system used. False negative results were
also likely for many samples, as the reported dilution endpoints may have been affected by
numerous sample, environmental, and methodological variables (See Appendix B-2
discussion). In spite of the limitations of the UPEC-HRBC anti-agglutination assay, the results
were determined to provide sufficient information to guide preliminary isolation efforts by
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identifying which samples were or were not active. The results of these studies indicated,
however, that this assay is not suitable for future quantitative assessments of the ability of test
samples to prevent UPEC adhesion, especially for small quantities (< 10 mg) of material with
unknown activity. Sample limitations therefore dictated that priority be given to the isolation
and structure elucidation of putative active components in preference to further testing of urine
fractions using this assay.
b. Results for Urine Fractions
The D urine fractions and DA Sephadex LH-20 fractions were tested across five
different test dates and all samples were not tested for each test date (Table 7). Retesting of
fractions DA1–DA8 yielded results with questionable reproducibility as some of samples that
showed activity in the 05/2006 test set were inactive in the 03/2007 test set and vice versa.
Retesting of fractions DA13–DA20 also yielded some results with questionable reproducibility,
but some of these samples maintained activity. Samples within this set that were considered
active included DA13, DA18, and DA19. A third retesting of fraction DA19 in the 07/2011 test
set showed that this sample retained activity as a dry powder stored at –20 oC for at least five
years. Insufficient amount of all DA materials were available for further isolation or structural
characterization.
The F urine fractions were tested across six different test dates (Table 8). The FF
sample (the aqueous fraction of the F urine crude material) was tested repeatedly as a positive
control for other urine samples. Although it was considered active, this sample did not always
result in numerical dilution endpoints that fell within the defined ranges for activity, and
dilution endpoints for replicate samples within a single test date were inconsistent. The
variations in UM Scores reflect this variation in dilution endpoints. The observed variation in
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sample activity may have been partly due to the complexity and heterogeneity of the sample
and the hygroscopic nature of the material, as well as to other reasons (see Appendix B-2
discussion). The FF sample was later submitted to preliminary versions of the UPEC-UEC
assay used for cranberry studies (see Chapter 3) and it also showed anti-adhesion activity in
this assay (data not shown). The FF sample retained activity for at least four to six years.
The FF fraction was separated using five different Sephadex LH-20 columns (Table 4),
and all fractions from these separations were submitted to the anti-agglutination assay (Table 9,
10). Fractions that showed consistent activity were those that eluted early from each column,
including F1-1, F1-2, F2-1, FF3-1, FF3-2, FF4-1, FF4-2, and FF5-1. These active FF fractions
were combined to give the FA fraction which was also found to be active (
Table 11). The FA fraction was further separated by Sephadex LH-20 (Table 5) and the
resulting fractions were tested on two different test dates (
Table 11). As before, early-eluting Sephadex LH-20 fractions (FA1 and FA2) showed
highest activity (09/2007 test date). Retesting of the FA fractions in the 06/2008 sample set
yielded negative activity for the FA1 and FA2 fraction. This apparent lack of activity was most
likely due to the submission of less than 10 mg of each sample (Appendix B-3: Tables 51, 54).
Control urine fractions were primarily inactive, as expected (Table 12), and the FC1
fractions were tested repeatedly as negative controls for other urine samples. Similar separation
methods were applied to the FC material as were used for active urine materials (Section B5a);
the fraction FC1 was analogous to fractions FF, HF and IF, and FC1-1 was analogous to FA1
and HF1-1. Fraction FCE showed possible activity and this activity may indicate the presence
of innate or other dietary-derived urine components that can interfere with HRBC agglutination
by E. coli. Limited FCE material was available for further analyses.
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The H urine material and H fractions were tested across three different test dates (Table
13). The HF fraction showed activity and fractionation of HF by Sephadex LH-20 (Table 6)
yielded early-eluting fractions with highest activity. This pattern of activity was similar to that
observed with the F urine material, with active components being retained in the aqueous
fraction after organic solvent extraction and eluting early from a Sephadex LH-20 column. The
HCE fraction also showed possible activity but a limited amount of this material was available
and attempts at isolating the constituents present were unsuccessful. Combination of selected
HF and IF fractions (see below) produced the three HI fractions shown, and the combined
fraction derived from early-eluting Sephadex LH-20 fractions (HI1) had the best activity.
The I urine material was tested across two different test dates and I fractions showed a
pattern of activity similar to that observed with H and F samples (Table 14). The IF fraction
was separated using Sephadex LH-20 (Table 6) but the resulting fractions were not tested.
Combinations of selected HF and IF Sephadex LH-20 fractions were, however, tested as HI
samples, confirming the activity of early eluting IF fractions (Table 13). The ICE fraction also
showed activity but a limited amount of this material was available. The I urine material was
subjected to a stability test followed by solvent-solvent extraction to yield the IZ and IZA
materials. Both of these IZ samples showed activity, indicating that the active constituents were
stable in 20% MeOH solution with other crude urine components for up to three months.
c. Results for Standards
Carbohydrate standards were submitted with the last two sets of test samples (Table 15)
with the objective of assessing assay specificity for different monosaccharides. Of the
submitted carbohydrate standards, D-glucose showed reproducible activity, suggesting that the
presence of this compound in urine fractions may be a cause for false-positive results. While
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glucose may be present in crude urine materials, it would have been removed from later,
enriched fractions (such as FA1 and HF1-1) by the chromatographic methods used (See
Appendix B-5: Figure 105). It also could not be detected in cranberry fractions that were later
collected and shown to be active in a different anti-adhesion assay (See Chapter 3, Sections
B5b, C2d, and C4b). A possible reason for the positive result obtained with glucose relates to
the fact that this compound can serve as a growth substrate for E. coli. The presence of this
compound in test media may cause E. coli to alter gene expression profiles associated with
adhesion (A. B. Howell personal communication). Glucose may therefore inhibit HRBC
agglutination by E. coli, but this inhibition may be due to an indirect mechanism of action that
is not clinically relevant. Additional studies would be necessary to fully investigate this
phenomenon.
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Table 7. Anti-agglutination assay results for D urine fractions and DA Sephadex LH-20
fractions tested in three different test date sets.
Samples within this set that were considered active included DA13, DA18, and DA19. Fraction
DA19 retained activity as a dry powder stored at –20 oC for at least five years.
UM
Test
UM
Test
UM
Test
Sample Description
Scorea
Dateb
Score
Date
Score
Date
D (crude urine)
––
03/2006
DE (D EtOAc fraction
––
03/2006
DS (D sec-BuOH fraction)
––
03/2006
DA (D aqueous fraction)
+/–
03/2006
DA1 (Sep LH-20 fraction)
–
05/2006 + + 03/2007
DA2 (Sep LH-20 fraction)
–
05/2006
+
03/2007
DA3 (Sep LH-20 fraction)
+/–
05/2006
+
03/2007
DA4 (Sep LH-20 fraction)
+/–
05/2006
––
03/2007
DA5 (Sep LH-20 fraction)
––
05/2006
––
03/2007
DA6 (Sep LH-20 fraction)
––
05/2006
––
03/2007
DA7 (Sep LH-20 fraction)
––
05/2006
––
03/2007
DA8 (Sep LH-20 fraction)
––
05/2006 + + 03/2007
DA9 (Sep LH-20 fraction)
––
05/2006
DA10 (Sep LH-20 fraction)
––
05/2006
DA11 (Sep LH-20 fraction)
––
05/2006
DA12 (Sep LH-20 fraction)
––
05/2006
DA13 (Sep LH-20 fraction)
++
05/2006 + + 08/2006
DA14 (Sep LH-20 fraction)
++
05/2006
–
08/2006
DA15 (Sep LH-20 fraction)
++
05/2006
–
08/2006
DA16 (Sep LH-20 fraction)
++
05/2006 +/– 08/2006
DA17 (Sep LH-20 fraction)
––
05/2006 + + 08/2006
DA18 (Sep LH-20 fraction)
++
05/2006 + + 08/2006
DA19 (Sep LH-20 fraction)
++
05/2006 + + 08/2006 + + 07/2011
DA20 (Sep LH-20 fraction)
––
05/2006
––
08/2006
a
The evaluation criteria for assigning the qualitative UM Scores are described in Table 3.
b
Samples with the same test date were submitted as part of the same shipment to RU but may
not have been tested on the same day or in the same batch. See Appendix B-2 for additional
discussion.
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Table 8. Anti-agglutination assay results for F urine fractions.
The FF sample (the aqueous fraction of the F urine sample) was tested repeatedly as a positive
control for other urine samples. The variations in UM Scores reflect the variation in dilution
endpoints both within and across test dates. These data indicate that the FF sample retained
activity for at least four years. Later testing in preliminary versions of the UPEC-UEC
indicated that anti-adhesion activity was still retained in the FF sample for at least six years.
UM
Sample Description
Test Date
Score
FB (F EtOAc fraction)

a

–

09/2007

FG (F solids)

––

03/2007 x3a

FF (aqueous fraction)

+/–

03/2007

FF (aqueous fraction)

+/–

03/2007

FF (aqueous fraction)

++

05/2007

FF (aqueous fraction)

+

05/2007

FF (aqueous fraction)

–

05/2007

FF (aqueous fraction)

+/–

06/2007

FF (aqueous fraction)

+/–

06/2007

FF (aqueous fraction)

–

06/2007

FF (aqueous fraction)

–

09/2007

FF (aqueous fraction)

–

09/2007

FF (aqueous fraction)

+

07/2011

FF (aqueous fraction)

+

07/2011

This sample was submitted and tested in triplicate for this test date.
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Table 9. Anti-agglutination assay results for FF Sephadex LH-20 fractions, columns 1 and 2.
The FF Sephadex LH-20 fractions that showed consistent activity were those that eluted early
from the columns: F1-1, F1-2, and F2-1. F2-2 – F2-4 may also have been active. Fraction FF17 was contaminated with a small amount of FF1-1 during sample transfers.
UM
Sample Description
Test Date
Score
FF1-1 (Sep LH-20 fraction)

++

03/2007

FF1-2 (Sep LH-20 fraction)

++

03/2007

FF1-3 (Sep LH-20 fraction)

––

03/2007

FF1-4 (Sep LH-20 fraction)

––

03/2007

FF1-5 (Sep LH-20 fraction)

–

03/2007

FF1-6 (Sep LH-20 fraction)

+/–

03/2007

FF1-7 (Sep LH-20 fraction)

++

03/2007

FF1-8 (Sep LH-20 fraction)

––

03/2007

FF1-9 (Sep LH-20 fraction)

––

03/2007

FF2-1 (Sep LH-20 fraction)

++

05/2007

FF2-2 (Sep LH-20 fraction)

+

05/2007

FF2-3 (Sep LH-20 fraction)

+

05/2007

FF2-4 (Sep LH-20 fraction)

+

05/2007

FF2-5 (Sep LH-20 fraction)

––

05/2007

FF2-6 (Sep LH-20 fraction)

+/–

05/2007

FF2-7 (Sep LH-20 fraction)

+/–

05/2007

FF2-8 (Sep LH-20 fraction)

––

05/2007
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Table 10. Anti-agglutination assay results for FF Sephadex LH-20 fractions, columns 3, 4, and
5.
The FF Sephadex LH-20 fractions that showed consistent activity were those that eluted early
from the columns: FF3-1, FF3-2, FF4-1, FF4-2, and FF5-1.
UM
Sample Description
Test Date
Score
FF3-1 (Sep LH-20 fraction)

++

05/2007

FF3-2 (Sep LH-20 fraction)

++

05/2007

FF3-3 (Sep LH-20 fraction)

––

05/2007

FF3-4 (Sep LH-20 fraction)

––

05/2007

FF3-5 (Sep LH-20 fraction)

––

05/2007

FF3-6 (Sep LH-20 fraction)

+/–

05/2007

FF4-1 (Sep LH-20 fraction)

+

06/2007

FF4-2 (Sep LH-20 fraction)

+

06/2007

FF4-3 (Sep LH-20 fraction)

–

06/2007

FF4-4 (Sep LH-20 fraction)

––

06/2007

FF4-5 (Sep LH-20 fraction)

––

06/2007

FF4-6 (Sep LH-20 fraction)

––

06/2007

FF4-7 (Sep LH-20 fraction)

––

06/2007

FF4-8 (Sep LH-20 fraction)

––

06/2007

FF5-1 (Sep LH-20 fraction)

++

06/2007

FF5-2 (Sep LH-20 fraction)

––

06/2007

FF5-3 (Sep LH-20 fraction)

––

06/2007

FF5-4 (Sep LH-20 fraction)

––

06/2007

FF5-5 (Sep LH-20 fraction)

––

06/2007

FF5-6 (Sep LH-20 fraction)

––

06/2007

FF5-7 (Sep LH-20 fraction)

––

06/2007

FF5-8 (Sep LH-20 fraction)

–

06/2007
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Table 11. Anti-agglutination assay results for FA urine fractions.
In the 09/2007 sample set, the FA sample showed probable activity and the early-eluting
Sephadex LH-20 fractions (FA1 and FA2) showed highest activity, as before. When all FA
samples were retested in the 06/2008 sample set, however, FA1 and FA2 showed no activity.
This result is probably a false negative due to the submission of less than 10 mg of each sample
(see Appendix B-3: Tables 50, 53).
UM
UM
Sample Description
Test Date
Test Date
Score
Score
FA (combined active FF samples)

+/–

09/2007

+/–

06/2008

FA1 (Sep LH-20 fraction)

++

09/2007

––

06/2008

FA2 (Sep LH-20 fraction)

+

09/2007

––

06/2008

FA3 (Sep LH-20 fraction)

––

09/2007

––

06/2008

FA4 (Sep LH-20 fraction)

+/–

09/2007

+/–

06/2008

FA5 (Sep LH-20 fraction)

––

09/2007

+/–

06/2008

Table 12. Anti-agglutination assay results for FC urine fractions.
The FC1 fractions were tested repeatedly and were inactive each time, as expected. Fraction
FCE showed possible activity, but limited material was available for further analyses. The
presence of possible activity in the FCE fraction indicated that other innate or dietary-derived
urinary components may be present in this fraction that can inhibit agglutination.
UM
Sample Description
Test Date
Score
FC (control urine)

––

09/2007

FCE (FC EtOAc fraction)

+/–

09/2007

–

07/2011 x2, 09/2007 x3, 12/2008

FC1-1 (Sep LH-20 fraction)

––

06/2008, 12/2008, 07/2011 x2

FC1-2 (Sep LH-20 fraction)

––

06/2008, 07/2011

FC1-3 (Sep LH-20 fraction)

––

06/2008

FC1 (aqueous fraction)
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Table 13. Anti-agglutination assay results for H urine fractions.
The H crude urine material and the HF aqueous fraction both showed activity. The HCE
fraction also showed possible activity. Fractionation of HF by Sephadex LH-20 yielded earlyeluting fractions with activity: HF1-1 and HF1-2. Combination of HF and IF Sephadex LH-20
fractions produced the HI fractions shown, and the fraction derived from early-eluting H and I
Sephadex LH-20 fractions (HI1) had the best activity of the HI fractions.
UM
Sample Description
Test Date
Score
H (crude urine)

+/–

08/2008, 12/2008, 07/2011

HG (H solids)

––

08/2008

+

08/2008

HCM (H EtOAc fraction, MeOH soluble)

––

08/2008

HD (H EtOAc:MeOH fraction, water soluble)

––

08/2008, 12/2008

+

08/2008, 12/2008

HF1-1 (Sep LH-20 fraction)

++

12/2008

HF1-2 (Sep LH-20 fraction)

+/–

12/2008

HF1-3 (Sep LH-20 fraction)

–

12/2008

HF1-4 (Sep LH-20 fraction)

–

12/2008

HF1-5 (Sep LH-20 fraction)

––

12/2008

HF1-6 (Sep LH-20 fraction)

–

12/2008

HF1-7 (Sep LH-20 fraction)

––

12/2008

++

07/2011

+

07/2011

––

07/2011

HCE (H EtOAc extract, water soluble)

HF (H aqueous fraction)

HI1 (combined H & I active fractions,
HF2-1 + IF1-1)
HI2 (combined H & I active fractions,
HF1-1 + HF2-2 + IF1-2)
HI3 (combined H & I active fractions,
HF1-2 + IF1-3 + HF2-3)
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Table 14. Anti-agglutination assay results for I urine fractions.
The I urine material and the IF fraction both showed activity. The ICE fraction also showed
activity but a limited amount of this material was available. The Sephadex LH-20 fractions of
IF were not tested. The IZ and IZA materials derived from the stability test both showed
activity, indicating that active components of the urine are not degraded under the conditions
used.
Sample Description
UM Score
Test Date
I (crude urine)

+/–

12/2008

ICE (I EtOAc:MeOH fraction, water soluble)

++

12/2008

ICM (I EtOAc:MeOH fraction, EtOAc soluble)

––

12/2008

ID (EtOAc:MeOH fraction, water soluble)

––

12/2008

IF (I aqueous fraction)

+/–

12/2008

+

12/2008

++

07/2011

IZ (I stability test)
IZA (IZ aqueous fraction after stability test)

Table 15. Anti-agglutination assay results for submitted reference compounds.
Of the submitted carbohydrate standards, D-glucose showed reproducible activity, suggesting
that the presence of this compound in test samples may cause false-positive results. Queries
directed at RU regarding the activity of glucose in the assay led to the proposal that glucose
may inhibit agglutination of HRBCs by E. coli via an indirect mechanism of action that is not
clinically relevant for UTI prevention.
Sample Description
UM Score
Test Date
D-Glucose (Sigma Aldrich 99.5%)

+/–

12/2008

D-Glucose (Sigma Aldrich 99.5%)

++

07/2011 x2

Glucose Tabs (ReliOn Glucose Tablets
commercial product, powdered)

++

07/2011 x2

D-Glucuronic Acid

––

12/2008

D-Galacturonic Acid

––

12/2008

D-Sorbitol

––

12/2008

–

07/2011 x2

––

12/2008, 07/2011

D-Fructose (CalBioChem)

Sucrose (Great Value Brand)
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2. Initial Results with Early (D, E, & F) Source Materials
The first shipment of active urine material (D) provided information relevant to method
development but did not provide sufficient material from which to purify the active
components. This material was handled under the premise that the target metabolites were
PACs or PAC-derived. Methods that would normally be used for PAC isolation, such as those
previously applied to cranberry materials (Foo et al. 2000a), were therefore attempted,
including EtOAc and sec-BuOH extraction and Sephadex LH-20 chromatography with 100%
EtOH. The use of SPE cartridges (Oasis® HLB) and hydrophobic extraction resins (Diaion,
XAD-8 and XAD-16) was also attempted based on the premise that PACs would be retained by
such sorbents.
The fractions from solvent-solvent extraction using EtOAc and sec-BuOH were sent to
the anti-agglutination assay, and the aqueous fraction (DA) yielded the best activity (Table 7).
The DA material was therefore the focus of additional work. Of the methods attempted, the
Sephadex LH-20 column yielded the most useful information for further method development.
This column was packed in 100% EtOH but the sample would only partially dissolve in 75%
EtOH and fell out of solution upon loading. The eluting solvent subsequently used was a
gradient, with gradual 10% decreases in EtOH concentration in 1–2 L increments so as to
redissolve the sample without overexpanding the Sephadex and breaking the glass column.
This gradient method resulted in elution of anti-adhesive constituents at ~70–75% EtOH, as
fractions DA13-DA19. Low amounts of material were recovered and half of the material for
most fractions collected was sent for initial testing in the anti-agglutination assay (Table 7,
Appendix B-3: Tables 42–44). Later retesting of the DA column fractions confirmed activity
for fractions DA13, DA18 and DA19. Unexpectedly, D fractions that showed activity gave
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negative results for an anthocyanidin test, indicating that PACs were not present in these
fractions (Ofek et al. 1996). The active D fractions from this separation were analyzed by 1H
NMR spectroscopy and LC-MicroTOF-MS, but data quality was poor and the spectra obtained
could not be reliably interpreted. The low-quality 1H NMR spectra for fractions DA18 and
DA19 (Appendix B-5: Figures 106, 107) were later determined to have similar features as
spectra obtained for other active urine fractions (FA1 and HF1-1).
Early studies also indicated that active fractions of unknown composition were soluble
in water, dimethyl sulfoxide, and water-alcohol mixtures (EtOH or MeOH) of up to 80%
alcohol with diluted material. Active metabolites were found to be stable after exposure to
moderate heat (up to 60 oC), light, alcohols (EtOH, MeOH, sec-BuOH), EtOAc, DMSO, ether,
and acid at room temperature (titrated to pH 2.5 using 1 M HCl). Activity also remained after
freezing in powder or liquid form for long periods of time (up to 5 years or more) in both
complex mixtures and in more purified active fractions.
The second shipment of active urine material (E) was used for further attempts at
method development using numerous approaches. Many fractions of this material were sent for
assay testing and the results indicated that the material supplied to UM may have lost activity.
Issues with this apparent loss of activity prompted consideration of mechanisms by which the
unknown (at that time) metabolites could be degraded or inactivated. The E urine samples had
been lyophilized as crude urine by the UWM group prior shipment to UM and issues during
this stage of processing could have contributed to the degradation of active components. Raw
urine material is difficult to lyophilize due to relatively high solute concentrations, the presence
of fats and surfactants, and the logistics of processing large volumes of liquid via
lyophilization. Of the possible scenarios, crude urine material could have been subjected to
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extended periods of time in untreated aqueous solution and to multiple freeze-thaw cycles.
During such times, active metabolites could have been degraded by native enzymes present in
crude active urine or could have chemically reacted with other crude urine components (Saude
et al. 2007). Enzymatic degradation can be prevented by mixing crude urine samples with
MeOH or other alcohols to denature proteins, but alcohol addition would have interfered with
lyophilization, freezing, and shipping. The alternative addition of common urine stabilizing
agents, such as sodium azide, may have interfered with the unknown active metabolites and the
assay results (Saude et al. 2007). Degradation can also be avoided, and lyophilization
efficiency improved, by filtering and extracting urine samples with organic solvents prior to an
initial lyophilization step. Later urine samples were therefore kept frozen for the entire time
between collection and extraction, including during shipping, and up to 20% of MeOH was
added to urine samples immediately upon thawing.
The stability test later performed using the crude I urine sample confirmed that the
active constituents were stable at room temperature in a 20% MeOH solution in the presence of
crude urine constituents. During the three month incubation time, a precipitate formed, the
color of the material changed from amber yellow to dark chocolate brown, and the smell of the
material changed. All of these observations indicated the presence of oxidation and other
chemical changes that were not prevented by the presence of MeOH. When tested in the antiagglutination assay, the IZ-A material showed higher activity than the analogous aqueous
material (IF) prepared without the room temperature incubation. These data suggested that
additional enrichment for the active constituents may have occurred, possibly through
degradation of non-active urinary components or assay-confounding materials. As MeOH
denatures proteins, it is likely that enzymatic mechanisms may have been responsible for the
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loss of activity in the E urine material. Additional testing and analyses would be required to
profile the chemical and biological changes that could affect the stability of active urinary
components, but such studies were not feasible during the present project.

3. Enrichment for Active Components
Active urinary components were consistently present in aqueous fractions after
extraction with organic solvents (using EtOAc, EtOAc-MeOH mixtures, sec-BuOH, or ether)
or with the use of solid phase extraction (SPE) cartridges, or XAD resins. Low antiagglutination activity was present in some EtOAc fractions (HCE, ICE; Tables 13, 14) but not
others (FB; Table 8). Attempts were made to isolate components from HCE, but insufficient
amounts of this and similar materials were available to pursue further purification. The control
urine EtOAc fraction (FCE; Table 12) also displayed low anti-agglutination activity, indicating
that constitutive urinary metabolites or dietary sources other than cranberry may be responsible
for the activity observed in some EtOAc fractions. Efforts were therefore focused on the
isolation of possible active components from aqueous fractions (FF, HF, IF).
The anti-agglutination assay data for the FF sample Sephadex LH-20 fractions (Tables
9, 10) provided certainty as to methods that allowed for satisfactory enrichment of the active 1–
2% of total urine material. Active fractions consistently eluted within the first 1–3 fractions of
each Sephadex LH-20 column regardless of variations in column dimensions or EtOH
percentages (50–70%). The total amount of active material enriched from the F urine samples
accounted for ~0.7% of the starting material by weight, giving an estimated starting urine
concentration for active metabolites of less than 0.14 mg/mL. Some of this material was used
for method development and fraction characterization without success. Remaining anti-
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adhesive urine fractions from the five separate Sephadex LH-20 columns of the FF material
were combined to give F Actives (FA; 1.75 g). This material was separated on Sephadex LH20 (Table 5), to give two anti-adhesive fractions (FA1 and FA2). Half of each FA1 and FA2
sample was submitted to the anti-agglutination assay (
Table 11), and fraction FA1 was used primarily for analytical HPLC separations and
comparative analyses due to its limited quantity. Method development with FA1 and FA2 used
HPLC-UV with HILIC and XCMSC18 sorbents and various solvent systems (see analytical
HPLC example in Appendix B-5: Figure 108). All fractions isolated from FA2 using UV
detection, however, gave inconclusive or negative assay results, and LC-MicroTOF-MS of both
FA1 and FA2 gave inconclusive results (not shown) regarding possible fraction composition.

4. Characterization of Active Components
Comparisons between the 1H NMR data of active urine fractions FA1 and FA2 (Figure
5), commercial fruit pectin (Figure 6), and galacturonic acid (Figure 7), a monomeric
component of pectin, indicated that the active fractions could contain complex carbohydrates.
While the 1H NMR spectra of active urine fractions and pectin appeared similar, the urine
fractions had significantly different characteristics in aqueous solution than pectin. The
composition of the FA1 sample could also not be sufficiently distinguished from that of other,
inactive, FA fractions by NMR (Figure 5).
Analysis of FA1 via analytical HPLC-ELSD/UV indicated that the major components
of this fraction lacked chromophores and therefore required the use of ELSD or other
chromophore-independent detection methods to monitor and guide HPLC separations (see
Appendix B-4: overview of ELSD principles). Purification and structure elucidation of the
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compounds present in the FA1 fraction was impractical, however, due to material limitations.
The observation that active fractions with the highest anti-agglutination activity lacked UVdetectable components was later supported by HPLC-ELSD/UV analysis of HF1-1 (Figure 8).
Further guidance regarding the possible composition of the FA and HF1-1 active
mixtures was obtained from additional 1H NMR data. Comparisons between the 1H NMR
spectra of FA1 and HF1-1 (Figure 9) indicated a similar composition. Comparisons of these
spectra with the 1H NMR spectra of synthetic trimeric and tetrameric PACs (Figure 10),
however, indicated that the active urine fractions did not contain these compounds. This was
established by the lack of characteristic overlapping aromatic resonances from the A- & Brings of different PAC monomer units that would correspond to PACs or possible PAC-related
metabolites. Although NMR spectra of crude active urine fractions (HF; Figure 11) did contain
resonances in the aromatic region (Figure 12), these resonances were also present in the
inactive enriched control urine fraction (FC1-1), and in inactive fraction HI3 (Figures 13, 14).
Aromatic resonances were present only at trace levels in enriched fractions with higher antiagglutination activity (FA, HF1-1, HI1; Figures 11–14).These aromatic region resonances were
therefore likely due to the presence of simple aromatic acids commonly found in mammalian
urine (Saude et al. 2007, Bouatra et al. 2013).
The dominant 1H NMR resonances present in all active fractions were indicative of
carbohydrates even though the possible presence of monosaccharides within these fractions had
been eliminated through chromatography (see Appendix B-5: Figure 105) and comparisons to
various carbohydrates and other standards (galacturonic acid, apple pectin, D-glucose, sucrose,
fructose, corn starch, sodium citrate, and epicatechin) using multiple TLC spray reagents (e.g.
ninhydrin, p-anisidine, bromocresol green) (not shown). The use of TLC spray reagents that
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produced color reactions indicative of flavonoids (e.g. vanillin, p-anisaldehyde) further
indicated that PACs and other flavonoids were not present in the active fractions (not shown).
Inactive Sephadex LH-20 fractions also lacked the characteristic profile present in the HPLCELSD spectra of active urine fractions (Figures 15, 16). It was therefore concluded that the
active components of interest in enriched samples were complex oligosaccharides.

Figure 5. Comparison of the 1H NMR spectra for FA and fractions FA1–FA5, 400 MHz, D2O.
Fraction FA1 and FA2 exhibited the best anti-agglutination activity but could not be
significantly distinguished from the other FA fractions using NMR data alone. The FA1
fraction also resulted in a low resolution NMR spectra.
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Figure 6. The 1H NMR spectrum of pectin (from apples) reference sample, 400 MHz, D2O.
The overlapping resonances between 3–5.5 ppm are indicative of numerous monomeric
carbohydrate substituents with similar chemical shift values.

Figure 7. The 1H NMR spectrum of galacturonic acid reference sample, 400 MHz, CDCl3.
Pure galacturonic acid, one of the monomer components of pectin yields an NMR spectrum
with distinct resonances. This spectrum has little similarity to that of pectin or urine samples of
interest.
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Figure 8. HPLC of HF1-1 visualized by ELS and UV (max plot).
Comparison of the ELS and UV chromatograms for the active urine fraction HF1-1 indicates
that a set of major fraction components (box) is not visible by UV detection methods. Similar
UV-transparent components were present in the active FA1 fraction without the presence of
additional UV-absorbing components (see Appendix B-5: Figure 108). The semi-quantitative
nature of ELSD makes it possible to determine that the UV-visible component of HF1-1 is of
relatively low concentration (arrows) (see Appendix B-4: ELSD overview).
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Figure 9. Comparison of the 1H NMR spectra for active fractions FA1 and HF1-1, 400 MHz,
D2O.
The FA1 and HF1-1 materials both had activity in the anti-agglutination assay and produced 1H
NMR spectra with similar profiles even though the parent material was collected from different
source animals. The HF1-1 spectrum showed improved resolution over that of FA1 but still
provided insufficient information for structural assignments.

Figure 10. The 1H NMR spectra of synthetic PAC oligomers, 400 MHz, Acetone-d6.
Spectra for the proanthocyanidin trimer and pentamer both contained sets of complex
multiplets in the 6.2 – 8.5 ppm region corresponding to the multiple aromatic protons present in
these compounds.
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Figure 11. Comparison of the 1H NMR spectra for FC1-1, HF, FA and HF1-1 samples, 400
MHz, D2O.
Fraction 1H NMR profiles changed as samples increased in anti-agglutination activity, from
inactive (FC1-1), to probably active (HF), to active (FA), to highly active (HF1-1).
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Figure 12. Comparison of the 1H NMR spectra for FC1-1, HF, FA and HF1-1 samples,
expansion of the aromatic region, 400 MHz, D2O.
Samples with a higher degree of activity (FA1 and HF1-1), and, presumably, a corresponding
higher degree of enrichment for active components, lacked aromatic resonances, while inactive
samples and samples with lower or no activity (HF and FC1-1, respectively) contained these
resonances.
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Figure 13. Comparison of the 1H NMR spectra for HI1, HI2, and HI3, D2O, 400 MHz.
Fraction HI1 had the highest activity, fraction HI2 had moderate activity and fraction HI3
lacked activity.

Figure 14. Comparison of the 1H NMR spectra for HI1, HI2, and HI3, expansion of the
aromatic region, D2O, 400 MHz.
The fraction with highest activity, HI1, lacked distinct resonances in the aromatic region.
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Figure 15. Analytical HPLC-ELSD of Sephadex LH-20 fractions HF1-1, HF1-2, and HF1-3
(AtldC18).
The UV transparent components of interest (box) identified in the active fraction HF1-1 are
detectable at low concentrations in the moderately active fraction HF1-2 and absent from the
inactive fraction HF1-3. All three of these samples were injected at the same concentration.
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Figure 16. Analytical HPLC-UV (Max Plot) of Sephadex LH-20 fractions HF1-1, HF1-2, and
HF1-3 (AtldC18).
The ELS-detectable components present at 18-22 min (box) in Figure 15 are not detectable by
UV spectroscopy using wavelengths of 210-400 nm (Max Plot).
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5. Isolation of Urine Oligosaccharides from H & I Source Materials
a. Sephadex LH-20 Fractionation
The H and I urine samples were separately extracted with EtOAc and fractionated
following the Sephadex LH-20 protocols developed for F urine samples (Figure 3; Tables 4–6).
As with the F urine fractions, the major active constituents remained in the aqueous layer after
EtOAc extraction and eluted early from a Sephadex LH-20 column, with fractions HF1-1, HI1,
and HI2 giving the best anti-agglutination assay results of the enriched samples tested (Tables
13, 14). All fractions were not tested to conserve material, and comparisons of the HPLCELSD profiles of active and inactive fractions were used to guide isolation efforts (Figures 17–
21). Comparative analysis via HPLC-ELSD indicated that a series of UV-transparent
compounds with a distinct profile, eluting between 17–25 min (Figure 17) with optimized
HPLC methods, was consistently present in all active samples and absent from inactive
samples. The HF2-2 fraction series (Figures 19–21) is representative of the HPLC-ELSD
fraction profiles observed for the HF and IF Sephadex LH-20 column fractions.
Method development for HPLC separations was pursued under the new paradigm that
the target compounds were carbohydrates. Purification for all components of the UVtransparent mixture was attempted, but these efforts were complicated by many factors related
to the structural nature of the compounds, the complexity of the mixture, and the
chromatographic systems used.
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Figure 17. Comparison of the HPLC-ELSD data for active fraction HF1-1 and untested samples
IF1-2, IF1-3, HF2-2, showing a similar profile of ELS detectable peaks.
The profile of peaks eluting in the region of interest for each sample was similar. The gradient
used for the HF1-1 sample was slightly different than that used for the other samples, resulting
in shifts of retention times but a similar overall profile.
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Figure 18. Analytical HPLC-ELSD of IF1-1, IF1-2, and IF1-3 (AtldC18).
The components of interest (18–24 min) were readily detectable in Sephadex LH-20 fractions
IF1-2 and IF1-3 but could only be detected at trace levels in fraction IF1-1.
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Figure 19. Analytical HPLC-ELSD of HF2-1, HF2-2, and HF2-3 (AtldC18).
The components of interest (18–24 min, box) were predominantly present in Sephadex LH-20
fraction HF2-2 with trace amounts present in fractions HF2-1 and HF2-3.
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Figure 20. Analytical HPLC-ELSD of HF2-2, HF2-3, HF2-4 and HF2-5 (AtldC18).
The components of interest (22–28 min) present in Sephadex LH-20 fraction HF2-2 were
detected at trace levels in fraction HF2-3, and were not detected in fractions HF2-4, and HF2-5.
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Figure 21. Analytical HPLC-UV (Max Plot) of HF2-2, HF2-3, HF2-4 and HF2-5 (AtldC18).
The components of interest (22–28 min) present in Sephadex LH-20 fraction HF2-2 were not
detectable by UV and the HF2-2 fraction could not be readily distinguished from the other
fractions using only UV detection.
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b. Preparative AtldC18 HPLC-ELSD
Reverse phase HPLC separations were performed with H and I Sephadex LH-20
fractions that contained UV-transparent oligosaccharides by ELSD and 1H NMR spectroscopy,
starting with those fractions that were available in the highest quantity (Table 16). These
included HF1-1, HF1-2, HF1-3, HF2-1, HF2-2, IF1-1, IF1-2 and IF1-3 (Table 6).
The majority of the HF1-1, HF1-2, and HF1-3 samples were used for method
development. Attempts were made to resolve the components of these fractions using direct
injection onto both XTMSC18 and Polyamine semi-preparative columns with both PDA and/or
ELS detection, but were unsuccessful at yielding pure compounds. The fractions collected from
these separations were not combined with later materials due to the differences in the
chromatographic methods used. Efforts were also made to isolate compounds from the inactive
fraction HF2-6 and the compounds isolated were found to be known urinary metabolites (not
shown).
Once an acceptable method was obtained, the same or highly similar methods were used
for all subsequent separations and the results are included below (Tables 18, 19; Figures 22–
24). H and I fractions were initially kept separate with the goal of identifying and comparing
the components from both source animals. As isolation efforts proceeded, chromatographic
profiles indicated that the components of both samples were similar and selected fractions from
both materials were therefore combined. Aliquots of fractions that were available in lower
quantities were co-injected with samples from more abundant fractions to aid in the alignment
of peaks, to account for instrument variations between separations, and to account for possible
sample matrix effects.
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Attempts at method optimization during preparative separations led to several method
variations. The method for HF2-2 R1 used 5 min at 100% water, a 30 min gradient to 30%
MeOH, and a 20 min gradient to 100% MeOH. The ELSD conditions were adjusted for HF2-2
R1. Initial conditions were an evaporator temperature of 100 oC, a nebulizer temperature of 50
o

C, and a gas flow rate of 1.0 SML. At 40 min into the separation, corresponding to 50%

MeOH, the evaporator temperature was changed to 90 oC to account for the increase in the
percentage of organic solvent. This modification did not improve detector resolution and
changes to the evaporator temperature were not made in subsequent separations. The method
for HF2-2 R2–R6, IF1-2 R1, IF1-3 R1–R3, and HF2-1+IF1-1 R1 used 5 min at 100% water, a
30 min gradient to 20% MeOH, and a 10 min gradient to 100% MeOH. The method for HF21+IF1-1 R2 used modified gradient times with 5 min at 100% water, a 10 min gradient to 20%
MeOH, and a 30 min gradient to 100% MeOH. The ELSD conditions were maintained at an
evaporator temperature of 100 oC, a nebulizer temperature of 50 oC, and a gas flow rate of 1.0
SML.
Selected fractions of the AtldC18 preparative separations were combine across different
parent materials: HF2-2P1t20, IF1-3P1t20, H/IF2/1-1P1t20 were combined into fraction HF22P1t20, and HF2-2P1t22 + IF1-3P1t22 were combined into fraction HF2-2P1t22 (17.1 mg).
Both 1D and 2D NMR data were acquired for HF2-2P1t20 and HF2-2P1t22 combined samples
(Figures 25–27).
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Table 16. Details of preparative-scale sample preparations for AtldC18-based separations of
oligosaccharide-containing Sephadex LH-20 fractions.
Samples were assessed by analytical HPLC-ELSD to determine their composition prior to
preparative separation. All of the fractions show below were determined to contain the
components of interest.
Sample
Filter Sample
Parent
Amount
Injected per Run
Separation
Dissolved In Wash
Vol.
Fraction
(mg)
(mg/µL)
Dates
Water (µL)
(µL)
(µL)
IF1-1

12

200

200
a

400

HF2-2

122

675

500

775

HF2-2

208

800

200

1000

IF1-2

53.3

250 (HF2-2
wash)b

100

250

IF1-3

182

600 (+ IF1-2
wash)b

150
(IF1-2
wash)b

750

HF2-1 +
IF1-1c

67.5 +
59.7

300

200

500

a

R1: 6 mg/200 µL
R1: 50/250
R2: 50/275
25/150a + IF1-2R1
R3: 50/250
R4: 50/250
R5: 50/250
R6: 50/250
R1: 53.3+/250
(contained small
amount of HF2-2)
R1: 60/250
R2: 60/250
R3: 60/250
R1: 60/250
R2: 60/250

2009/06/24
2009/07/09

2009/07/10

2009/07/10
2009/07/10
2009/07/14

This material was combined with the sample shown.
The filter wash collected from the fraction shown was used as the dilution solvent for this
material
c
These fractions were determined to be sufficiently similar by analytical HPLC-ELSD to
justify combining them.
b
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Table 17. Combined preparative HPLC fractions resulting from HF2-2 and IF1-2 separations,
designated HF2-2P1.
Fractions t20 and t22 were analyzed by NMR spectroscopy and the results are discussed below.
Fraction mg Notes
Retention
Time (min)a
1.7–3.7
03
92.9
3.7–4.57
04
14.4
4.57–5.52
05
10.4
5.52–9
06-09
13.1
18.3–19.4
19
10.6
19.4–20.0
20 *
11.9 Major fraction of interest
20.0–20.8
21
8.0
20.8–22.0
22 *
17.1 Major fraction of interest
22.0–24.0
24
14.7
24.0–25.0
25
25.0–26.0
26
5.1
Baselineb
B
a
Time points for fraction numbers were based on HF2-2 R4 and R5.
b
Baseline contains all peaks not accounted for by other time points.

Table 18. Combined preparative HPLC fractions resulting from IF1-3 separations, designated
IF1-3P1.
Fractions t20 and t22 from these separations appeared to have the same composition as
analogous fractions from the HF2-2 and IF1-2 parent materials.
Retention
Fraction mg Notes
Time (min)
1.7–3.7
03
77.6
3.7–5.0
04
10.1
5.0–8.3
05-08
14.2
8.3–11
08-11
8.0
18.5–19.4
19
4.3
19.4–20.0
19.5
2.4
20.0–20.5
20 *
4.3 Major fraction of interest
20.5–21.4
21
16.4
21.4–22.0
22 *
3.5 Major fraction of interest
22.0–22.8
22.5
2.7
22.8–23.5
23
2.1
23.5–24.1
24
2.3
24.1–25.0
25
1.7
25.0–60
B
25.4
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Table 19. Combined preparative HPLC fractions resulting from HF2-1 and IF1-1 separations,
designated H/IF2/1-1P1.
The HF2-1 and IF1-1 fractions were determined to be of similar composition and the
subfractions from these separations were therefore combined.
Retention Time (min) Fraction mg Notes
R1
R2
R1 + R2
1.5–7.0
1.5–8.5
02
24.2
7.0–14
8.5–11.5 B
Part of baseline
14–22.6
11.5–15.0 20
12.6 Major fraction of interest
22.6–37.7 15.0–17.5 25
17.0
37.7–48.0 17.5–30.0 40
32.9
48.0–70.0 30.0–60.0 B
Part of baseline

Figure 22. Preparative HPLC-ELSD of HF2-2, R1 (AtldC18).
The gradient used for this separation varied from that used for subsequent separations. ELSD
parameters were also changed during this separation in an effort to improve ELSD resolution,
but resulted in no apparent improvement. The parameters used for subsequent separations
(below) were preferred for later separations.
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Figure 23. Preparative HPLC-ELSD of HF2-2, R2-6 (AtldC18).
Retention times were similar across preparative separations and chromatographic resolution
was not significantly affected by slight variations in injection volumes or sample amounts.
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Figure 24. Preparative HPLC-ELSD of IF1-2 and IF1-3 R1–3 (AtldC18).
Retention times were similar across preparative separations and chromatographic resolution
was not significantly affected by slight variations in injection volumes or sample amounts.
Fractions from the IF1-2 separation (top pane) were combined with those of HF2-2 to give
HF2-2P1 subfractions, and fractions from the IF1-3 separations were combined to give IF1-3P1
subfractions.
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Figure 25. Comparison of the 1H NMR spectra for HF2-2P1t20 and HF2-2P1t22 showing
highly similar composition, DMSO-d6, 400 MHz.
The HF2-2P1t20 sample was later determined to be relatively pure while HF2-2P1t22 was
determined to be a mixture of three major components in approximately equal amounts.
Resonances were not present in the regions of the spectra that are not displayed.

Figure 26. Comparison of the 13C NMR spectra for HF2-2P1t20 and HF2-2P1t22 showing
highly similar composition, DMSO-d6, 400 MHz.
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Figure 27. Comparison of the HMQC spectra for HF2-2P1t20 and HF2-2P1t22 showing the
similarity of composition for these fractions, DMSO-d6, 400 MHz.
The anomeric, methylene, and glycosyl ring regions are indicated for the HF2-2P1t22
spectrum. Integration of the anomeric region of the 1H NMR spectrum and consideration of the
data shown here led to the refined working hypothesis that the carbohydrates of interest were
oligosaccharides with 7-9 monomeric units. It was later determined that a reducing glucosyl
unit was responsible for two of the anomeric resonances shown and that the two high intensity
resonances indicated for the HF2-2P1t20 spectrum were duplicated anomeric resonance sets
corresponding to two Xyl and two Ara residues.
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c. Semi-Preparative Polyamine HPLC-ELSD
Methods for semi-preparative separations were developed using the refined working
hypothesis that the compounds of interest were oligosaccharides. Fractions eluting from the
AtldC18 column were combined based on retention time and profile and were further analyzed
by normal-phase analytical HPLC-ELSD (Figures 28–30). Selected fractions were further
purified using the Polyamine column (Figures 31– 34, Table 20). Resulting Polyamine fractions
were cautiously combined across parent materials in an effort to obtain sufficient material for
detailed structural analysis. Analytical scale HPLC-ELSD data (Figures 28–30) and
considerations of the results of sample co-injections (Table 20) were both used to aid in
comparisons and sample fraction combinations (Tables 21–26).
Fraction HF2-2P1t24 was used to evaluate the effects of changes in starting solvent
percentages and gradient length on the resolution of semi-preparative separations. A consistent
flow rate of 4 mL/min was used for all separations. The method for HF2-2P1t24 R1 used
MeCN:water, with 10 min at 70% MeCN, a 30 min gradient to 40% MeCN, and a 3 min
gradient to 70% MeCN. The method for HF2-2P1t24 R2 used MeCN:water, with 5 min at 65%
MeCN, a 30 min gradient to 40% MeCN, and a 3 min gradient to 65% MeCN. The method for
HF2-2P1t24 R3–R5 (Figure 31) used MeCN:water, with 5 min 65% MeCN, a 25 min gradient
to 45% MeCN, and a 3 min gradient to 65% MeCN. This last method was also used for HF22P1t21 R1–R5 and later separations.
Initial ELSD conditions used for HF2-2P1t24 were an evaporator temperature of 90 oC,
a nebulizer temperature of 45 oC, and a gas flow rate of 1.0 SLM. The instrument configuration
and ELSD conditions were modified for HF2-2P1t21 and later separations with changes in the
ELSD inlet tubing to give 3.9 mL/min to collection and 0.1 mL/min to ELS detection. These
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changes dictated that the ELSD gas flow rate be decreased to 0.8 SLM to maintain sensitivity;
other temperature conditions remained the same.
Fractions from Polyamine separations were minimally combined due to minor shifts in
retention times between samples and the difficulties of obtaining NMR data on small quantities
of material. The three major components of the HF2-2P1t22 fraction (A17, A18 and A19;
Figure 33; Table 25) were of interest, but the 1H NMR (Figure 35) and LC-MS data for these
fractions could not be reliably interpreted and insufficient material was available for further
analyses at the time.
All fractions that corresponded to HF2-2P1t20A17 (Table 26) were combined and the
resulting material was further purified using the same Polyamine method as before to yield a
single major component. This material was submitted for CCRC derivatization analyses and for
high resolution NMR data at 700 MHz.
Fraction 02 and baseline elutions (B) were combined across all HF and IF separations.
These materials had low solubility in either DMSO or water, yielding precipitate and cloudy
solutions. Preliminary 1H NMR data was acquired for these samples in an attempt to determine
the nature of these fractions but provided little useful information.
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Figure 28. Analytical HPLC-ELSD comparisons of AtldC18 fractions HF2-2P1t19, IF13P1t19, and IF1-3P1t23 showing the composition of these fractions in support of preparative
combinations (Polyamine).
Fractions HF2-2P1t19 and IF1-3P1t19 were combined for semi-preparative separations while
IF-3P1t23 was combined with IF1-3P1t22.5 (Figure 30) based on the results of additional
analytical analyses (not shown).
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Figure 29. Analytical HPLC-ELSD comparisons of AtldC18 fractions HF2-2P1t19, IF13P1t20, and IF1-3P1t25, and showing the composition of these fractions in support of
preparative combinations (Polyamine).
The parent fractions shown here were determined to be distinct enough to warrant independent
separations and fraction recombinations. Fraction IF1-3P1t20 appears to contain the same
major component as HF2-2P1t20.
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Figure 30. Analytical HPLC-ELSD comparisons of AtldC18 fractions HF2-2P1t21, IF13P1t22, IF1-3P1t22.5 and HF2-2P1t24, and showing the composition of these fractions in
support of preparative combinations (Polyamine).
The parent fractions shown here were determined to be distinct enough to warrant independent
separations and fraction recombinations.
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Table 20. Details of semi-preparative-scale sample preparations used for Polyamine-based
separations of HF and IF AtldC18 fractions.
Samples were separated in the sequential order shown (Separation Date) and chromatographic
separations with the same date were often performed back-to-back within a single session.
Sample Filter Sample
Parent
Amount
Injected per Run Separation
Dissolved Wash
Vol.
Fraction
(mg)
(mg/µL)
Date
In (µL)
(µL)a
(µL)
R1: 2/20
R2: 4/40
HF2-2P1t24
14.7
150
0
150
2009/10/04
R3: 4.5/45
R4, R5: 3.5/35b
IF1-2P1t24 +
Added to HF26.8
45b
25
70
2009/10/04
HF2-2P1t24c
2P1t24 R4 & R5
R1: 4.3/35
2009/10/04
HF2-2P1t21 +
8.0
200
0
200
R2:
5.5/45
IF1-3P1t21c
16.4
R3: 4.9/40
HF2-2P1t21 +
80
(prev.
R4: 5/60
(9.76)d
40
120
2009/10/11
c
IF1-3P1t21
sample)
R5: 5/60
R1: 4.0/30
HF2-2P1t19
10.6
75
0
80
6.6/50 added to
2009/10/11
MixR1–R2
R1: 3.3/40
IF1-3P1t19 +
4.3 +
60
20
80
3.4/40 added to
2009/10/11
IF1-3P1t19.5c
2.4
MixR1–R2
HF2-2P1t19
(6.6)d
MixR1: 4.2/50
50 + 45
25
120
2009/10/12
c
d
IF1-3P1t19
(3.4)
MixR2: 5.8/70
IF1-3P1t20
4.3
30
0
30
R1: 4.3/30
2009/10/12
R1: 2.5/50
IF1-3P1t22
3.5
25
45
70
1.0/20 added to
2009/10/12
IF1-3P1t23 R2
IF1-3P1t23 +
2.1 + 2.7
R1: 3.2/60
50
40
90
2009/10/12
c
d
IF1-3P1t22.5
+ (1.0)
R2: 2.6/50a
R1: 5.3/40
R2: 4/30
HF2-2P1t22
17.1
100
50
130
2009/10/14
R3e: 5.3/40
R3: 5.0/40b
R1: 4/50
R2: 2/25
HF2-2P1t20
11.9
50
90
140
R3, R4: 2.4/30
2009/10/14
1.1/10 added to
HF2-2P1t22 R3
a
Samples for which the filter wash amount is 0 µL were not filtered. b Contained material from
an additional parent fraction. c These fractions were determined to be sufficiently similar by
analytical HPLC-ELSD to justify combining them during separations. d Material from a
previously prepared sample. e Sample and data were lost due to instrument/operator
malfunction.
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Table 21. Combined semi-preparative HPLC fractions resulting from HF2-2P1t24 separations,
designated HF2-2P1t24A.
Fractions eluting at t16, t18, t20 and t22 were assessed by 1H NMR spectroscopy and were
found to contain-closely related oligosaccharides, but full structural assignments could not be
made.
Fraction mg Notes
Retention
Time (min)a
1.2–15
02
1.2 few compounds between 0–6, low % of sample
15.0–16.0
15
0.5
16–16.8
16 *
0.8 Major component of interest
16.8–17.6
17
0.6
17.6–18.7
18 *
1.6 Major component of interest
18.7–19.8
19
0.9
19.8–20.8
20 *
1.7 Major component of interest
20.8–21.5
21
0.3
21.5–22.5
22 *
0.8 Major component of interest
22.5–24.0
23
0.4
a
Time points for fraction numbers were based on R2, as R1 had an extended gradient time.

Table 22. Combined semi-preparative HPLC fractions resulting from HF2-2P1t21 and IF13P1t21 separations, designated HF2-2P1t21A.
Fractions eluting at t15, t17, and t21 were assessed by 1H NMR spectroscopy and were found to
contain closely-related oligosaccharides, but full structural assignments could not be made.
Retention
Fraction mg Notes
Time (min)a
0–2.5
02
large peak, inconsistent profile, large % of sample
2.5–14
04
2.9 multiple peaks between start and 8 min –
inconsistent retention times
14–15
14
1.2
15–16
15 *
1.1 Major component of interest
16–17
16
0.9
17–18
17 *
1.2 Major component of interest
18–18.5
18
0.5
18.5–19.2
19
0.9 first of 19–20 double peak
19.2–20
20
1.0 second of 19–20 double peak
20–21
21 *
1.2 Major component of interest
21–21.5
21.5
0.4 shoulder of 21
21.5–23
22
0.6
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Table 23. Combined semi-preparative HPLC fractions resulting from HF2-2P1t19, IF1-3P1t19
and IF1-3P1t19.5 separations, designated HF2-2P1t19A.
Fraction mg Notes
Retention
a
Time (min)
0–3
2
4.6
3–4
4
0.5
4–13
B
3.0 flat line before eluting peak set
13–14.5
14
0.2 first minor peak
14.5–16.5
15
0.6 baseline peaks between 14 and 17
16.5–17.5
17 *
1.9 major peak for t19 fractions, possibly same as
HF2-2P1t20A17
17.5–18.5
18
0.5 side peak of 17 (minor component)
18.5–20
19
0.4 last minor peak of set
20–22
21
0.3 baseline peaks tailing off end of separation
a
Time points for fraction numbers were based on HF2-2t19R1 & IF1-3t19R1.

Table 24. Combined semi-preparative HPLC fractions resulting from IF1-3P1t22 and IF13P1t23 separations, designated IF1-3P1t23A.
Fractions eluting at t15, t16, and t18 were assessed by 1H NMR spectroscopy and were found to
contain closely-related oligosaccharides, but full structural assignments could not be made.
Retention
Fraction mg Notes
a
Time (min)
1.3–4.0
2
4.0–13.5
B
baseline between early eluting
impurity and major peak set
14.5–16
15 *
0.6 Major component of interest
16–17
16 *
0.5 Major component of interest
17–18
17
0.5
18–19
18 *
1.0 Major component of interest
19–20
19
0.9
20–21.5
21
0.9 mix of baseline minor components
21.5–22.5
22
0.8 mix of baseline minor components
a
Times points for fraction numbers were based on IF1-3P1t23 R1.
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Table 25. Combined semi-preparative HPLC fractions resulting from HF2-2P1t22 separations,
designated HF2-2P1t22A.
Fractions eluting at t17, t18, and t19 were assessed by 1H NMR spectroscopy and were found to
contain closely-related oligosaccharides, but full structural assignments could not be made.
Fraction t17 from this separation appears to be the same compound as HF2-2P1t20A17 based
on co-injection of the HF2-2P1t20 and HF2-2P1t22 samples.
Fraction mg Notes
Retention
a
Time (min)
1.3–4.0
2
4.0–13.5
B
baseline between early eluting impurity and major peak set
13.5–14.5
14
0.9
14.5–15.5
15
0.4 minor – almost baseline relative percent
15.5–16.5
16
0.5
16.5–17.5
17 *
1.9 same compound as major component of HF2-2t20
17.5–18.5
18 *
1.8 first major peak of set found in HF2-2t22 sample
18.5–20.0
19 *
1.9 second major peak of set found in HF2-2t22 sample
20.0–22
21
0.4 minor baseline peak set
a
Times points for fraction numbers were based on HF2-2P1t22 R2 as this sample contained a
portion of the HF2-2Pt120 sample.

Table 26. Combined semi-preparative HPLC fractions resulting from HF2-2P1t20 and IF13P1t20 separations, designated HF2-2P1t20A.
Fraction t17 was the primary source of compound 1; other fractions with similar retention times
were combined with this sample and the resulting material was re-purified to yield the sample
of 1 that was submitted to the CCRC for analysis and analyzed by NMR spectroscopy at 700
MHz.
Fraction mg Notes
Retention
Time (min)a
1.3–4.0
02
3.2
4.0–12.5
B
1.1 baseline between early eluting impurity and major peak set
12.5–13.5
13
1.0
13.5–14.5
14
1.6
14.5–15.8
B
baseline peaks just before major component – perhaps one
primary component
15.8–17.8
17 *
8.8 major peak/major component of sample mass
17.8–19
18
0.8 baseline minor peak (mixture)
19–21
20
0.9 baseline minor peak set (mixture)
a
Time points for fraction numbers were based on HF2-2P1t20 R2 & R3.
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Figure 31. Semi-preparative HPLC-ELSD of HF2-2P1t24 R2–5 (Polyamine).
Fractions eluting at t16, t18, t20 and t22 were assessed by 1H NMR spectroscopy and were
found to contain closely-related oligosaccharides.

90

Figure 32. Semi-preparative HPLC-ELSD of HF2-2P1t21 R1–5 (Polyamine).
Fractions eluting at t15, t17, and t21 were assessed by 1H NMR spectroscopy and were found to
contain closely-related oligosaccharides. (% MeCN shown)
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Figure 33. Semi-preparative HPLC-ELSD of HF2-2P1t22 R1–3 (Polyamine).
Fractions eluting at t17, t18, and t19 were assessed by 1H NMR spectroscopy and these data are
discussed further below. The t17 peak for the third separation (R3) is of increased intensity
presumably due to co-injection of a small amount of HF2-2P1t20. If the same compound is
indeed present in the HF2-2P1t22 sample, this data indicates the low resolution obtained with
the AtldC18 separations. The increased intensity of t17 may also indicate, however, similar
retention times for two different components as resulted with many of these fractions (see
Section C5d). Although fraction t17 from this separation appears to be the same compound as
HF2-2P1t20A17 these materials were kept separate.
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Figure 34. Semi-preparative HPLC-ELSD of HF2-2P1t20 R1–4 (Polyamine).
Fraction t17 was the primary source of compound 1. The fraction of IF1-3Pt20 with similar
retention time was combined with this sample. The resulting material was re-purified to yield
the sample of 1 that was submitted to the CCRC for analysis and analyzed by NMR
spectroscopy at 700 MHz. (% MeCN shown)
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Figure 35. Comparison of the 1H NMR spectra for HF2-2P1t22A fractions eluting at 17, 18,
and 19 min, D2O, 400 MHz.
No resonances were present in the spectra regions not displayed. Characteristic resonances
were present at 4.5, 5.0, 5.1 and 5.15 ppm (arrows) in all three spectra shown. These
resonances could not be interpreted at the time these spectra were collected but were later
determined to potentially correspond to the anomeric protons for arabinoxyloglucan type
oligosaccharides. All three spectra are similar to that of 1. HF2-2P1t22A17 may be the same
compound as 1 based on the results of co-injection during preparative separations.
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d. Challenges of HPLC-ELSD-Based Oligosaccharide Isolation
Carbohydrates such as oligosaccharides are often purified using amino or polyamine
stationary phases. Multiple attempts were therefore made to directly separate the components
of HF1-1 using amino, polyamine, and other normal phase sorbents with various solvent
systems and conditions. These efforts did not yield sufficient resolution for the compounds of
interest (Figure 36). Attempts at reverse phase separations with more nonpolar sorbents, such
as the XTMSC18 column, and with sorbent appropriate starting solvents of 10% or more
MeOH or MeCN, were also unsuccessful for retaining and resolving the oligosaccharide
components (Figure 37). The method that yielded the best results employed a reverse phase
AtldC18 column but still did not yield baseline resolution of the components of interest. The
AtldC18 sorbent has polar groups embedded into the silica-bound C18 stationary phase,
allowing complete wetting with water without the need for an organic modifier such as MeOH
or MeCN. The ability to equilibrate and use the column in 100% water appears to have
contributed to the resolution that was achieved with this sorbent.
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Figure 36. Examples of the analytical HPLC-ELSD chromatograms produced during HF1-1
method development with an amino HPLC sorbent.
These HPLC chromatograms correspond to variations in solvent systems (changes in solvent
%, use of MeOH or MeCN) using a YMC NH2 column (4.6 x 150 mm, 5 µm) and a flow rate
of 1 mL/min.
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Figure 37. Examples of the analytical HPLC-ELSD chromatograms produced during HF1-1
method development attempts using a C18 HPLC sorbent.
These HPLC chromatograms correspond to variations in solvent systems (changes in solvent
%, use of MeOH or MeCN) using an XTMSC18 column (4.6 x 150 mm, 5 µm) and a flow rate
of 1 mL/min.
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The enriched fractions obtained from the AtldC18 separations could be further resolved
by amino, polyamine, or other normal phase sorbents. Multiple sorbents and solvent systems
were tested and the polyamine sorbent yielded the best resolution with MeCN as the solvent.
The lack of resolution previously observed for attempts at direct, normal phase separation of
oligosaccharide components could be explained by observations made with AtldC18 fractions.
Fractions collected from a single AtldC18 separation (e.g. IF1-3; Figure 24) were separated
sequentially using the polyamine sorbent with an optimized analytical instrument and
controlled, repeated conditions. Comparisons of the resulting analytical HPLC-ELSD spectra
showed that fractions eluting with different AtldC18 retention times, and therefore different
major components, contained compounds that had similar retention times on the polyamine
sorbent (Figures 38–40). For example, during semi-preparative separation, the IF1-3P1t20
subfraction collected from the AtldC18 column contains a major compound that appears at 16–
17 min on the Polyamine column (Figure 41). This component overlaps in retention time with
compounds in the t22 and t23 subfractions even though they are derived from different parent
AtldC18 fractions and are unlikely to contain the same components. Peaks that appear to
contain single or major components in the AtldC18 chromatogram (e.g. the peak at 22 min;
Figure 24) were also found to contain multiple components when examined on the Polyamine
stationary phase (Figure 39). In non-enriched parent fractions, all such compounds would have
overlapped and led to the observed poor resolution. These phenomena also made the
recombination of fractions from multiple separations especially challenging, as there was little
guarantee, based solely on retention time data, that any two peaks from related fractions
represented the same compounds.
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Figure 38. Analytical Polyamine HPLC-ELSD comparisons of IF1-3 AtldC18 fractions t03,
t05-08, 08-11, 19, and B, showing the changes in elution profile associated with the change in
sorbent.
The fractions shown here eluted at distinct times on the AtldC18 sorbent, but the major
components of each all had similar retention times on the Polyamine sorbent (~18 min). The
lack of distinct components in the IF1-3P1B fraction indicates that the major components of the
IF1-3 parent material have been collected as parts of other fractions.
99

Figure 39. Analytical Polyamine HPLC-ELSD comparisons of IF1-3 AtldC18 fractions t19.5,
t20, t21, t22, and t22.5, showing the changes in elution profile associated with the change in
sorbent.
The fractions shown here eluted at distinct times on the AtldC18 sorbent, but the major
components of each all had similar retention times on the Polyamine sorbent.
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Figure 40. Analytical Polyamine HPLC-ELSD comparisons of IF1-3 AtldC18 fractions t122.5,
t23, t24, and t25, showing the changes in elution profile associated with the change in sorbent.
The fractions shown here eluted at distinct times on the AtldC18 sorbent, but the major
components of each all had similar retention times on the Polyamine sorbent.
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Figure 41. Semi-preparative HPLC-ELSD separations for IF1-3P1 subfractions (Polyamine).
The IF1-3P1t20 subfraction was similar in ELSD profile to the HF2-2P1t20 subfraction and
both were collected at 20 min from the AtldC18 column (Figure 24). This fraction contains a
major compound that appears at 16-17 min (indicated as t17) on the Polyamine column. This
component overlaps in retention time with compounds in the t22 and t23 subfractions (box)
even though these fractions are derived from different parent AtldC18 fractions and are
unlikely to contain the same components.
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A factor that further detracted from efforts to isolate sufficient quantities of pure
oligosaccharides was the requirement for destructive, ELSD-based detection and collection.
The preparative HPLC configuration involved the placement of a flow splitter after the UV
detector but before the ELSD. This splitter directed the majority of the flow to collection
vessels, with a smaller portion directed to the detector. Typically, 2–4% of the eluting solvent
entered the detector for the flow rates of 20–25 mL/min used with the preparative AtldC18
column, but this percentage may have been as high as 10% for the slower flow rates (5–10
mL/min) used with the semi-preparative Polyamine column. At the time, a larger, preparativescale, polyamine column was not available. This arrangement meant that as much as 10% of a
given sample would be lost to the detector with every injection and separation. All attempts
were made with available resources to decrease this percentage of sample loss but such efforts
were limited by the sensitivity and configuration of the detector and by the flow dynamics of
the system.
The issue of poor baseline resolution combined with the need for split detection and
collection further hindered isolation efforts. Steps were taken to design the system in such a
way as to ensure that the sample would reach the detector and the collection vessel at the same
time, but as little as a ten second delay or shift could change the composition of the collected
fraction from that observed on the chromatogram. This phenomenon further contributed to the
need for multi-step purification protocols involving more than one chromatographic sorbent.
Multiple, instrument-related issues could also interfere with the re-combination of
fractions from different samples based on retention times. These were typically due to (a)
alterations in HPLC instrument configuration due to clogged tubing or leaks, (b) changes in
HPLC instrument performance due to inappropriate methods of switching between normal and
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reverse solvent systems, and (c) decreased detector sensitivity or response due to the deposition
of unknown, insoluble sample materials on the ELSD nebulizer, within the evaporator tube, or
on the detection optics. Most of these issues were due to abuse of the instruments by other
individuals.
Numerous efforts were therefore made to ensure the stability of the chromatographic
system to achieve repeatable retention times and to maintain the highest possible detector
sensitivity. For the majority of samples, material was divided into portions that were
intensively separated over a series of back-to-back preparative separations. Instrument
performance was checked with known samples prior to batches of separations and instrument
back-pressure data was acquired with every separation to monitor instrument and column
performance. Sets of separations were also typically performed over a period of several days
when the instrument was not accessible to other users.
The amounts of material obtained for AtldC18-Polyamine purified fractions (0.5–5 mg)
were typically insufficient to obtain quality 1H NMR data. This was likely due partly to the
high-MW of the compounds in question and partly to the high resonance overlap inherent to
oligosaccharides. The oligosaccharide nature of many purified compounds could be established
by 1H NMR, but the data obtained could often not reliably distinguish two components that
were known to have different retention times and originated from different parent fractions.
These issues further contributed to the difficulty of recombining samples to obtain higher
quantities and additional data. For most samples, sufficient purity could not be assured for the
pursuit of chemically based structure elucidation approaches, and the limited quantities
available made additional ELSD-based separations impractical due to the losses inherent to the
system.
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Many of these factors did provide useful information even though they made isolation
and structural characterization challenging. The difficulty of obtaining baseline resolution
between the components of the series indicated that the compounds present possessed similar
chromatographic properties, most likely due to similar structures. Similarities in the NMR data
that could be obtained indicated that many of the distinct compounds present have structures
closely related to that subsequently established for 1.

6. Structure Elucidation
The primary and secondary structure of 1 was established using standard carbohydrate
derivatization and analysis procedures, MSn fragmentation data, and 1D and 2D NMR
experiments as discussed below.
a. Results of Carbohydrate Derivatization Analyses
Glycosyl composition analysis by GC-MS of the TMS methyl glycosides of 1 indicated
it was composed of arabinose, xylose and glucose with a molar ratio of 1:1:2 (Table 27). Mass
fragments of the TMS methyl glycosides at m/z 204 and 217 (not shown) indicated that 1
contained neutral sugars. MALDI-TOF-MS (Figure 42) analysis showed an [M+Na]+ ion of
1218.117 for the highest intensity molecular ion, consistent with an octasaccharide composed
of two arabinosyl, two xylosyl and four glucosyl residues.
GC-MS analysis of the (S)-(+)-butyl glycoside TMS derivatives of 1 as compared to
standards (Figure 43) indicated that the absolute configurations of these residues were D-Glc,
D-Xyl, and L-Ara, consistent with the natural abundances of these monosaccharides.

The linkage positions on each monomer were determined using partially methylated
alditol acetate derivatives of 1 (Jahfar & Azadi 2004). These data, when evaluated in
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conjunction with the molar ratio and mass results, indicated that 1 contained two terminallylinked arabinofuranosyl residues, two 2-linked xylopyranosyl residues, one terminally-linked
glucopyranosyl residue, one 4-linked glucopyranosyl residue, and two 4,6-linked
glucopyranosyl residues. The 2-linked xylopyranosyl residues, the 4-linked glucopyranosyl
residue, and the 4,6-linked glucopyranosyl residues could also be linked through the anomeric
position.
Further MS and NMR analyses were used to confirm glycosyl linkages, to confirm
connectivity through anomeric positions, and to assign anomeric configurations.

Table 27. Results of the glycosyl composition analysis for 1.
Arabinose, xylose, and glucose were determined to be the monosaccharides present in 1 in a
ratio of 1:1:2.
Residue
Weight (µg) Mole%
Arabinose (Ara)
26.5
22.0
Ribose (Rib)
0.0
0.0
Rhamnose (Rha)
0.0
0.0
Fucose (Fuc)
0.0
0.0
Xylose (Xyl)
30.4
25.1
Glucuronic Acid (GlcUA)
0.0
0.0
Galacturonic Acid (GalUA)
0.0
0.0
Mannose (Man)
0.0
0.0
Galactose (Gal)
0.0
0.0
Glucose (Glc)
76.7
52.9
N-Acetyl Galactosamine (GalNAc)
0.0
0.0
N-Acetyl Glucosamine (GlcNAc)
0.0
0.0
Heptose (Hep)
0.0
0.0
3 Deoxy-2-Manno-2-Octulsonic Acid (KDO)
0.0
0.0
Sum
100
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Figure 42. Results of the MALDI-MS analysis for 1 showing an m/z of 1218.117 corresponding
to the sodium adduct of the compound in the (+) ionization mode.
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Figure 43. Results of the GC-MS analysis of the TMS derivatives of (S)-(+)-butyl glycosides of
authentic standards D-Glc, L-Ara, D-Xyl and 1.
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b. Partial Fragmentation Pattern Analysis for Linkage Positions
A pure sample of 1 was derivatized via per-O-methylation and then subjected to NSIMS with fragmentation by CID in MS/MS and MSn modes using direct infusion of the sample.
As the only material in the sample was the compound of interest, resulting fragment ions were
presumed to have been generated from this material. The derivative produced from 1 was
detected as singly and doubly (2+) charged species (Figure 44) and selected ions were
subjected to additional fragmentation (Figures 44–58).
Two possible structures for 1 were consistent with the data from previous analyses
(Figure 45). These could be distinguished using the results of the fragmentation pattern
analysis, even though mass fragments were only generated at unit resolution due to the nature
of the method used. Methylation patterns and knowledge of typical fragmentation sites
(glycosidic bonds) and fragmentation sequences for oligosaccharides made it possible to
distinguish between different mass fragments and associate the resulting mass losses with the
two putative structures for 1 (Domon et al. 1990, Costello & Vath 1990, Hisamatsu et al. 1992,
York et al. 1996). Terminal, internal, and reducing glucopyranosyl residues could be
distinguished based on unit mass differences of 218 (terminal), 190 (internal), and 236
(reducing) amu. Arabinofuranosyl and xylopyranosyl residues could also be distinguished
based on mass losses of 174 and 160 amu, respectively, or 334 amu for an Ara-Xyl side chain.
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Figure 44. Results of the NSI-MS-based glycosyl linkage analysis showing mass fragments for
the per-O-methylated derivative of 1.
The per-O-methylated derivative of 1 was detected as singly and doubly (2+) charged species.
The parent ion at m/z 1526 was selected for further fragmentation.
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Figure 45. Possible structures for 1 showing alternate placements of a Xyl-Ara side chain on
either Glcp-B (a) or Glcp-A (b).

111

The NSI-MS2 fragmentation at m/z = 1526 for the per-O-methylated derivative of 1
(Figure 46) gave indicative mass fragments of m/z 1352, 1308, 1290, 1192, and 784. The mass
fragment of m/z 1352 is consistent with the loss of a terminal arabinose (∆m/z = 174), m/z 1308
is consistent with the loss of terminal glucose (∆m/z = 218), m/z 1290 is consistent with the loss
of reducing end glucose (∆m/z = 236), m/z 1192 is consistent with the loss of a terminal
arabinose and an internal xylose (∆m/z = 334), and m/z 784 is consistent with the loss of a
terminal arabinose, an internal xylose, an internal glucose and a terminal glucose (∆m/z = 742).
These mass fragments were consistent with structure (a) (Figure 47), as structure (b) (Figure
48) did not result in the production of an m/z 1290 fragment corresponding to the loss of a
reducing end glucose (∆m/z = 236).

Figure 46. The NSI-MS2 fragmentation at m/z = 1526 for the per-O-methylated derivative of 1.
Mass losses of ∆m/z 174, 218, 236, and 334 were indicative of key putative fragments
consistent with structure (a). Ions at m/z 1308 and 1352 were selected for further fragmentation.
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Figure 47. Structure (a) putative mass fragments produced from the m/z = 1526 parent ion of
per-O-methylated 1.
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Figure 48. Structure (b) putative mass fragments produced from the m/z = 1526 parent ion of
per-O-methylated 1.
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The NSI-MS3 fragmentation at m/z = 1526 → 1308 for the per-O-methylated derivative
of 1 (Figure 49) gave indicative mass fragments of m/z 1134, 1072, 974, and 784. The mass
fragment of m/z 1134 is consistent with the loss of a terminal arabinose (∆m/z = 174), m/z 1072
is consistent with the loss of a reducing end glucose (∆m/z = 236), m/z 974 is consistent with
the loss of a terminal arabinose and an internal xylose (∆m/z = 334), and m/z 784 is consistent
with the loss of a terminal arabinose, an internal xylose, and an internal glucose (∆m/z = 524).
These mass fragments were consistent with structure (a) (Figure 50), as the putative m/z 1308
fragment of structure (b) (Figure 51) did not produce a fragment at m/z 1072 corresponding to
the loss of a reducing end glucose (∆m/z = 236).

Figure 49. The NSI-MS3 fragmentation at m/z = 1526 → 1308 for the per-O-methylated
derivative of 1.
This spectrum was generated using CID = 30%. Mass losses of ∆m/z 174, 236, 334, and 524
were indicative of key putative fragments consistent with structure (a).
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Figure 50. Structure (a) putative mass fragments produced from the m/z = 1308 fragment of
per-O-methylated 1.
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Figure 51. Structure (b) putative mass fragments produced from the m/z = 1308 fragment of
per-O-methylated 1.
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The NSI-MS3 fragmentation at m/z = 1526 → 1352 for the per-O-methylated derivative
of 1 (not shown; see Figures 47, 48 for putative structures of the m/z 1352 ion) yielded a high
intensity, indicative fragment at m/z 1192, with additional low intensity mass fragments of m/z
1178, 1017, 955, 857, and 784. The m/z 1178 fragment was consistent with the loss of a
terminal arabinose (∆m/z = 174), and the m/z 1192 fragment was consistent with the loss of an
internal xylose (∆m/z = 160). The fragmentation pattern for the m/z 1352 ion was of minimal
utility in distinguishing between the two putative structures for 1, and the highest intensity ion
at m/z 1192 was therefore selected for further fragmentation.
The NSI-MS4 fragmentation at m/z = 1526 → 1352 → 1192 for the per-O-methylated
derivative of 1 (Figure 52) gave indicative mass fragments of m/z 1017, 974, 955, 857, and 784.
The mass fragment of m/z 1017 is consistent with the loss of a terminal arabinose (∆m/z = 174),
m/z 974 is consistent with the loss of a terminal glucose (∆m/z = 218), m/z 955 is consistent
with the loss of a reducing end glucose (∆m/z = 236), m/z 857 is consistent with the loss of an
internal xylose and a terminal arabinose (∆m/z = 334), and m/z 784 is consistent with the loss of
a terminal and an internal glucose (∆m/z = 408). These mass fragments were consistent with
structure (a) (Figure 53), as the putative m/z 1192 fragment of structure (b) (Figure 54) did not
produce a fragment at m/z 955 corresponding to the loss of a reducing end glucose. The m/z
1192 fragment of structure (b) would also have been expected to result in a fragment at m/z 579
corresponding to the loss of a terminal glucose and two internal glucose units (∆m/z = 612).
This fragment was not present in the NSI-MS4 data at m/z 1192.
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Figure 52. The NSI-MS4 fragmentation at m/z = 1526 → 1352 → 1192 for the per-Omethylated derivative of 1.
Mass losses of ∆m/z 174, 218, 236, 334, and 408 were indicative of key putative fragments
consistent with structure (a). The ion at m/z 1192 was selected for further fragmentation.
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Figure 53. Structure (a) putative mass fragments produced from the m/z = 1192 fragment of
per-O-methylated 1.
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Figure 54. Structure (b) putative mass fragments produced from the m/z = 1192 fragment of
per-O-methylated 1.
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The NSI-MS5 fragmentation at m/z = 1526 → 1352 → 1192 → 784 for the per-Omethylated derivative of 1 (Figure 55) gave indicative mass fragments of m/z 609, 565, 547,
and 449. The mass fragment of m/z 609 is consistent with the loss of a terminal arabinose (∆m/z
= 174), m/z 565 is consistent with the loss of a reducing end glucose minus an oxygen (∆m/z =
219), m/z 547 is consistent with the loss of a reducing end glucose (∆m/z = 236), and m/z 449 is
consistent with the loss of an internal xylose and a terminal arabinose (∆m/z = 334). These
mass fragments were consistent with structure (a) (Figure 56), as the putative m/z 784 fragment
of structure (b) (Figure 57) did not produce fragments at m/z 547 or 565 corresponding to the
loss of a reducing end glucose. The m/z 784 fragment of structure (b) would also have been
expected to result in fragments at m/z 579, corresponding to the loss of an internal glucose
(∆m/z = 204), and at m/z 563, corresponding to the loss of an internal glucose minus an oxygen
(∆m/z = 221). These fragments were not present in the NSI-MS5 data.
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Figure 55. NSI-MS5 fragmentation at m/z = 1526 → 1352 → 1192 → 784 for the per-Omethylated derivative of 1.
Mass losses of ∆m/z 174, 219, 236, and 334 were indicative of key putative fragments
consistent with structure (a).
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Figure 56. Structure (a) putative mass fragments produced from the m/z = 784 fragment of perO-methylated 1.
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Figure 57. Structure (b) putative mass fragments produced from the m/z = 784 fragment of perO-methylated 1.
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Structure (a) was therefore confirmed as the structure of 1 through the presence of key
putative fragments produced from partial and sequential fragmentation of the m/z 1526 parent
ion. These data supported the presence of a reducing, unsubstituted glucosyl moiety connected
via a single glycosidic bond to the remainder of the compound, and allowed placement of the
two Xyl-Ara side chains on the two internal glucosyl residues of the tetrameric backbone.
Alternative placement of one of the side chains on the reducing glucosyl unit (structure b)
would have resulted in a different pattern of MSn fragments. A key indicator of the presence of
the 4-linked glucosyl unit was a mass loss of ∆m/z = 236 from all fragment ions analyzed (m/z
1526, 1308, 1192, and 784). If the reducing glucosyl unit had instead been substituted with a
side chain on C-6, the mass loss of ∆m/z = 236 would not have been detected. Additional
fragments indicative of C-6 substitution on the reducing glucosyl unit would instead have been
detected. Placement of the Xyl-Ara side chains was further confirmed using NMR analyses.
All data obtained from the CCRC analyses were used to assign the structure of 1 as
shown (Figure 58), with a D-glucopyranosyl-(1→4)-D-glucopyranosyl backbone and two Larabinofuranosyl-(1→2)-D-xylopyranosyl side chains connected to the internal glucosyl
residues via D-xylopyranosyl-(1→6)-D-glucopyranosyl linkages. Configurations at the C-1
positions were determined using NMR analyses.
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Figure 58. The structure of 1 as determined by the CCRC analyses.
Anomeric configurations could not be assigned using the data collected from the CCRC
analyses, but all other structural features shown could be conclusively determined.

c. NMR Spectroscopy
The complexity of the compound and the extensive degree of overlap for monomer ring
resonances made it necessary to assign putative NMR values based on comparisons with
reference compounds and previously determined knowledge of compound structure. This
approach is considered appropriate as the majority of the structure had been previously
determined using chemical derivatization and associated analyses. The NMR data was
primarily used to confirm or refute previously made assignments and to assign anomeric
configuration (York et al. 1990, Hisamatsu et al. 1992, York et al. 1996). Spectra were
therefore compared to those of purified cranberry oligosaccharides (Auker 2013, Auker et al.
2014) as the oligosaccharides isolated from both cranberry and urine sources were determined
to be similar.
The NMR spectra indicated the presence of minor impurities, but sufficient resolution
could be obtained to assign putative 1H and 13C values for 1 (Figure 59–Figure 62, Table 28).
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These assignments were supported by HMQC (Figure 64), COSY (Figure 65), and TOCSY
(Figure 66) data, and by comparisons to reference values for monomer units, cellotetraose, and
cranberry oligosaccharides (Auker 2013, Auker et al. 2014). Duplicate resonance sets were
detectable for the two pairs of Ara and Xyl units, but could not be assigned independently.
These duplicated resonance sets indicated a high degree of structural symmetry for the local
environment of each side chain. These observations were consistent with the structural
assignments made using the partial-fragmentation pattern analyses.
The anomeric positions of Glc-B, Glc-C, and Glc-D were assigned β-orientation based
on their downfield (δH < 4.70) chemical shifts and coupling constants of JH1,H2 > 5 Hz, while
Xyl-E, and Xyl-F were assigned α-orientation due to their upfield (δH > 4.70) chemical shifts
and coupling constants of JH1,H2 < 5 Hz (Duus et al. 2000). The anomeric positions of the AraG and Ara-H residues were assigned α-orientation due to their JH1,H2 ≈ 1–2 Hz, although the
exact J-value for these residues could not be assigned as a result of resonance overlap (Duus et
al. 2000, Islam et al. 2011). The reducing glucosyl residue indicated by MSn-fragmentation
patterns was assigned to Glc-A and its presence confirmed by duplicate resonances for the αand β-anomers of this monomer (Table 28).
Numerous COSY, TOCSY, and HMBC correlations further confirmed the identities and
connectivity of the units indicated by the CCRC analyses and the MSn fragmentation patterns
(Figures 63–66). Key HMBC correlations between H-1 of Araf-G and H (δH 4.93) and C-2 of
Xylp-E and F (δC 78.9), and between H-2 of Xylp-E and F (δH 3.21) and C-1 of Araf-G and H
(δC 109.9), supported the assignment of α-L-arabinofuranosyl-(1→2)-α-D-xylopyranosyl side
chains. These side chains were linked to C-6 of the two internal glucose residues Glcp-B and C
through HMBC correlations between H-1 of Xylp-E and F (δH 4.79), and δC 67.1. Key HMBC
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correlations also further confirmed the connectivity of the glucose backbone with a correlation
between H-1 of Glcp-C (δH 4.27) and C-4 of Glcp-B (δC 81.0). The structure of the resulting
octasaccharide (1) was assigned as β-D-glucopyranosyl-(1→4)-[α-L-arabinofuranosyl-(1→2)α-D-xylopyranosyl-(1→6)]-β-D-glucopyranosyl-(1→4)-[α-L-arabinofuranosyl-(1→2)-α-Dxylopyranosyl-(1→6)]-β-D-glucopyranosyl-(1→4)-β-D-glucopyranose.
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Figure 59. The 1H NMR spectrum of 1 in DMSO-d6, 700 MHz, showing sufficient resolution to
obtain structural information.

Figure 60. Expansions of the 1H NMR spectrum of 1, DMSO-d6, 700 MHz, showing
integration and chemical shift assignments.
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Figure 61. The 13C NMR spectrum of 1 in DMSO-d6, 175 MHz, showing sufficient resolution
to obtain structural information.

Figure 62. Expansions of the 13C NMR spectrum of 1, DMSO-d6, 175 MHz, showing chemical
shift assignments.
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Table 28. Proposed 1H and 13C NMR assignments for 1, DMSO-d6, 700/175 MHz.
Duplicate resonance sets were observed for the two sets of Xyl and Ara residues. The same
chemical shift values were therefore assigned to the two sets of Xyl and Ara residues. Values
for the Glc residues were assigned using the aid of reference compounds including glucose,
cellotetraose, and the two oligosaccharides of similar structure isolated from cranberry
materials. The majority of these assignments were supported by 2D correlations. Numerical
assignments for the 2- and 3-positions of the glucosyl residues are tentative.
δH (multa;
Monomer Position
δC
δH (multa;
Monomer Position
δC
JHH)
JHH)
Glcp-A
1
92.2 4.92 (3.9)
Glcp-D
1
103.5 4.36 (8.0)
α-anomer
2
72.0
3.59
2
73.2
3.12
3
72.3
3.24
3
75.1
3.37
4
81.7
3.32
4
73.7
3.63
5
77.3
3.21
5
81.5
3.38
6
61.5 3.61, 3.71
6
61.0 3.55, 3.75
Glcp-A
1
96.9 4.35 (6.8)
Xylp-E
1
99.1 4.79 (3.3b)
β-anomer
2
73.7
3.01
2
78.9
3.21b
3
70.9
3.29
3
71.9
3.76
4
81.6
3.28
4
70.9
3.29
5
76.9
3.16
5
62.0
3.42
6
61.1 3.44, 3.72
Xylp-F
1
99.1 4.79 (3.3b)
Glcp-B
1
102.9 4.43 (8.1)
2
78.9
3.21
2
73.1
3.15
3
71.9
3.76
3
74.7
3.01
4
70.9
3.29
4
81.0
3.36
5
62.0
3.42
b
5
79.0
3.20
Araf-G
1
109.9
4.93c
6
67.1 3.70, 3.85
2
82.1
3.91
Glcp-C
1
103.8 4.27 (7.8)
3
77.6
3.63
2
73.5
3.66
4
83.9
3.81
3
75.2
3.40
5
61.7 3.42, 3.59
4
82.1
3.91
Araf-H
1
109.9
4.93c
5
79.0
3.20
2
82.1
3.91
6
67.1 3.75, 3.83
3
77.6
3.63
4
83.9
3.81
5
61.6 3.42, 3.59
a
b
All protons appeared as overlapping multiplets. Approximate J value
c
A reliable numerical J value assignment could not be made due to resonance overlap.
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Figure 63. The structure of 1 with putative 1D NMR numerical assignments shown.
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Figure 64. The HMQC spectrum for 1, DMSO-d6, 700/175 MHz.
Anomeric correlations and methylene correlations have been indicated on the spectrum.
Remaining correlations were assigned to ring carbons and protons. Two resonances
corresponding to C-1/H-1 of the Glc-A moiety were present due to the reducing nature of this
moiety.
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Figure 65. The COSY spectrum for 1, DMSO-d6, 700 MHz.
These correlations were used to confirm HMQC assignments for ring protons and are shown
below on the structure of 1 (Figure 68).
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Figure 66. The TOCSY spectrum for 1, DMSO-d6, 700 MHz.
These correlations were used to provide further support for the assignment of ring protons and
associated carbons.
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Figure 67. The HMBC spectrum for 1, DMSO-d6, 700 MHz.
Key HMBC correlations (arrows) supported the assignments of connectivity between monomer
units and were consistent with the structure determined by the CCRC analyses.
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Figure 68. Structure of the urinary octasaccharide (1) showing putative COSY and HMBC
correlations.

D. Conclusions
This project was initiated on the premise that the active compounds present in treated
swine urine would be A-type PACs or metabolically-transformed PACs (Chapter 1). Such
compounds would be expected to retain aromatic protons detectable by 1H NMR spectroscopy,
even in complex mixtures and regardless of metabolic transformations such as polymer
hydrolysis or glycosidic conjugation. As the project progressed, it became evident that active
fractions contained no indication of PACs, flavonoids, or related compounds. These results did
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not support the original PAC-based hypothesis. The isolation and purification approach was
therefore changed to focus on the isolation and characterization of unknown compounds from
active aqueous fractions. During the subsequent method development it was determined that
the major components of the active fractions lacked chromophores, making them undetectable
by conventional UV-based methods.
The use of ELSD made it possible to detect and characterize a group of urinary
compounds from active fractions that were not PAC-derived and were instead determined to be
complex carbohydrates, specifically oligosaccharides. A single compound from the series of
oligosaccharides detected by HPLC-ELSD was purified in sufficient quantity for full structural
elucidation. This compound (1) was found to be an octasaccharide composed of a tetrameric, β(1→4)-linked glucose backbone with two xylose-arabinose side chains. Preliminary NMR data
and chromatographic characteristics of the other purified compounds indicates that 1 is
representative of the complex pool of oligosaccharides that is present.
The structure of 1 is similar to that of arabinoxyloglucans isolated from solanaceous
plants (York et al. 1996). Such compounds are believed to be derived from the hemicellulose
polymers that serve as structural components of plant primary cell walls. These hemicellulose
polymers are enzymatically cleaved and solubilized during the process of fruit ripening (York
et al. 1996, Brummell et al. 2004, Goulão & Oliveira 2008). The presence of similar
compounds in cranberry would support the hypothesis that the oligosaccharides present in
swine urine originate from cranberry hemicelluloses, but little is known about the composition
of cranberry hemicelluloses or cranberry oligosaccharides.
Oligosaccharide urinary metabolites were consistently present in active urine collected
from three different swine after cranberry consumption and were present in active fractions but
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not in inactive fractions, control urine, or control urine fractions. Retrospective examination of
NMR data from the first active D fractions also confirmed the evidence of oligosaccharides, but
this evidence was discounted at the time it was collected as it did not indicate the presence of
PACs. The concentration range estimates for the urinary metabolites isolated during this study
are within a reasonable range for bioactivity, with single components being present at ~1–5
µg/mL urine (Saude et al. 2007, Bouatra et al. 2013). These data strongly indicated that
arabinoxyloglucan oligosaccharides are a component that may be responsible for the antiadhesion properties of urine and urine fractions following cranberry consumption, but E. coli
anti-adhesion properties had not been previously reported for this class of compounds.
At the conclusion of this study, insufficient amounts of urinary oligosaccharides were
available for testing in the UPEC-HRBC anti-agglutination assay and the reproducibility of the
assay had been questioned. The source of the urinary oligosaccharides was also unknown, as
arabinoxyloglucan oligosaccharides had not been previously reported from cranberry or other
Vaccinium species. The information available suggested a major paradigm transition regarding
the mechanism by which cranberry juice prevents UTIs, but, alone, provided insufficient direct
evidence to support such a proposition with certainty. Additional studies using cranberry
materials were therefore pursued (Chapter 3).
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CHAPTER 3: CRANBERRY COMPOSITION

A. Introduction
The majority of previous cranberry juice chemical composition studies have focused on
the low-MW, relatively nonpolar compounds of cranberry which are responsible for the aroma,
flavor, color, and anti-oxidant properties of the juice (Pappas & Schaich 2009, Singh et al.
2012, Vu et al. 2012, Su et al. 2010). Compounds previously investigated include terpenoids,
aromatic acids, monosaccharides, simple phenolics, polyphenols, and a wide variety of
flavonoids (Chapter 1, Section B).
The compounds believed to be responsible for the anti-adhesion properties of cranberry
juice are PAC oligomers of epicatechin units containing at least one A-type linkage (Foo et al.
2000a,b). Cranberry PACs are typically isolated from the EtOAc fraction of acetone-extracted
whole cranberry fruit (Howell et al. 1998, Foo et al. 2000a,b) and make up a relatively small
percentage of whole cranberry starting material (Gu et al. 2004, Santos-Buelga & Scalbert
2000, Gu et al. 2003). Studies examining the anti-adhesion properties of cranberry-derived
PACs and whole cranberry juice have indicated that additional compounds may be present that
could contribute to the anti-adhesion properties of the juice (Turner et al. 2007, Pinzón-Arango
et al. 2009, Holguin et al. 2008, Mathison et al. 2013, Kimble et al. 2014).
Studies investigating the anti-adhesive components of urine after cranberry
consumption (Chapter 2) have indicated that arabinoxyloglucan oligosaccharides with anti-
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adhesion properties may be present in cranberry materials, but relatively little is known
regarding the oligosaccharide components of cranberry fruit or juice products. The gel-forming
characteristics of cranberries, as exhibited by the classic cranberry sauce, led to early structural
investigations of complex carbohydrates including pectins and other cell wall-associated
insoluble polysaccharides (Holmes & Rha 1978), but other complex carbohydrates including
oligosaccharides have received limited attention. In addition, studies on soluble cranberry
carbohydrates are typically limited to known mono- and di-saccharide components using
comparisons to standards (Marlett & Vollendorf 1994).
The objectives of these studies were therefore to characterize additional components of
cranberry that could contribute to anti-adhesion activity and to determine if cranberry is
potentially the source of the oligosaccharides found in active urine fractions. This objective was
based on the outcome of the studies discussed in Chapter 2 and on the newly formed hypothesis
that complex carbohydrates with anti-adhesion properties are present in cranberry materials and
are related to the identified urinary metabolites.
These studies used primarily chemically-guided fractionation methods to focus on the
isolation of compounds that could be similar to putative active urinary metabolites. Cranberry
fractions were submitted to the previously used UPEC-HRBC anti-agglutination assay and to a
newly-developed assay that assessed the ability of uropathogenic P-fimbriated E. coli (UPEC)
to adhere to uroepithelial cells (UECs).

142

B. Materials & Methods

1. General Experimental Equipment
Lyophilization was performed using a variety of Labconco FreeZone Systems housed in
the NCNPR and Faser Hall at the University of Mississippi. All sample materials were stored at
–20 or –60 oC. The centrifuge used was a Thermo IEC Centra CL3R instrument with
exchangeable holders for different sizes of Falcon tubes. Preparative and analytical HPLC
separations for CJE fractions were performed on a Waters Delta Prep 4000 system with #5
pump heads and a Prep LC Controller connected to a 2487 dual-wavelength UV detector.
Analytical HPLC separations for most samples were performed on a Waters Alliance 2695
Separations Module with a 996 PDA connected in series to a Polymer Laboratories PLELS2100 analytical scale ELSD. Preparative HPLC separations for CJ-P1 samples were
performed on a Waters Delta Prep 4000 system with #5 pump heads and a Prep LC Controller
connected in series to a 2487 dual-wavelength UV detector and a Polymer Laboratories PLELS1000 ELSD. Additional analytical and preparative HPLC separations were performed on a
Waters Delta Prep 600 with a Waters 600 Controller and a Waters 996 PDA detector connected
in series to a Softa 300S ELSD. Two different Bruker Avance III 400 MHz NMR instruments
were used to record NMR spectra and both were housed in Faser Hall at the University of
Mississippi, School of Pharmacy. They were equipped with UltrashieldTM and UltrashieldTM
Plus magnets and 5 mm probes.
Regular solvents, TLC plates, HPLC solvents, and most reagents were obtained from
Fisher Scientific, Inc., Sephadex LH-20 and additional reagents and were obtained from SigmaAldrich, Inc., and HPLC sample filters and Amicon Ultra MW cut-off filters were obtained
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from Millipore, Inc. Water used for all experiments was obtained from ultrafiltration systems
located in Faser Hall or the NCNPR. Water for HPLC was additionally filtered within two days
prior to use.

2. Materials
Spray-dried cranberry juice powder (CJ) was supplied by Ocean Spray Cranberries, Inc.
through NIH grant no. 1R21AT002076-01. This same material was used for swine feeding to
generate the urine samples discussed in Chapter 2. Cranberry juice concentrate (CC) was also
supplied by Ocean Spray Cranberries, Inc. This material is used in the cranberry industry for
preparation of various cranberry juice products. Commercially produced cranberry dietary
supplements (Table 29) and juices (Table 30) were purchased at local grocery stores. Color
images and additional label and product information for these materials can be found in
Appendices A & C (color plates: Figures 98–101; Appendices C-2 – C4).
Table 29. Descriptions of cranberry dietary supplements obtained from local grocery stores.
The information included in this table was derived from the label information provided with
each product. Examples of these labels and associated dietary supplement product literature can
be found in Appendix C. Images of these products can be found in Appendix A color plates:
Figure 98.
Brand
Cranberry
Form
Label Description
Observations
Name
Ingredient
Finest
fruit
140 mg/capsule from 12:1
softgel
Dark purple-mauve
Natural
powder
concentrate: equivalent to
capsule
goo
(FN)
concentrate 1680 mg fruit powder/capsule
Nature’s
fruit
40 mg/capsule from 50:1
softgel
Bounty
powder
concentrate: equivalent to
Dark pink goo
capsule
(NB)
concentrate 2000 mg fruit powder/capsule
Sundown
powder fruit
Dry, bright pink
Naturals
475 mg/capsule
capsule powder
powder
(SN)
Nature
Undescribed
softgel
450 mg/capsule from 15:1
Made
fruit extract
extraction method;
capsule
concentrate of a fruit extract
(NM)
pinkish-mauve goo
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Table 30. Descriptions of cranberry juices obtained from local grocery stores.
The information shown below was derived from the label of each product. These labels and
images of the juice material can be found in Appendix A color plates: Figures 100, 101.
Total Juice
Ingredients Listeda
Brand Name
Label Name
Content (%)
Best Choiceb
grape juice, cranberry juice, apple juice,
“Cranberry Blend”
100
(BCB)
natural flavors, ascorbic acid, citric acid
b
Great Value
“Cranberry Juice
30
cranberry juice, sugar, ascorbic acid
(GVC)
Cocktail”
“No Sugar Added
Great Valueb
grape juice, cranberry juice, apple juice,
Cranberry Juice
100
(GVNS)
natural flavors, ascorbic acid
Blend”
Ocean Spray “Cranberry Juice
cranberry juice, cane or beet sugar,
27
(OSC)
Cocktail”
ascorbic acid
apple juice, cranberry juice, calcium
“Cranberry Plus”
gluconate, calcium lactate, natural
Langers
(with vitamins A, C
100
flavors, citric acid, fruit and vegetable
(LCP)
& E and Calcium
juice for color, ascorbic acid, vitamin E
acetate, vitamin A palmitate
apple juice, cranberry juice, pear juice,
grape juice, citric acid, natural flavor,
Northland
“Cranberry
vegetable color, fruit extracts (grape skin,
100
(NL)
Flavored Blend”
blueberry, pomegranate, cranberry, red
grapes and apple), ascorbic acid, vitamin
A palmitate, vitamin E acetate
a
Water was an ingredient for all products, and all juices were listed as juice concentrates.
Ingredients are listed here in the order they are shown on product labels.
b
These products were store brands specific to the grocery store company.

3. Characterization of Cranberry Material
a. Molecular Weight Cut-Off Filtration
Cranberry juice powder (CJ) was dissolved in water (5 mg/mL) and subjected to
centrifugal filtration using Amicon Ultra regenerated cellulose centrifugal filters with MW cutoff sizes of 3, 10 and 30 kDa. Samples (4 mL each; 20 mg/filter tube insert) were centrifuged
(4000 x g, 20 min), filtrate and retentate were transferred to separate vials, and filter inserts and
centrifuge tubes were washed with water (3–4 x 0.5 mL, combined with their respective

145

fractions). Samples were lyophilized, weighed, analyzed by 1H NMR, and submitted to the
UPEC-HRBC anti-agglutination assay for testing.
b. Acid/Base Incubation
Aliquots (98–104 mg) of cranberry juice powder (CJ) were dissolved in water (7–10
mL) in 4 dram glass vials and titrated to pH 2, 6, or 8 using 10–100 mM NaOH, 100 mM HCl,
and an electronic microscale pH meter. The final volume per sample was adjusted after titration
to give final concentrations of 10 mg/mL. Samples were incubated at 37 oC with shaking for 2,
4, or 8 h. After incubation, samples were directly frozen, lyophilized, weighed, and analyzed by
1

H NMR spectroscopy and C18 HPLC-PDA. Aliquots (20–25 mg) of each sample were

submitted to the UPEC-HRBC anti-agglutination assay for testing.

4. Detection & Isolation of Cranberry Oligosaccharides
a. Analytical HPLC-ELSD of Cranberry Material
Cranberry juice powder (CJ) and the aqueous fraction of this material (CJA) were
examined by analytical HPLC using the same column and a similar method as used for
detection of oligosaccharides in active urine fractions (AtldC18, 4.6 x 150 mm, 5µm). The
method was as follows: 100% water for 5 min, 100% water to 30% MeOH over 30 min, 30%
MeOH to 100% MeOH over 20 min, and 100% MeOH for 5 min, followed by a 10 min
gradient from MeOH to 100% water with 20 min of re-equilibration with 100% water before
injection of the next sample. Chromatograms were collected using ELS/PDA detection, with
ELS conditions of a gas flow rate of 1.0 SLM, an evaporator temp of 100 oC, and a nebulizer
temp of 50 oC. Max plot chromatograms (200–400 nm) were extracted from PDA data for
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detection of UV-active metabolites. Samples were prepared in a single session, were not
filtered due to low sample volumes, and were sequentially separated using a single method and
without flow interruptions between injections. Different sample concentrations and column
load volumes were used (Table 31) to preserve enriched reference materials (HF1-1 and HF22) and to ensure the detection of putative oligosaccharides in crude cranberry materials (CJ and
CJA).
Table 31. Sample details for analytical HPLC-ELSD comparisons between CJ and HF
materials.
Amount
Water
Conc.
Injection Amount
Sample Code
(mg)
(µL)
(mg/mL)
(µL; mg/inj)
CJ
6.5
300
21.7
50; 1.09
CJA
6.0
200
30.0
40; 1.20
HF2-2
1.6
160
10.0
25; 0.25
HF1-1
2.6
100
26.0
20; 0.52

b. Preparative HPLC-ELSD of Cranberry Juice Powder
Cranberry juice powder (CJ) was directly separated using the same methods and
preparative instrument configuration as used previously for urinary fraction HF2-2 separations
(Chapter 2, Section B7). These methods used a preparative AtldC18 column (19 x 250 mm, 10
µm particle size) with a flow rate of 25 mL/min as follows: 100% water for 5 min, 100% water
to 20% MeOH over 30 min, 20% MeOH to 100% MeOH over 10 min, 3 min at 100% MeOH,
followed by a 17 min gradient from MeOH to 100% water with an equilibration of 10 min at
100% water prior to the next separation. The ELSD settings for this separation were a gas flow
rate of 0.8 SLM, an evaporator temperature of 100 oC, and a nebulizer temperature of 50 oC.
These ELSD values remained constant throughout the course of each separation, and the ELSD
was allowed to equilibrate for at least 30 min at the appropriate settings prior to initial data
acquisition.
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Two batches of CJ (99.2 mg for R1 and R2, and 250 mg for R3) were dissolved in water
(800 µL and 1 mL), filtered (0.2 µm nylon filter), and separated over three separations with
different amounts of material injected per separation (R1: 200 µL, R2: 500 µL and R3: 1 mL).
Fractions from these separations (Table 32) were combined based on chromatographic profile
and time points (Figures 69–71), and were concentrated under reduced pressure with a water
bath temperature of ~40 oC to remove solvent and decrease water content. Resulting samples
were dissolved in water, frozen, and lyophilized. Fractions CJ-P1t22, CJ-P1t23, CJ-P1t25, and
CJ-P1t38 were analyzed by 1H NMR.

Table 32. Fractions collected from direct HPLC separation of cranberry juice powder (CJ-P1).
Time points for fraction recombination were compared to those of urinary fractions and
materials were combined across three separate injections.
Retention
Fraction mg Notes
Time (min)a

a
b

0–6

01

82.7 early eluting mass majority – mixture, UV active

6–21.5

16

9.5

21.5–22.7

22b

3.3 first short peak set in area of interest – no UV

22.8–23.7

23b

4.0 tallest peak of set in area of interest – no UV

23.8–25.8

25b

25.8–30

28

30–37.7

35

37.7–39.1

38b

39.1–47

40

no peaks – blank area before next set – some minor
peaks by UV

low peaks before and second tallest peak in area of
interest – no UV
low peaks after three primary eluting peaks of set –
7.6
mixture – no UV
wash between peak set of interest and final gradient
12.8
peak
final peak – elutes with gradient to MeOH – no or low
6.5
UV – mixture
7.3

6.1 end wash – UV chromophores (pink)

Time points for fraction numbers were based on CJP-crude R1.
These fractions were analyzed by 1H NMR spectroscopy.
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Figure 69. Preparative HPLC-ELSD chromatograms of CJ-P1 separations, R1–3.
Different amounts of material were injected over the three separations, resulting in the differing
intensities of the ELSD chromatograms shown. All eluting material was collected as fractions
and fractions t22, t23, t25 and t38 were analyzed by NMR spectroscopy.
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Figure 70. Preparative HPLC-UV (215 nm) chromatograms of CJ-P1 separations, R1–3.
Comparison of these chromatograms to those in Figure 69 shows the absence of chromophores
for the compounds eluting from 18–38 min and the presence of weak chromophores for
compounds eluting from 0–8 min. The profile of compound chromophores visible between 38
and 46 min does not appear to correlate to the profile of the fraction eluting at 38 min,
suggesting that fraction CJP1t38 lacks a chromophore. The components eluting from 39–47
min showed a visible pink color in solution suggesting the presence of known anthocyanins.
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Figure 71. Preparative HPLC-UV (254 nm) chromatograms of CJ-P1 separations, R1–3.
The characteristics for the chromatographic profile of the CJ-P1 separations at 254 nm were
similar to the chromatographic profile visible at 210 nm (Figure 70) and further supported the
lack of chromophores for the compounds eluting from 18–38 min. The low intensity
absorbance for the components eluting from 39–47 min further supported the conclusion that
this fraction contained anthocyanins.
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5. Enrichment for Cranberry Oligosaccharides
a. Cranberry Juice Powder Separations
Cranberry juice powder (CJ) (1.24 kg, in 80–120 g aliquots) was dissolved in water
(450 mL/100 g) and extracted with EtOAc (10 x 1:3 v/v EtOAc:water). The EtOAc extracts
(CJE) were combined (12.706 g; 1.02% w/w of CJ), solvent removed under reduced pressure
and the residual amorphous burgundy solid was resuspended in a minimum amount of water
and lyophilized. Aqueous material (CJA) was combined, residual solvent removed under
reduced pressure, and the resulting burgundy liquid was diluted, frozen and lyophilized in 1–2
L batches.
The CJA and CJE fractions were both assessed using an anthocyanidin test: 1 mg of
material was combined with 5 mL of isopropanol: 3 N HCl (4:1) (test samples) or
isopropanol:water (4:1) (control samples) and heated for 30 min at 96 oC under pressure. Both
CJE and CJA materials were used for further separations. The CJE fraction was investigated by
TLC, PLC, Sephadex LH-20, HPLC with reverse phase sorbents, and derivatization via
methylation and acetylation. Purified components were characterized using UV, LC-MS, and
NMR. The further characterization of CJ and CJA materials will be discussed below.
The CJ aqueous residue (CJA) was fractionated on Sephadex LH-20 using protocols
similar to those developed for urine samples (Table 33). The CJA samples were dissolved in
water and EtOH (100%) was added gradually with intermittent sonication to give a final
concentration of 70% EtOH (v/v). The sample was briefly centrifuged to remove precipitate
and samples in 70% EtOH were loaded onto Sephadex LH-20 and eluted with 70% EtOH
(isocratic) (Appendix A color plates: Figure 102). Columns were washed with 80% EtOH and
60–100% acetone after the majority of the fractions eluted. Fractions were combined based on
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appearance and elution volume, concentrated under reduced pressure to remove EtOH,
dissolved or diluted in water, frozen, and lyophilized. Selected CJA fractions were submitted
for bioassay testing and further characterized by 1H NMR and HPLC-ELSD/UV.

Table 33. Details of Sephadex LH-20 separations for CJA samples 1 & 2.
The recombination of fractions collected from columns CJA1 and CJA2 differed slightly and
fractions were labeled with different numbers, but both columns yielded similar percentages of
oligosaccharide-containing material.
Column Designation
CJA1
CJA2a
Amount of Loaded Material (g)

25.6

25.3

Loaded Volume &
Sample Concentration
Column Dimensions
(cm; width x height)

100 mL
256 mg/mL

100 mL
253 mg/mL

7 x 37

7 x 37

Solvent Composition

70% EtOH

70% EtOH

1.5–1.7

1.5–1.7

300

450

Solvent Flow Rate (mL/min)
Total Elution Volume for
Oligosaccharide Fractions (mL)
Oligosaccharide-containing
Fractions (g)

CJA1-02 (3.619)
CJA1-02B (1.280)
CJA1-03B (1.669)

Total Oligosaccharide-containing
Material per Column (g)
Oligosaccharide % of Loaded Material
a

CJA2-03 (2.090)
CJA2-04 (3.980)
CJA2-05 (1.740)

6.568

7.810

25.6%

30.8%

Some information for this separation is also reported in Auker 2013 and Auker et al. 2014.

b. Cranberry Juice Concentrate Separations
Cranberry juice concentrate (CC) syrup was also used as starting material for the
isolation of cranberry oligosaccharides via protocols similar to those used for urine and CJ
samples. Syrup (500 mL) was diluted with water (300 mL) and exhaustively extracted with
EtOAc (8 x 200 mL; CCE). Aqueous residue (CCA) was lyophilized and portions were
separated by Sephadex LH-20 (Appendix A color plates: Figures 103, 104). As before, CCA
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samples were dissolved in water and 100% EtOH was added gradually, with sonication, to
yield concentrated material in column solvent (70% EtOH). This material was briefly
centrifuged to remove precipitate and separated on two different Sephadex LH-20 columns
(Table 34). The columns were washed with 80% EtOH and 60–100% acetone after the majority
of the fractions eluted. Fractions were concentrated under reduced pressure, dissolved or
diluted with water, frozen, and lyophilized. Selected CCA fractions were submitted for
bioassay testing and further characterized by 1H NMR and HPLC-ELSD.

Table 34. Details of Sephadex LH-20 separations for CCA samples 1 & 2.
The recombination of fractions collected from columns CCA1 and CCA2 differed and fractions
were labeled with different numbers, but both columns yielded similar percentages of
oligosaccharide-containing material. The elution flow rate for column CCA2 was higher than
that of column CCA1 to account for the larger diameter of this column. The CCA2 fractions
yielded higher resolution between different oligosaccharide components than the CCA1
fractions.
Column Designation
CCA1
CCA2
Amount of Loaded Material (g)

50.53

151.33

Loaded Volume &
Sample Concentration
Column Dimensions
(cm; width x height)

200 mL
250 mg/mL

500 mL
303 mg/mL

7 x 37

10 x 49

Solvent Composition

70% EtOH

70% EtOH

1.2–1.5

1.5–2.0

520

1500

Solvent Flow Rate (mL/min)
Total Elution Volume for
Oligosaccharide Fractions (mL)
Oligosaccharide-containing
Fractions (g)

CCA1-01 (0.377)
CCA1-02 (0.913)
CCA1-03 (0.733)
CCA1-03 (0.026)

Total Oligosaccharide-containing
Material per Column (g)
Oligosaccharide % of Loaded Material
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CCA2-01 (0.032)
CCA2-02 (0.215)
CCA2-03 (1.686)
CCA2-04 (3.158)
CCA2-05 (1.739)

2.05

6.83

4.06%

4.51%

6. Preliminary Characterization of Commercial Cranberry Products
Aliquots of commercial cranberry dietary supplements (Table 29) were removed from
their gel capsules (one capsule per product) dissolved in water, sonicated, and left to sit for
about 4 h to yield aqueous solutions (Appendix A color plates: Figure 98). Dissolved material
was removed from insoluble matter with a pipette, filtered with glass wool in a glass pipette
and then filtered with a 20 µm syringe filter (30 mm). Samples of CJ and CJA were prepared in
a similar manner (0.2 µm filter) and analyzed at the same time for comparison. Filtered samples
(Table 35) were injected as part of a single analysis set onto an analytical HPLC column
(AtldC18, 4.6 x 150 mm, 5 µm, with 4.6 x 20 mm guard cartridge) and separated using a
method similar to that used for enriching and detecting oligosaccharides in active urine
samples. This method was as follows: 5 min 100% water, 30 min gradient to 30% MeOH, 10
min gradient to 100% MeOH, 10 min at 100% MeOH, 10 min gradient to 100% water, with 20
min of re-equilibration with 100% water before injection of the next sample. Chromatograms
were collected using ELS/PDA detection with ELS conditions of a gas flow rate of 1.0 SLM,
an evaporator temp of 100 oC, and a nebulizer temp of 50 oC. Max plot chromatograms (200–
400 nm) were extracted from PDA data for detection of UV-active metabolites.
Samples of each commercially obtained juice were directly injected onto the HPLCELSD instrument with injection volumes of 50 µL each. The dry weights of each juice material
corresponding to the 50 µL injection volumes are not known. All juice samples were analyzed
within a single sample set using automated sample handling to avoid changes in instrument
performance and retention times between injections. The same HPLC-ELSD method was used
for the analysis of juice samples as was used for the dietary supplement samples and urine
samples (see above).
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Table 35. Sample details for analytical HPLC-ELSD comparisons of cranberry dietary
supplement products.
Multiple injection amounts were used for the commercial product samples in an attempt to
detect minor components. Data was not available to assess the “fruit equivalents” of the CJ
materials.
Sample
Injected Fruit
Fruit Powder
Water
Injection Amount
Sample Amount
Conc.
Equivalent
Equivalenta
(mL)
(µL; mg/inj)
Code
(mg)
(mg)
(mg/mL)
(mg)
Commercial Products
FN
140
1680
10
14.0 25; 0.35 & 50; 0.70
4.2–8.4
NB
40
2000
5
8.0 50; 0.40 & 100; 0.8
20.0–40.0
SN
475
475
10
47.5 25; 1.20 & 50; 2.40
1.2–2.4
NM
450
6750
10
45.0 25; 1.13 & 50; 2.25
16.9–33.8
Reference Cranberry Juice Powder
CJ
2.9
N/A
0.2
14.5
50; 0.73
N/A
CJ
6.5
N/A
0.3
21.7
50; 1.08
N/A
CJA
6.1
N/A
0.3
20.3
50; 1.02
N/A
CJA
6.0
N/A
0.2
30.0
50; 1.50
N/A
a
Based on manufacturer labeling.

7. Bioassay Testing
a. Anti-agglutination Assay
The UPEC-HRBC anti-agglutination assay used for cranberry-derived samples was the
same as that used for urine samples (Chapter 2: Section B4). Several CJ-derived samples
(Sections B3) and selected CJA1 and CJA2 fractions (Section B5) were submitted to this assay.
b. Anti-adhesion Assay
Selected CJA1 and CJA2 fractions were submitted to an early version of the
uroepithelial cell-uropathogenic E. coli (UPEC-UEC) anti-adhesion assay developed at
Washington State Univ. (WSU). This early version of the assay used radiolabeled E. coli, and
the number of E. coli that adhered to uroepithelial cells were quantified using scintillation
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counts (Mathison et al. 2013). Samples were tested in duplicate at different dilutions (Auker
2013).
The CCA1 fractions (~10 mg each) were submitted to a later version of the UPEC-UEC
anti-adhesion assay that used fluorescent-labeled E. coli and uroepithelial cells according to
previously established protocols (Kimble et al. 2014). Samples were tested using serial dilution
and each sample was tested in duplicate. Duplicate results were corrected for baseline
fluorescence and averaged to give fluorescence values for each dilution tested. Samples were
tested using five to eight serial dilutions and IC50 values were calculated.
c. Antimicrobial Assays
Selected cranberry samples (CJ: 35.6 mg, CJE: 12 mg, CJA: 24.7 mg) were submitted
to the antibacterial, antifungal, and antiprotozoal screening programs available at the UM
National Center for Natural Products Research (NCNPR). Samples were tested according to
previously reported methods (Zhang et al. 2012, Rahman et al. 2011) modified from the
methods of the Clinical and Laboratory Standards Institute (CLSI), formerly the National
Committee for Clinical and Laboratory Standards (NCCLS 2002a,b, NCCLS 2003, NCCLS
2006). Samples were tested against a panel of pathogens: five fungi (Candida albicans ATCC
90028, C. glabrata ATCC 90030, C. krusei ATCC 6258, Cryptococcus neoformans ATCC
90113, and Aspergillus fumigatus ATCC 204305), five bacteria (Staphylococcus aureus ATCC
29213, methicillin-resistant Staph. aureus ATCC 33591, E. coli ATCC 35218, Pseudomonas
aeruginosa ATCC 27853, and Mycobacterium intracellulare ATCC 23068), and two protozoa
(Leishmania donovani and Plasmodium falciparum D6 Clone)
In the antibacterial and antifungal assays, samples were tested at concentrations of 50
µg/mL. In the antiprotozoal assays, samples were tested at a concentration of 15.9 µg/mL
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against Plasmodium falciparum and at 80 µg/mL against Leishmania donovani. Amphotericin
B served as the positive control for the Leishmania donovani assay and resulted in 100%
inhibition under the parameters used. Percent growth inhibition for each organism was
calculated relative to positive and negative controls.

C. Results & Discussion

1. Characterization of Cranberry Material
The EtOAc soluble CJE fraction composed 1% w/w of the starting CJ material and the
results of the anthocyanidin test indicated that PACs were present primarily in this fraction.
The CJE test sample, but not the control sample or the CJA samples, produced an intense
fuchsia color. This color indicated the formation of anthocyanins resulting from acid-catalyzed
cleavage of leucoanthocyanidins and PACs (Berhow 2002, Fletcher et al. 1977). The CJE
fraction also showed similar TLC Rf values when compared to PAC reference dimers,
procyanidins A2 and B1 (benzene:acetone, 4:6, v/v), indicating the presence of these
compounds. Sephadex LH-20 of CJE yielded 20 fractions that were further separated by PLC
and HPLC and derivatized via methylation and acetylation. Purified components were
characterized using UV, LC-MS, and NMR. These separations yielded a series of known
flavonoids and phenolic compounds (not shown).
The CJ and CJA materials were the focus of the remaining studies discussed below.
Selected samples from these studies were submitted to the UPEC-HRBC anti-agglutination
assay in conjunction with the urine samples discussed in Chapter 2. The results of this assay for
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the cranberry samples were evaluated using the same methods described in Chapter 2, Section
B4d, to provide relative activity scores (UM Scores; Table 3). The results of the MW cut-off
filtration and acid/base incubation assessments are shown below (Table 36). Additional antiagglutination assay results for CJA Sephadex LH-20 fractions are discussed below (Section
C4a). The raw data for these evaluations can be found in Appendix B-3: Tables 52, 58.

Table 36. Anti-agglutination assay results for experiments characterizing cranberry (CJ)
material.
The CJ material consistently showed UPEC-HRBC anti-agglutination activity. Use of MW cutoff filters indicated that low-MW components of CJ were unlikely to contribute to the observed
anti-agglutination activity.
Sample Description
UM Scorea
Test Date
CJ (cranberry juice powder)
++
06/2008 x2b
CJ-MA3a (3 kDa retentate)
++
06/2008
CJ-MB3a (10 kDa retentate)
++
06/2008
CJ-MC3a (30 kDa retentate)
++
06/2008
CJ-MA3b (3 kDa filtrate)
––
06/2008
CJ-MB3b (10 kDa filtrate)
––
06/2008
CJ-MC3b (30 kDa filtrate)
––
06/2008
CJ pH 2.0, 2 h
+
06/2008
CJ pH 2.0, 4 h
+
06/2008
CJ pH 2.1, 8 h
+
06/2008
CJ pH 5.9, 2 h
++
06/2008
CJ pH 6.0, 4 h
++
06/2008
CJ pH 6.1, 8 h
++
06/2008
CJ pH 7.9, 2 h
++
06/2008
CJ pH 8.0, 4 h
++
06/2008
CJ pH 8.2, 8 h
++
06/2008
CJ Native pH (2.7), 2 h
++
06/2008
CJ Native pH (2.7), 4 h
++
06/2008
CJ Native pH (2.7), 8 h
++
06/2008
a
The criteria used to assign the UM Score can be found in Table 3. Raw data for these samples
can be found in Appendix B-3: Table 52.
b
Sample was tested in duplicate for this test date.
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a. Molecular Weight Cut-off Filtration
CJ material partitioned in similar ratios across the three sizes of centrifugal filters used,
with 3.25–3.5 mL of filtrate recovered from each separation. After lyophilization, the filtrate
accounted for 70–75% of the total recovered sample mass. Both retentate and filtrate fractions
did not lyophilized to powders, instead producing viscous goo. Filtrate samples were bright
pink in color, similar to the starting material, while retentate samples were tan in color. Filter
inserts also retained a slight pinkish tinge after washing. The anti-agglutination assay results
indicated that the active constituents from the cranberry juice powder were concentrated into
the retentate portion of the filtered samples (Table 36).
The active components of cranberry juice powder were retained and enriched by 3, 10
and 30 kDa regenerated cellulose centrifuge filters under the conditions used. Retention could
have been the result of molecular size, sample concentration and filtration time, or repellant
interactions between the active compounds and the filter material. The physics of centrifugal
filtration dictates that the smallest molecules will pass through the filter matrix before larger
molecules in solution, and the filter matrix of regenerated cellulose can bind to certain
compounds (pink color) while repelling others. Hydrogen bonding between compounds in
solution, yielding larger apparent MW complexes, may also have contributed to the retention of
the active constituents.
b. Acid/Base Incubation
Cranberry juice powder in solution has a native pH of about 2.7. The adjusted pH of
each sample remained the same from the beginning to the end of the incubation periods. All
samples had anti-agglutination activity (Table 36). The pH 6 and pH 8 samples showed slightly
higher activity than the non-incubated reference material, while the pH 2 samples showed
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slightly lower activity. Incubation time did not appear to have any effects on the antiagglutination activity profile.
Cranberry juice powder samples were incubated at human body temperature for three
time periods and three different pH values similar to those that could be experienced by
cranberry juice components during digestive processes (Evans et al. 1988). The presence of
anti-agglutination activity after incubation under these conditions is consistent with the
presence of active metabolites in both cranberry and urine materials. These data indicate that
the active constituents are relatively stable to moderate acid/base chemical degradation and to
moderate heat and would be likely to remain intact when subjected to non-enzymatic digestive
conditions.

2. Detection & Isolation of Cranberry Oligosaccharides
a. Analytical HPLC of Cranberry Materials
Analytical scale HPLC-ELSD analysis of cranberry starting material in comparison to
active urine fractions showed that cranberry contains the same HPLC-ELSD/UV profile in the
region of interest as active urine fractions (18–24 min; Figure 74). The chromatographic
behavior of the cranberry material suggested that these compounds were also oligosaccharide in
nature with chromophores absent for all cranberry peaks, as was seen with urine fractions
(Figure 73). The elution times for the cranberry profile could be directly overlaid with those of
the urine fractions and the relative ratios of the components of the mixture were similar (Figure
74). As ELSD is a semi-quantative, mass-sensitive method (see Appendix B-4: ELSD
overview), this observation further supports the hypothesis that similar components are present.
Although the cranberry material was injected at 2–4 x higher concentrations than the urine
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fraction material (Figure 74) retention times and relative peak ratios remained similar further
suggesting that the compounds present in cranberry material and urine were similar, and that
the compounds present were unaffected by the cranberry sample matrix. The cranberry profile
appears to be more complex than that found in urine samples, but this could be due to higher
concentrations of individual metabolites present in the cranberry sample. Overall, it appears
that many of the oligosaccharides present in the urine sample are directly derived from
oligosaccharides present in the cranberry material, even at the same approximate concentration
ratios.
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Figure 72. Analytical HPLC-ELSD comparison of cranberry material (CJ and CJA) and urine
fractions (HF2-2 and HF1-1).
The same profile of oligosaccharide components was present in both urine- and cranberryderived materials. Additional complexity was apparent in the CJ and CJA materials, possibly
due to higher sample concentrations. The higher intensities of the peaks for the cranberry
material also likely reflect higher sample concentrations and higher injection amounts.
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Figure 73. Analytical HPLC-ELSD/UV of CJA compared to HF1-1 confirming the absence of
chromophores for cranberry oligosaccharides.
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Figure 74. Analytical HPLC-ELSD of CJA compared to HF1-1 and HF2-2 (overlay).
This comparative profile indicated that urine and cranberry fractions have similar relative
quantities of what appear to be the same set of components. Several of these components have
been highlighted (arrows) and other components present also appear to vary in similar ratios.

b. Preparative HPLC of Cranberry Juice Powder
Direct preparative HPLC separation of 349.2 mg of crude cranberry juice powder (CJ)
resulted in a total fraction weight of 139.8 mg from the starting amount to give 40% recovery
(w/w). It is possible that most of this loss was due to split-ELSD detection-collection, with
additional material being retained by the sample filter, lost during transfers, lost due to loop
overflow during injection, or lost due to irreversible retention on the HPLC column. From the
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fractions collected, 22.2 mg of material eluted in the oligosaccharide region of interest (21.5–30
min, Figure 69) to give 15.9% of the total recovered CJ material (139.8 g) as being composed
of oligosaccharides. Most of the CJ-P1 fractions contained mixtures of compounds, but the
fraction at 22.8–23.7 min, designated CJ-P1t23 (4.0 mg), had similar HPLC-ELSD
characteristics as 1 isolated from urine samples (Chapter 2). Comparison of this sample to that
of the enriched fraction HF2-2P1t20, containing primarily 1, via 1H NMR spectroscopy
confirmed the similar chemical composition of the two materials (Figure 75). Insufficient pure
material of CJ-P1t23 was available for full structural characterization, but resonances in the
anomeric region indicated the probable presence of an arabinoxyloglucan with eight monomer
units. The presence of a series of oligosaccharides with structural composition similar to each
other and to the previously isolated urinary compounds was further supported by 1H NMR data
of the other enriched cranberry oligosaccharide fractions (Figure 76). In particular, fractions
CJ-P1t22 and CJ-P1t25 also contained resonances in the anomeric region indicative of
arabinoxyloglucans. Fraction CJ-P1t38, however, yielded a 1H NMR spectrum unique from
those of the other CJ-P1 fractions. This spectrum indicated that CJ-P1t38 is also probably a
complex carbohydrate but not an arabinoxyloglucan. Larger quantities of cranberry
oligosaccharides were needed for further structural studies and bioactivity assessments, and
direct preparative HPLC separations were not necessarily an optimum method for obtaining
this material.
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Figure 75. Comparison of the 1H NMR spectra for the enriched cranberry oligosaccharide
fraction CJ-P1t23 and the urinary fraction HF2-2P1t20, enriched for compound 1, DMSO-d6,
400 MHz.
The spectra for both fractions were highly similar indicating similar chemical composition.
These data suggested that the cranberry fraction was also an arabinoxyloglucan
oligosaccharide.
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Figure 76. Comparison of the 1H NMR spectra for major CJ-P1 oligosaccharide fractions,
DMSO-d6, 400 MHz.
Fractions CJ-P1-22, CJ-P1-23, and CJ-P1-25 all contained resonances similar to those of
arabinoxyloglucan oligosaccharides. The spectrum of CJ-P1-38 was distinct and is probably not
an arabinoxyloglucan, but is likely to be another type of oligosaccharide.
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c. Cranberry Juice Powder Separations
The CJ material was processed and separated using Sephadex LH-20 via methods
similar to those applied to urine samples. The color of fractions can be used to track the
progressive elution of compounds and shows that the majority of the pigmented components of
the juice elute at later retention times (Appendix A color plates: Figure 102). Later fractions
(CJA1-04 – CJA1-06) are also more hygroscopic, probably due to the presence of high
concentrations of simple sugars such as fructose. Fractions of CJA that eluted early, at similar
retention times as active urine fractions (e.g. CJA2-03), were found to contain oligosaccharide
mixtures of similar composition as active urine fractions by HPLC-ELSD (Figures 77–79) and
NMR spectroscopy (Figure 80). The appearance of CJA oligosaccharide fractions was cloudy
white to pale lavender in appearance in 70% EtOH, and these fractions eluted just before or in
conjunction with the visible lavender band that appeared on the column (CJA1 column;
Appendix A color plates: Figure 102). Changes in both the HPLC system and the ELS detector
resulted in lower-resolution chromatography and different retention times for some fractions
than obtained previously, but UV-transparent oligosaccharides could still be detected (20–30
min; Figure 79).
Fraction CJA2-03 served as part of the source material for the further isolation of two
oligosaccharides in sufficient purity and quantity to assign structures (Auker 2013) (Figure 81).
Methods used to make these assignments included NMR and carbohydrate derivatization
methods similar to those discussed in Chapter 2 Methods.

169

Figure 77. Analytical HPLC-ELSD comparison HF1-1, CJ, CJA, and CJA2-03 (AtldC18)
showing the similarity of oligosaccharide profiles present in all four samples.
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Figure 78. Analytical HPLC-ELSD of CJA2 fractions 02, 03, 04, 05, and 06 (AtldC18)
showing the resolution and composition of these Sephadex LH-20 fractions.
Oligosaccharide components of interest are present in fractions 03, 04, and 05.
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Figure 79. Analytical HPLC-ELSD of CJA1 and CJA2 oligosaccharide-containing fractions in
comparison to SN-04 (% MeOH shown).
These fractions were analyzed using an HPLC instrument that produced lower chromatographic
resolution and the Softa ELS detector. This instrument configuration was sufficient for
detecting oligosaccharide content by comparisons to fractions with previously known
oligosaccharide content, but instrument parameters and the chromatographic system shown
here would need to be further optimized for preparative separations.
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Figure 80. Comparison of the 1H NMR spectra for fractions CJA1-02 and CJA2-03, D2O, 400
MHz.
These spectra show the similarity of composition for the oligosaccharide-enriched fractions
from both CJA1 and CJA2 columns. These spectra do not contain resonances in the regions that
are not displayed.
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Figure 81. Structures of the two oligosaccharides isolated from fraction CJA2-03 (Auker 2013).
These compounds are highly similar in structure to that of 1, discussed in Chapter 2.

d. Cranberry Juice Concentrate Separations
The aqueous fraction of CC material (CCA) yielded early eluting sub-fractions from
both CCA1 and CCA2 Sephadex LH-20 columns that were composed of oligosaccharides. As
with the CJA separations, these fractions were cloudy white to pale lavender in appearance in
70% EtOH, and eluted just before the visible lavender band that appears on the column (CCA2
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column; Appendix A color plates: Figure 103). Fractions 1–3 from column CCA1 (CCA1-01,
CCA1-02, CCA1-03) contained mixtures of penta- to octameric oligosaccharides as determined
by the number and integration of anomeric resonances observed in 1H NMR spectra (Figure
84). The components of these three fractions are similar in structure and have similar HPLC
retention times and profiles as those isolated previously from CJ cranberry materials (CJ and
CJA) and CJ-derived urine samples (Figure 82). Fraction CCA1-04 also contained
oligosaccharides, but 1H NMR and HPLC-ELSD data suggest differences in monosaccharide
composition and branching patterns as compared to fractions CCA1-01 – CCA1-03. Fractions
CCA1-05 – CCA1-12 contained a variety of other classes of compounds and lacked the
oligosaccharide components of interest. Fractions CCA1-01 – CCA1-03 accounted for a total
of ~2 g of material and ~4% w/w of the loaded aqueous cranberry extract. Column 2 (CCA2)
yielded 19 fractions with improved resolution of oligosaccharide components across fractions
CCA2-01 – CCA2-05 as determined by 1H NMR spectroscopy. The oligosaccharide fractions
of interest from CCA2 separations accounted for ~7 g of material and ~5% w/w of the loaded
CCA sample.
Changes in both the HPLC system and the ELS detector resulted in lower resolution
chromatography than obtained previously for the CCA1 fractions (Figures 82, 83). Use of the
same HPLC column and method, and comparisons to other fractions with previously
established oligosaccharide composition still made it possible, however, to detect the presence
of the UV-transparent oligosaccharides of interest, eluting between 12–18 min, in CCA
fractions (Figures 82, 83).
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Figure 82. Analytical HPLC-ELSD of CCA1 fractions 01, 02, and 03, compared to CJA2-04
showing a similar elution profile (AtldC18, % MeOH shown).
The chromatographic resolution for these separations is lower than that shown previously due
to changes in the instruments used. These materials were highly enriched for oligosaccharides
as evidenced by the lack of other compounds that eluted during the full gradient. From previous
chromatographic analyses, glucose, fructose and sucrose were determined to elute at < 5 min
with the conditions used (See Appendix B-5: Figure 105). The minimal quantity of compounds
eluting at this retention time for fractions CCA1-01 – CCA1-03 indicates that these samples are
unlikely to contain monosaccharide contaminants such as glucose.
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Figure 83. Analytical HPLC-ELSD of CCA1-03, 04, 04P, 05, and 06 showing the absence of
oligosaccharide components in the CCA1-04 and later Sephadex LH-20 fractions (AtldC18, %
MeOH shown).
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Figure 84. Comparison of the 1H NMR spectra for fractions CCA1-01, CCA1-02, CCA1-03,
and CCA1-04, D2O, 400 MHz.
Fractions CCA1-01, CCA1-02 and CCA1-03 were determined to probably contain
arabinoxyloglucan oligomers based on the presence of indicative resonances at 4.4, 5.0, 5.1,
and 5.2 ppm. These arabinoxyloglucan mixtures are likely composed of penta- to octameric
oligosaccharides as determined by the number and integration of these observed anomeric
resonances. Fraction CCA1-04 does not contain the indicative anomeric resonances and instead
appears to contain only a reducing glucose moiety based on the presence of α- and β-anomeric
resonances at 5.15 and 4.55 ppm, respectively. Additional analyses would be required to
determine the full composition and structural assignments for each of these fractions.
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3. Preliminary Characterization of Commercial Cranberry Products
An optimized HPLC-ELSD method was used to detect oligosaccharides in commercial
cranberry products. The semi-quantitative nature of ELSD (see Appendix B-4: ELSD
overview) makes it possible to assess the relative ratios and concentrations of components
across and within samples, regardless of the nature of the compounds. Direct quantification of
oligosaccharides was not possible during these studies due to the lack of available standards,
the complexity of the mixture, and instrument and detector limitations. Previous studies with
urine samples (Chapter 2) using the same equipment and method indicated, however, that this
system could be used to detect oligosaccharides in 20 µL samples at concentrations of less than
10 mg/mL (Table 35; Figure 72). The use of a full gradient from 100% water to 100% MeOH
allows for the elution of the majority of compounds present, with polar compounds eluting
earlier (< 10 min) and nonpolar compounds eluting later (35–55 min) within a chromatogram.
Possible evidence of oligosaccharides was detected in one of the four commercial
cranberry dietary supplement products analyzed, the SN fruit powder (Figure 85). Of the
samples tested, the SN product appeared to have the least amount of processing. Based on
labeling (Appendix C-2), SN was a powder obtained through direct lyophilization of
cranberries. It was therefore expected that it would contain components seen in the cranberry
juice powder (18–30 min) as well as additional compounds (eluting between 4–18 min). When
in solution, the SN material was different in appearance than the CJ material (Appendix A color
plates: Figure 99), but this is likely due to the presence of fruit-derived components that had
been removed during juice manufacturing. Further work with 100 g of the SN material in
conjunction with CJA2 material resulted in the identification of two arabinoxyloglucan
oligosaccharides from both sources (Master’s Thesis of Kimberly Auker 2013).
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Evidence of oligosaccharides was not apparent in three of the four dietary supplement
products analyzed: FN, NB, and NM (Figure 86). Based on the label claims of these products
(Table 29, Appendices C-3, C-4), the amounts injected of these commercial “concentrates”
should have been equivalent to much higher concentrations of cranberry metabolites (Table
35), but there was no detectable evidence of such a concentration effect. Additionally, the
HPLC-ELSD profiles of the dietary supplement fruit powder concentrates were markedly
different from those of the SN cranberry fruit powder and the cranberry juice powder (CJ). This
was consistent with the appearance of these materials as observed during preparation for HPLC
(Table 29, Appendix A color plates: Figure 98). These data suggest that manufacturer
processing methods for producing “concentrates” significantly alter the composition of the final
product and probably remove the oligosaccharides of interest (see Appendix C-1 discussion).
The HPLC-ELSD profile characteristic of oligosaccharides (18–24 min) was readily
detected in four of the juice products analyzed: OSC, LCP, GVC, and GVNS (Figures 87–90).
The other two juice products, BCB and NL also appeared to contain the profile of interest but
these components were present at much lower concentrations and were almost undetectable
(Figures 87, 89). All putative oligosaccharide components were minor constituents relative to
the rest of the material present in the samples, and they could not be detected without baseline
expansions (Figures 88, 90). The putative oligosaccharide components of LCP and OSC
materials were similar to each other in appearance and relative concentrations (box; Figure 90).
The GVC and GVNS profiles were also similar to each other, with lower concentrations of
metabolites in the region of interest (18–24 min) for the GVNS material (box; Figure 88). The
juice chromatograms for GVC, GVNS, OSC, and LCP were similar to each other from 18-48
min with differences in relative concentrations.
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The similarity of oligosaccharide profiles across juice brands indicates the presence of
similar constituents, presumably due to the presence of cranberry juice concentrate in each
product. As the same amount of each juice sample was analyzed for each product, the
differences in relative concentration of putative oligosaccharides may reflect different
percentages of cranberry juice in the different products. Only two of the six products analyzed
indicated the percent content of cranberry juice (OSC: 27% and GVC: 30%), and both of these
contained only sugar (presumably sucrose) and ascorbic acid as the other two added
ingredients. These two products also had the highest detectable concentrations of
oligosaccharide components. Of the other four products analyzed, cranberry juice is the second
ingredient listed on the labels, indicating that it is at lower relative concentration than the first
ingredient listed (either grape or apple juice concentrate). These other juice concentrates are
added as a way to naturally sweeten and balance the flavors of cranberry juice, and are
relatively less expensive to manufacture. Higher relative percentages of grape or apple juice
therefore decrease the overall cost of the cranberry juice product for the manufacturer and
provide the sweetness many consumers expect with the marketing benefit of a label claim of
100% juice. Based on the semi-quantitative results of the preliminary HLPC-ELSD analyses in
these studies, it is therefore likely that the products with lower apparent oligosaccharide
concentrations (GVNS and LCP) have corresponding lower overall percentages of cranberry
juice as an ingredient (probably less than 27%).
All six juice products had a similar color (Appendix A color plates: Figures 100, 101),
even though they differed in apparent cranberry oligosaccharide content, and therefore
cranberry content, as detected by HPLC-ELSD. Products that contained grape or apple juice as
the first ingredient still appeared to be the same color as cranberry-only products even though
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both apple and grape juices are known to have distinct color profiles. This observation may
reflect the efforts of manufacturers to ensure that their products meet consumer expectations of
appearance for a juice product advertised as “cranberry juice.” The addition of “vegetable
color” to products that have apple juice as the first ingredient (LCP and NL) may therefore
further indicate lower relative concentrations of cranberry juice, as the resulting products
without added “vegetable color” may not necessarily satisfy consumer expectations.
The results of the preliminary studies of commercial juice products also indicate that
grape and apple juices probably lack the oligosaccharide components of interest that are found
in cranberry. The primary ingredient for the BCB product is grape juice, while the primary
ingredient for the NL product is apple juice. Both of these products also contain cranberry juice
as a reported ingredient, but have trace (NL) or undetectable (BCB) levels of the characteristic
cranberry oligosaccharide profile. These observations would support previous reports that the
consumption of apple or grape juice does not lead to the production of urine with anti-adhesion
properties by human volunteers (Howell et al. 2010).
Overall, HPLC-ELSD profiles of cranberry juice products, including those with
relatively lower percentages of cranberry, were similar in elution profile (8–48 min) to the
cranberry juice powder (CJ) used for swine feeding studies (Chapter 2). The juice products
profiles differed greatly from those of dietary supplement products, with juices containing
many more detectable constituents in both polar (early eluting) and nonpolar (later eluting)
regions of the chromatograms. These results further support the hypothesis that dietary
supplement products lack the oligosaccharide components of interest, while juice products
retain them. Additional studies will be necessary to fully quantify and characterize the
occurrence of cranberry oligosaccharides in various commercial products.
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Figure 85. Analytical HPLC-ELSD comparisons of commercial cranberry dietary supplements
(AtldC18).
Components of interest (box), indicative of possible oligosaccharide content, could not be
detected in FN, NM, or NB materials. Based on this analysis it was determined that compounds
of interest may have been present in SN material and further studies confirmed the presence of
oligosaccharides in this product.
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Figure 86. Analytical HPLC-ELSD comparisons of commercial cranberry dietary supplements,
baseline expansion (AtldC19).
Even with baseline expansions and multiple analytical separations, components indicative of
oligosaccharides could not be detected in FN, NM, or NB materials.
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Figure 87. Analytical HPLC-ELSD comparisons of commercial juice products (BCB, GVS,
and GVNS) to CJ material.
Early-eluting polar components constituted the majority of the BCB, GVS and GVNS juice
samples. The presence of the putative oligosaccharide components (box) was not readily
apparent.
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Figure 88. Analytical HPLC-ELSD comparisons of commercial juice products (BCB, GVS,
and GVNS) to CJ material with baseline expansions.
Putative oligosaccharide components (box) in the GVS and GVNS juice samples could be
detected with baseline expansion. The GVS and GVNS materials were similar in overall
composition (18-45 min) with differences in the relative concentrations of the detected
compounds. The BCB material contained lower concentrations of all compounds present and
the oligosaccharide profile of interest was not detectable in this product at the sample
concentration used.
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Figure 89. Analytical HPLC-ELSD comparisons of commercial juice products (OSC, LCP, and
NL) to CJ material.
Early-eluting, polar components constituted the majority of the OSC, LCP and NL juice
samples. The presence of the putative oligosaccharide components (box) was suggested for the
OSC and LCP but was not readily apparent.
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Figure 90. Analytical HPLC-ELSD comparisons of commercial juice products (OSC, LCP, and
NL) to CJ material with baseline expansions.
Putative oligosaccharide components (box) in the OSC and LCP juice samples could be
detected with baseline expansion. The OSC and LCP materials were similar in overall
composition (18-45 min), with differences in the relative concentrations of the detected
compounds. The NL material contained lower concentrations of most compounds present and
the presence of the oligosaccharide profile of interest is suggested but could not be confirmed
in this product at the sample concentration used.
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4. Bioactivity of CJ and CC Cranberry Components
Two different anti-adhesion assays were available at different points in time. Selected
samples were submitted to both assays based on the availability of the assay and logistical
considerations.
a. Anti-agglutination Assay
Samples of CJ, CJA and selected CJA fractions were submitted for preliminary testing
in the UPEC-HRBC anti-agglutination assay (Table 37). Samples that contained the
oligosaccharides of interest appeared to be active while fractions that lacked such
oligosaccharides (CJA2-05) were not active. The apparent low activity of fractions CJA2-03
and CJA2-04 may have been due to issues with the repeatability of the assay rather than to an
actual lack of activity, as exhibited by the differing results for the duplicated CJA samples. All
fractions from CJA separations were therefore not exhaustively tested because of the
questionable reproducibility of the assay.
Table 37. Anti-agglutination assay results for cranberry fractions (CJ, CJA and CJA Sephadex
LH-20 fractions).
The aqueous fraction of CJ and early-eluting fractions from CJA Sephadex LH-20 columns
showed anti-agglutination activity.
UM
Test Date
Sample Description
Scorea
CJ (cranberry juice powder)
+
07/2011
CJA (aqueous fraction)
+/–
07/2011
b
CJA (aqueous fraction)
++
07/2011
CJA1-02B (Sep LH-20 fraction)
++
07/2011
CJA2-02 (Sep LH-20 fraction)
++
07/2011 x2b
CJA2-03 (Sep LH-20 fraction)
+/–
07/2011
CJA2-04 (Sep LH-20 fraction)
+/–
07/2011
CJA2-05 (Sep LH-20 fraction)
–
07/2011 x2b
a
The criteria used to assign the UM Score can be found in Table 3. Raw data for these samples
can be found in Appendix B-3: Table 58. b Sample was tested in duplicate for this test date.
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b. Anti-adhesion Assay
Selected CJA2 and SN fractions were tested in the radiolabeled version of the UPECUEC anti-adhesion assay using methods described previously (Auker 2013, Mathison et al.
2013).
The fluorescence-based version of the UPEC-UEC anti-adhesion assay (Kimble et al.
2014) was used for the CCA1 fractions and IC50 values from these analyses are shown below
(Table 38). Fraction CCA1-01 had the highest activity (IC50 = 0.25 mg/mL), and fractions
CCA1-01 – CCA1-03 appear to account for the majority of the anti-adhesion activity observed
in the CCA material. Fractions CCA1-04 – CCA1-12 are either not active or have relatively
low activity. The differences in structure and composition as determined by NMR spectroscopy
and HPLC-ELSD for fraction 04 versus fractions CCA1-01 – CCA1-03 appear to correlate to
activity, with fraction 04 having lower activity than CCA1-01 – CCA1-03. Fractions CCA1-01
to CCA1-03 lack components that elute early in HPLC-ELSD chromatograms (Figure 82),
further supporting the assignment of anti-adhesion activity to the components of the complex
oligosaccharide mixtures present in these fractions.
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Table 38. UPEC-UEC anti-adhesion assay results for CCA1 fractions.
The aqueous fraction of the CC material (CCA) displayed higher anti-adhesion activity than the
EtOAc fraction (CCE). This anti-adhesion activity could be attributed to Sephadex LH-20
fractions CCA1-01 – CCA1-03P.
Sample
IC50 (mg/mL)
CCE (EtOAc fraction of CC material)
2.88
CCE (EtOAc fraction of CC material)
2.87
CCA1 (aqueous fraction of CC material)
1.21
CCA1 (aqueous fraction of CC material)
1.10
CCA1-01 (Sep LH-20 fraction)
0.25
CCA1-02 (Sep LH-20 fraction)
1.55
CCA1-03 (Sep LH-20 fraction)
1.22
CCA1-03P (precipitate from Sep LH-20
1.50
fraction CCA1-03 in EtOH)
CCA1-04 (Sep LH-20 fraction)
3.81
CCA1-04P (precipitate from Sep LH-20
2.06
fraction CCA1-04 in EtOH)
CCA1-05 (Sep LH-20 fraction)
3.05
CCA1-06 (Sep LH-20 fraction)
>10
CCA1-07 (Sep LH-20 fraction)
NAa
CCA1-08 (Sep LH-20 fraction)
>10
CCA1-09 (Sep LH-20 fraction)
4.03
CCA1-10 (Sep LH-20 fraction)
>10
CCA1-11 (Sep LH-20 fraction)
>10
CCA1-12 (Sep LH-20 fraction)
>10
a
This fraction was not available for testing when samples were submitted.
c. Antimicrobial Assays
For the NCNPR antimicrobial assays, compounds or fractions that show greater than
50% growth inhibition at the test concentration were considered to be active and would be
tested in secondary assays. All of the cranberry materials submitted to these assays had less
than 50% growth inhibition and were therefore considered inactive (Table 39). These results
indicate that cranberry materials do not possess cidal or growth-inhibitory activity against the
microbes tested at the concentrations used. Cranberry oligosaccharide fractions prepared from
SN and CJA2 cranberry material by K. Auker (2013) were also submitted to the antimicrobial
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assays offered by NCNPR at UM, as well as to two separate breast cancer cell viability assays.
These assays produced similar negative results, further confirming the lack of antimicrobial
activity and additionally indicating a lack of cytotoxicity.
The negative results for cranberry materials in the antimicrobial assays and cytotoxicity
assays of NCNPR supports the relative safety of cranberry in general, as would be expected for
a common food product. These results also support the hypothesis that cranberry components
exhibit anti-adhesion-specific bioactivity without concurrent antimicrobial effects.
Table 39. Results of the NCNPR antimicrobial assays for CJ material and fractions.
The CJ material and the water (CJA) and EtOAc (CJE) fractions of this material showed no
apparent antimicrobial activity in the NCNPR assays.
Conc.
Percent Growth
Tested
Inhibition
↓ Organism
(µg/mL)
by Sample (%)
CJ
CJE CJA
→ Sample Code
15.9
Plasmodium falciparum (D6 Clone)
29
6
7
80
4.37 7.89 5.07
Leishmania donovani
50
0
0
0
Candida albicans
50
0
8
0
Candida glabrata
50
0
9
1
Candida krusei
50
8
12
8
Candida neoformans
50
0
1
0
Aspergillus fumigatus
50
0
0
0
Staphylococcus aureus
50
Methicillin-Resistant Staphylococcus aureus
0
14
1
50
0
10
0
Escherichia coli
50
0
5
0
Pseudomonas aeruginosa
50
16
0
24
Mycobacterium intracellulare
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D. Conclusions
It is likely that a number of compounds are present in cranberry that contribute to the
anti-adhesion properties of the juice. Cranberry PACs and NDM are already known to have
anti-adhesion activity, and these compounds were likely to be retained by MW cut-off
centrifugal filters under the conditions used in these studies. Additional compounds, such as
oligosaccharides could also have been retained through reversible associations with high-MW
components. All three classes of compounds would also likely be stable under the acid/base
incubation conditions used.
The use of methods similar to those developed for the isolation of oligosaccharides
from urine enabled the identification of similar oligosaccharide components in cranberry.
Analyses using HPLC-ELSD/UV and NMR spectroscopy provide strong support for the
presence of an entire pool of such structurally related carbohydrate compounds in spray-dried
cranberry juice powder, cranberry juice concentrate and certain commercial products. Two
cranberry oligosaccharides were isolated and fully elucidated from CJA material (Auker Thesis
2013) and found to have similar structures as the fully elucidated urinary octasaccharide (1).
These studies are the first reports of arabinoxyloglucan oligosaccharides from cranberry.
The similarities in structures for the oligosaccharides from both cranberry and urine
sources, combined with the similar HPLC-ELSD profiles of oligosaccharides from both sources
(Figure 74), strongly supports the hypothesis that cranberry oligosaccharides are the source of
urinary oligosaccharides. In foods, hemicellulose oligomers such as arabinoxyloglucans are
considered to be a type of dietary fiber due to their lack of human metabolic biotransformation
(Haard & Chism 1996). The presence of β-(1→4)-linked glucose backbones in
oligosaccharides from both sources therefore further supports the hypothesis that these
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compounds are stable to normal digestive processes and may be directly excreted without
metabolic modification.
Numerous clinical trials that have tested the effectiveness of cranberry products have
used cranberry dietary supplements rather than cranberry juice or cranberry juice concentrate.
A possible reason for the failure of some of these trials is therefore the absence of anti-adhesive
cranberry metabolites from the products used. This hypothesis is supported by the observation
that oligosaccharides were absent from three of the four cranberry fruit dietary supplement
products analyzed. In contrast, the characteristic oligosaccharide HPLC-ELSD profile was
readily detectable in four of the six juice products analyzed at concentrations corresponding to
the marketed juice preparations. This observation supports the traditional use of cranberry juice
for preventing UTIs, and provides a possible reason for why cranberry dietary supplements
manufactured using current processes may not be as effective for this same application.
Knowledge of the active metabolites of cranberry will help to resolve many of the existing
issues with regards to clinical trial testing and cranberry dietary supplement composition.
In these studies, oligosaccharide mixtures with similar chemical profiles were isolated
in large scale from two sources, and comprised 2–6% of the CJ and CCA starting materials.
The oligosaccharide-containing fractions from the CJA separations constituted a relatively high
percentage of this starting material (25-30%), but this may reflect a lower degree of enrichment
rather than a higher actual yield of oligosaccharides. In contrast, only 1% of the total CJ
material was extractable by EtOAc. This EtOAc fraction was found to contain PACs and as
well as other known flavonoids. These data indicate that PACs and other flavonoids are present
at lower relative concentrations than oligosaccharides (Santos-Buelga & Scalbert 2000).
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The presence of a similar complex profile of oligosaccharide components in the CJ, CC,
and SN (Auker 2013) materials, as well as in commercial juice products from multiple
manufacturing sources, supports the hypothesis that these compounds are a native component
of cranberry that is naturally enriched in cranberry juice, rather than a processing or extraction
artifact. The structures of the two arabinoxyloglucan oligosaccharides isolated from cranberry
material and the 1H NMR data of the oligosaccharide-enriched Sephadex LH-20 fractions
indicate that the series of oligosaccharide compounds present are all structurally related and are
all likely to be arabinoxyloglucans derived from hemicellulose. Plant hemicellulose polymers
are components of plant primary cell walls that are enzymatically cleaved and solubilized
during fruit ripening (Redgewell & Fry 1993, York et al. 1996, Brummell et al. 2004, Goulão
& Oliveira 2008). Complex mixtures of such compounds with arabinoxyloglucan structures
unique to cranberry could therefore reasonably end up in the juice of pressed ripe cranberries at
relatively high concentrations. The relatively high yield of oligosaccharide mixtures from
cranberry materials indicates that cranberry could therefore be a valuable source from which to
obtain additional oligosaccharides.
The results from two independent anti-adhesion assays using fractions from three
cranberry source materials (CJ, CC, and SN) confirmed the anti-adhesion activity of cranberry
arabinoxyloglucan mixtures. These studies are the first report of the E. coli anti-adhesion
properties of arabinoxyloglucan oligosaccharides. Active cranberry samples, both crude and
enriched fractions, contained similar HPLC-ELSD and 1H NMR profiles as active urine
fractions, with the presence of a series of UV-transparent oligosaccharides. These results,
combined with the high degree of structural similarity between urinary and cranberry
oligosaccharides, further support the anti-adhesion properties of urinary oligosaccharides.
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Future studies are required to conclusively establish the bioactivity profiles of
individual arabinoxyloglucans oligosaccharides using additional bioassay resources and
methods. The large scale isolation of cranberry oligosaccharides during these studies has
resulted in the collection of sufficient amounts of material (~20 g) to facilitate future studies
involving the isolation and detailed structure elucidation of individual oligosaccharide
components. It also provides sufficient material for future bioassay testing and analytical
method development. The potential use of cranberry anti-adhesive oligosaccharides for the
prevention of infections, especially UTIs, warrants continued investigation into the structural
characteristics and biological properties of these compounds.
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CHAPTER 4: CHANGING THE CRANBERRY PARADIGM

A. Introduction: The Story of a Paradigm Transition

1. Swine Urine Studies
The primary objectives of these studies were (1) to isolate and identify the urinary
metabolites of cranberry juice that are responsible for the prevention of UPEC adherence, and
(2) to identify the compounds present in cranberry that are related to the anti-adhesive urinary
metabolites. This work started under the paradigm and guiding hypothesis that the compounds
of interest would be PACs or PAC-derived (Howell et al. 1998, Howell et al. 2010, Ofek et al.
1996). Efforts to isolate such compounds from active urine fractions failed, however, and
delayed the identification of the actual, active components of interest.
The chance observation of a 1H NMR spectrum for a pectin sample during a conference
presentation led to the realization that the 1H NMR spectra of active fractions FA1 and FA2
were similar to those of complex carbohydrates. Subsequent comparisons of active samples to
the 1H NMR spectra of commercial monosaccharides, pectin, synthetic PACs, and other
samples, combined with chemical analyses using TLC spray reagents, confirmed the
observation that the compounds of interest were probably UV-transparent carbohydrates. The
hypothesis that PACs were the target urinary metabolites was discarded based on data collected
during initial studies, and investigations were continued under the newly formulated hypothesis
197

that complex carbohydrates were the compounds of interest. These observations and this newly
formed hypothesis prompted the use of ELSD, a mass-sensitive, semi-quantitative detection
method, to monitor subsequent HPLC separations.
Multiple swine feedings were required to obtain sufficient material and suitable
methods for the isolation of the compounds of interest from active fractions. Ultimately, a
sufficient quantity (12 mg) of a single pure compound (1), low quantities of other pure
compounds (1-2 mg), and many other partially purified compounds were obtained from the
complex carbohydrate mixture. The structure of 1 was elucidated using multiple carbohydratespecific analyses and NMR spectroscopic techniques. This compound was highly similar in
structure to the other purified and partially purified compounds present in the mixture of
interest, and all were determined to be arabinoxyloglucan oligosaccharides. Data indicated that
these urinary oligosaccharides contained cellulose-type β-(1 → 4)-linked glucose backbones,
supporting the newly formed hypothesis that these compounds were plant-derived.
Circumstantial evidence suggested that components of this arabinoxyloglucan oligosaccharide
mixture were responsible for the UPEC-HRBC anti-agglutination activity of active fractions:
oligosaccharides were the only compounds detectable in some active fractions, were present in
all active fractions, and were absent from all inactive fractions. Material limitations and issues
with assay reproducibility made it impossible, however, to directly confirm the anti-adhesion
properties of the isolated urinary arabinoxyloglucan oligosaccharides. Additionally,
arabinoxyloglucans from cranberry had not been previously identified, and there were no
previous reports of anti-adhesion properties for arabinoxyloglucan oligosaccharides. The
conclusions of the urinary metabolites study led to the formulation of the new hypothesis that
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the anti-adhesive compounds present in urine after cranberry consumption were
arabinoxyloglucan oligosaccharides derived from cranberry.

2. Cranberry Studies
Cranberry materials were investigated using the same methods developed for urine
samples to determine if similar oligosaccharides were present in the starting material fed to
swine. Analytical HPLC-ELSD data showed evidence of a highly similar elution profile for the
compounds of interest from cranberry material. Direct separation of cranberry juice powder on
preparative HPLC, with no prior extractions or enrichments, led to the isolation of sufficient
quantities (2-4 mg) of several cranberry oligosaccharides, confirming that the same class of
compounds was present and was of highly similar chemical composition. More material was
required, however, for full structural elucidation of the cranberry oligosaccharides of interest.
Large scale isolation of cranberry oligosaccharide mixtures was pursued using the
Sephadex LH-20 methods similar to those developed for urine separations. Cranberry source
materials used included cranberry juice powder, cranberry juice concentrate, and cranberry fruit
powder. These isolations led to the total collection of approximately 20 g of enriched
oligosaccharide material from all three sources. Enriched cranberry oligosaccharide mixtures
were used for further analyses and bioactivity testing. The purification and structure elucidation
of two compounds from the cranberry oligosaccharide series was the subject of the Master’s
Thesis for Kimberly M. Auker (2013). The two purified and fully characterized cranberry
oligosaccharides were also found to be arabinoxyloglucan oligosaccharides that were highly
similar in structure to the urinary octasaccharide and the associated series of urinary
oligosaccharides. The similar structures of urine- and cranberry-derived oligosaccharides
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supports the hypothesis that swine urine oligosaccharides are derived from ingested cranberry
products and provided support for the new hypothesis that cranberry arabinoxyloglucan
oligosaccharides are absorbed and excreted unchanged into mammalian urine.
Oligosaccharide-enriched fractions from cranberry materials were submitted to two
different anti-adhesion assays and showed activity in both. These assays both used
uropathogenic P-fimbriated E. coli (UPEC) and included the original, qualitative, antiagglutination assay and a newly-developed, quantitative, uroepithelial cell (UEC) anti-adhesion
assay. The results of the newly-developed assay confirmed those of the original antiagglutination assay. The results from testing cranberry fractions in antimicrobial assays
provided additional support for the published hypothesis that cranberry-derived compounds
prevent adhesion without direct antimicrobial effects. The anti-adhesion assay results for the
cranberry oligosaccharides confirmed, by association, the previously putative anti-adhesion
activity of urinary oligosaccharides. The conclusions of these studies supported the hypotheses
that urinary and cranberry arabinoxyloglucan oligosaccharides can both prevent the adhesion of
UPEC to uroepithelial cells.
Analysis of commercial cranberry products (dietary supplements and juices) by an
oligosaccharide-optimized HPLC-ELSD method showed that some products lack detectable
levels of oligosaccharides while others contain readily detectable amounts of the
oligosaccharide mixture of interest. Many clinical studies testing the effectiveness of cranberry
for UTI prevention have used cranberry products enriched for PACs or standardized to PAC
content. Such products may therefore lack detectable levels of carbohydrates such as
arabinoxyloglucan oligosaccharides. These observations and the results of these studies
therefore support the hypothesis that the inconclusive results of certain clinical studies may be
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due, in part, to the use of cranberry products that lack cranberry oligosaccharide compounds
with anti-adhesion activity.

3. Overview of Results
As reported here, cranberry arabinoxyloglucan oligosaccharide mixtures prevent the
adhesion of uropathogenic P-fimbriated E. coli in two different anti-adhesion assays, are
present in relatively high percentages in renewable source material, and are present in
mammalian urine after the consumption of cranberry products. These observations and the
availability of enriched cranberry oligosaccharide fractions lay the groundwork for future
studies based on many new hypotheses concerning oligosaccharides.

B. Significance of Cranberry-Derived Urinary Oligosaccharides

1. Cranberry Oligosaccharides as Anti-adhesion Compounds
Carbohydrates have many roles with regards to host-pathogen interactions (Beachey
1981, Pieters 2007). Eukaryotic cell surface carbohydrates are the natural ligands for many
types of microbial adhesins, including the P fimbriae of E. coli (Enerbäck et al. 1987). Free
oligosaccharides are recognized to be natural interference ligands, and various sources of such
compounds with anti-adhesion properties are of significant medical interest for the prevention
of infections (Zopf & Roth 1996, Sharon 2006, Pieters 2007, Shoaf-Sweeney & Hutkins 2008).
Carbohydrates that mimic the natural carbohydrate ligands of microbial adhesins may be able
to directly interfere with microbial adhesion to cell surfaces by competitive binding.
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Alternatively, carbohydrates that bind to microbial fimbriae in other locations may prevent
fimbrial adhesion to target ligands by indirect mechanisms such as by altering fimbrial
conformations.
Carbohydrates are well recognized as compounds that can prevent P-fimbriated E. coli
adhesion. For example, globotriose [α-D-Gal-(1→4)-β-D-Gal-(1→4)-β-D-Gal], galabiose,
multivalent galabiose, and tetrasaccharides containing an α-Gal-(1→4)-β-Gal moiety are able
to inhibit E. coli adhesion both in vitro and in vivo by binding to P fimbriae in place of cell
surface receptors (Svanborg-Edén et al. 1984, Korhonen et al. 1986, Leach et al. 2005, Turner
et al. 2005, Salminen et al. 2007). The binding of the PapG adhesin of E. coli P fimbriae can
also be inhibited by dipentasaccharide fragments derived from the globoseries of glycolipids
that contain the minimum α-Gal-(1→4)-β-Gal binding epitope (Larsson et al. 2003). Studies
have shown that mixtures of neutral oligosaccharides isolated from breast milk and the urine of
breast-feeding babies are able to interfere with E. coli adhesion (Rosenstein et al. 1988, Coppa
et al. 1990). While these and other studies show proof-of-principle for the ability of
carbohydrates to prevent E. coli adhesion, currently known compounds are not clinically viable
agents due to non-specific lectin binding, limited material availability, and high manufacturing
costs, among other reasons (Larsson et al. 2003, Turner et al. 2005, Sharon 2006, Pieters 2007).
Additional carbohydrate-type compounds that can prevent the adhesion of P-fimbriated E. coli
are of great medical interest but suitable compounds have not yet been identified and developed
into therapies.
Studies investigating the effects of cranberry juice on the P fimbriae of individual E.
coli using the nanoscale tool of AFM microscopy indicate that cranberry components directly
interact with fimbriae and prevent adhesion by affecting the conformations of E. coli surface

202

macromolecules (Liu et al. 2006). Studies of E. coli strains with variations in Pap-G adhesin
types indicate that the conformation and overall structure of cell surface carbohydrate chains
influences bacterial binding (Strömberg et al. 1991). Specifically, the Pap-G adhesin isotype
that is most often found in UPEC preferentially binds to neutral, 4- and 5-sugar containing,
cell-surface glycosphingolipid isoreceptors containing the minimum Gal-(α1→4)-Gal binding
epitope, the major isoreceptor of uroepithelial cells (Strömberg et al. 1991, Strömberg et al.
1990). The UPEC-associated Pap-G adhesin isotype also preferentially binds to compounds
containing multiple versions of the target galabiose disaccharide (multivalent compounds),
showing higher binding affinities for these compounds than for compounds with a single
version of the galabiose disaccharide (monovalent compounds) (Figure 91) (Salminen et al.
2007).

Figure 91. Examples of monovalent and multivalent carbohydrate derivatives containing the
galabiose binding epitope (Salminen et al. 2007).
The octavalent compound shown inhibited the adhesion of UPEC with the PapGJ96 adhesin to
epithelial cells at an IC50 value of 22 µM and inhibited HRBC agglutination at an MIC of 7
µM. In contrast, the monovalent compound shown inhibited cell adhesion at an IC50 value of
170 µM and inhibited HRBC agglutination at an MIC of 320 µM in the same assays (Salminen
et al. 2007).
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Together, these data support the proposed hypothesis that the neutral cranberry
oligosaccharides identified in the present studies bind to the Pap-G adhesin of UPEC P
fimbriae, changing its conformation and thereby preventing the adhesion of UPEC to
uroepithelial cells. Numerous further studies are necessary, however, to fully characterize the
mechanisms by which cranberry oligosaccharides alter interactions between bacterial and
epithelial cells to prevent adhesion. Studies using AFM could be used to confirm that cranberry
oligosaccharides are able to cause the changes in fimbrial conformation observed with
cranberry juice (Liu et al. 2008). Modeling, crystal structures, and various types of labeling
could be used to investigate putative binding sites for oligosaccharides on P fimbriae and to
characterize how different PapG adhesin classes and isotypes interact with oligosaccharides of
different structures (Strömberg et al. 1991, Larsson et al. 2003, Salminen et al. 2007). The
effectiveness of oligosaccharides for preventing the adhesion of E. coli during different stages
of infection, of different clinical strains of E. coli, or of clinical E. coli strains with different
fimbrial variants could also be examined (Marrs et al. 2002, Howell & Foxman 2002, Justice et
al. 2004). Many additional types of studies are also likely to be proposed by other researchers
in relation to their chosen specialties.
Various clinical approaches that aim to interfere with adhesin-ligand binding between
pathogen and host cells have met with mixed success, due partly to the complexities of in vivo
systems and partly to the structural complexities of carbohydrates (Zopf & Roth 1996, Sharon
& Ofek 2000, Sharon 2006). The approaches that currently show the greatest potential are those
that use multivalent carbohydrates or mixtures of oligosaccharides (Sharon & Ofek 2000,
Pieters 2007, Salminen et al. 2007). Neutral oligosaccharides composed of four to six
monosaccharide units, or compounds containing multiple versions of the known carbohydrate
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binding epitope of E. coli (oligovalent or multivalent compounds; see Figure 92) have also
shown increased binding affinities and higher anti-adhesion activity against P-fimbriated E. coli
(Svanborg-Edén et al. 1984, Coppa et al. 1990, Larsson et al. 2003, Salminen et al. 2007,
Pieters 2007). Complex carbohydrates or oligosaccharide mixtures possess superior antiadhesion abilities as compared to mono- or disaccharides, and are believed to be more effective
at preventing adhesion due to their ability to mimic host cell carbohydrate receptors and their
simultaneous interactions with multiple bacterial adhesions (Pieters 2007, Salminen et al.
2007). Microbes typically express multiple adhesion mechanisms during infection, and
mixtures of compounds may be required to prevent all types of adhesion and obtain clinical
efficacy. These observations support the hypothesis that the anti-adhesion properties of
cranberry and urinary oligosaccharides may be enhanced due to the presence of mixtures of
complex, neutral oligosaccharides. Numerous studies would be necessary to investigate this
hypothesis, and all would require the availability of sufficient quantities of purified and fully
characterized individual oligosaccharides for the controlled testing of known ratios of
compounds.

2. Implications for Cranberry Bioactivity
The identification of oligosaccharides as anti-adhesive components of cranberry
products provides a new direction for all researchers interested in cranberry bioactivity. Data
from the present studies indicate that oligosaccharides are likely to be partly responsible for
previously observed cranberry product anti-adhesion effects (Ofek et al. 1996, Howell et al.
1998, Howell et al. 2010, Tao et al. 2011, Turner et al. 2005). The structural and
chromatographic characteristics of oligosaccharides also indicate that these compounds may be
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present, but undetected, in many other “enriched” bioactive fractions derived from cranberry.
Unlike many typical small molecule natural products, oligosaccharides are of relatively high
MW, are UV transparent and are not readily ionized or detected by generalized MS-based
methods (Table 40).

Table 40. Overview of reasons for the difficulty of detection, isolation, and structural
characterization of oligosaccharides using classical bioassay-guided fractionation.
Compound
Type

Typical Natural Product

Oligosaccharides

Extraction

Organic extracts

Water soluble, not organic soluble

Isolation

Relatively few components with Complex series of many structurally related
structural similarity in a series
components

Detection

UV detection possible

No chromophore, ELSD or other
chromatographic detection method required

Ionization

Readily ionized for detection by
(+) or (-) LC-MS

Poor ionization for LC-MS, requires
derivatization, specialized MS methods
and/or custom calibration

NMR Spectra

Simple NMR spectra, <30
carbons

Complex NMR spectra, >30 carbons

Structural
Elucidation

Full characterization possible
using spectroscopic/
spectrometric methods

MW

200-800 Da, < 10 mg yields
usable NMR data at 400 MHz

Bioassay
Types

Established, quantitative assays,
or identified by high-throughput
screening

Qualitative or new assays, specific to an
individual organism or research question

Bioassay
Endpoints

Based on clear endpoints such
as the death of the target
organism or growth inhibition

Based on a biological response of a living
organism that can be difficult to quantify
and correlate to in vivo effects. e.g. antiadhesion
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Full characterization requires multiple,
complementary methods that are typically
destructive
800-2000+ Da, requires 15 + mg to yield
usable NMR data at 400 MHz, MW >
typical LC-MS detection threshold

As PAC-enriched fractions are typically characterized through the use of MS or UV
data (Porter et al. 2001, Kandil et al. 2002, Howell et al. 2005, Ermel et al. 2012),
oligosaccharide constituents would not have been detected. Many methods for enrichment or
partial purification would also not necessarily have eliminated oligosaccharides as possible
components of the “enriched” final product. Oligosaccharides may also form reversible
hydrogen bonds with PAC oligomers or other oligosaccharide components in solution to form
complexes with high apparent MWs. It is therefore possible that oligosaccharides may be
present in the PAC-enriched or high-MW fractions used by many researchers and may
contribute to the anti-adhesion effects and other biological properties observed for these
fractions (Delehanty et al. 2007, Shmuely et al. 2004, Steinberg et al. 2004). Future studies will
be necessary to investigate the contributions of cranberry oligosaccharides to the various
biological properties attributed to cranberry.
Multiple compounds with various mechanisms of action are likely to be involved in the
reported bioactivities of cranberry products (Shmuely et al. 2012). With regards to the antiadhesion properties of cranberry, multiple compounds have been identified that have been
shown to prevent microbial adhesion. These include fructose (Zafriri et al. 1989, Ofek et al.
1996), mannose (Ofek & Beachey 1978), PACs (Howell et al. 1998, Foo et al. 2000a,b),
myricetin (Mathison et al. 2013, Kimble et al. 2014), and now also oligosaccharides, as shown
by the present studies. All of these compounds, and possibly others that have yet to be
identified, are likely to act together by various mechanisms to prevent bacterial-mammalian
cell adhesion in different parts of the human body after cranberry consumption. All may
participate in the prevention of biofilm formation within the human mouth, and all may affect
gut microbes by altering species composition or gene expression profiles, including that of E.

207

coli (Ofek et al. 1996, Weiss et al. 1998, Rajan et al. 1999, Yamanaka et al. 2004, Howell et al.
2005, Duarte et al. 2006, Labrecque et al. 2006). Current data, however, give the strongest
support to the hypothesis that carbohydrate-type compounds including mannose, fructose, and
now oligosaccharides have the most significant roles for the prevention of microbial adhesion
in the urinary tract, and therefore for the in vivo prevention of urinary tract infections. Many
types of additional studies of cranberry products and cranberry-derived compounds will be
necessary to fully elucidate all of the ways in which cranberry components may work together
to prevent microbial adhesion to epithelial cells.

3. Cranberry Oligosaccharides as Urinary Components
Data from the present studies support the hypothesis that cranberry oligosaccharides are
absorbed intact and excreted into urine without modification by mammalian enzymes or
digestive processes. The urinary octasaccharide (1) and the octa- and hepta-saccharides (2 & 3)
purified from cranberry oligosaccharide mixtures (Auker 2013) are arabinoxyloglucans with
highly similar structures, all have cellulose-type β-(1 → 4)-linked glucose backbones, and all
are relatively stable over time. In general, hemicelluloses such as these are considered to be a
type of dietary fiber, are water soluble, acid stable, and resistant to degradation during
mammalian digestion, as mammals lack β-glucosidase digestive enzymes (Haard & Chism
1996, Robyt 1998). Crude cranberry materials containing oligosaccharides were also found to
retain anti-adhesion activity after incubation at human body temperature at pH 2, 4, and 8.
Comparison of analytical HPLC-ELSD profiles for urinary and cranberry oligosaccharide
mixtures indicated similar ratios for the different components of the mixture in both materials
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(Figure 74), further supporting the hypothesis that many of the compounds present in the
cranberry mixture are absorbed and excreted intact into the urine in similar ratios.
The primary objective of the present studies was to identify active urinary constituents,
but attempts were also made to monitor sample recovery for relative quantification of the active
constituents. Such quantification proved difficult, however, due to numerous, uncontrollable
sources of sample loss (ELSD-based separations) and to the need for pooling starting materials
across collection periods and study animals to provide sufficient cumulative amounts for the
isolation of active components. Conservative estimates can be made for oligosaccharide urinary
concentrations in relation to cranberry consumption, but additional, detailed studies will be
necessary to fully quantify cranberry oligosaccharide absorption, distribution, and excretion
profiles. Currently available data suggests a minimum urinary oligosaccharide mixture
concentration of approximately 0.15 mg/mL, corresponding to a minimum excretion of 0.04%
w/w oligosaccharides per gram of ingested cranberry powder. This concentration is expected to
vary based on the urinary solute concentrations of individual organisms, but is within a
reasonable range for compounds that are excreted into the urine (Saude et al. 2007, Bouatra et
al. 2013). Currently available data also indicates that the cranberry powder used for swine
feedings contained a maximum oligosaccharide content of 16-30% w/w, with the wide range
based on the method used for enrichment. Together, these data indicate that a minimum of
0.13-0.25% of ingested cranberry oligosaccharides are excreted into urine. While the values
presented here are rough estimates, these data support the hypothesis that orally ingested
cranberry oligosaccharides are also excreted through feces or retained in body compartments
and excreted into urine over time.
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Direct absorption and rapid elimination of unmodified oligosaccharides into
mammalian urine would be consistent with the reported rapid appearance of anti-adhesion
activity in human urine after the consumption of cranberry juice (Howell et al. 2005).
Oligosaccharides have been previously isolated from normal human urine (Parkkinen & Finne
1984), and reports have shown that mixtures of complex oligosaccharides ranging in size from
trimers to heptamers and larger can be ingested and subsequently found in adult and infant
human urine (Rosenstein et al. 1988, Coppa et al. 1990). These studies have reported 500-800
mg/day of uncharacterized oligosaccharide mixtures in the urine of adult women (Coppa et al.
1990). Mice gavaged with high doses of globotriose [Gal-(α1→4)-Gal-(β1→4)-Glc] (Figure
92) were found to rapidly clear this trisaccharide from plasma (t½ = 6 min) and excrete it
primarily into urine without metabolic biotransformation at levels of > 5 mg/mL for 4-12 hours
after administration, indicating that this compound is orally bioavailable and retaind for later
excretion over time (Leach et al. 2005).

Figure 92. Structure of globotriose [Gal-(α1→4)-Gal-(β1→4)-Glc] depicted with IUPAC
stereodescriptors (a) and chair conformers (b).
Together these observations further support the hypothesis that cranberry-derived
oligosaccharides are orally bioavailable and excreted relatively rapidly into urine without
metabolic biotransformation. These data also support the feasibility of oral administration of
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cranberry juice for the prevention of UTIs. Future detailed studies regarding cranberry
oligosaccharides will be needed to quantitatively examine the absorption, distribution,
metabolism, and excretion (ADME) profiles of these compounds, individually and as mixtures.
Such studies will be facilitated by the availability of cranberry compounds as analytical
standards, and the apparent lack of biotransformation, but will require the development of
targeted, sensitive methods for oligosaccharide detection and quantification. High-throughput
analytical platforms optimized for oligosaccharide detection and quantification will also be
required for effective evaluation of clinical samples and dietary source materials that may
contain oligosaccharides.

4. Implications for Human Clinical Trials
Studies are currently in progress at UM to identify the anti-adhesive components of
human urine collected after cranberry juice consumption using isolation and detection methods
similar to those applied to swine urine samples and cranberry oligosaccharides. Human urine
fractions with anti-adhesion activity are hypothesized to contain cranberry-derived
oligosaccharides and preliminary evidence suggests that these compounds are indeed present.
The identification and characterization of cranberry-derived oligosaccharides from human urine
is the minimum piece of information necessary to directly link the current report to probable in
vivo efficacy. Additional studies will be necessary to assess the clinical relevance of
oligosaccharides for the prevention of UTIs in various patient populations. Knowledge of these
active compounds will make it possible to quantify oligosaccharide consumption and excretion
for individual study subjects. These data could then be correlated to long and short term clinical
outcomes, including an absence of UTIs and the oligosaccharide content and anti-adhesion
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properties of patient urine. Improved knowledge regarding the anti-adhesive components of
cranberry that are excreted into urine will also help to resolve many of the current uncertainties
regarding the efficacy of cranberry for preventing UTIs (Jepson et al. 2012).
The variation in procedures for commercial cranberry product preparation and the
probable lack of oligosaccharide constituents in certain products is a possible explanation for
some of the heterogeneity of results obtained from cranberry-focused clinical trials (Jepson et
al. 2012). Preliminary profiling of cranberry dietary supplements with regards to
oligosaccharide content indicates that “concentrated” cranberry dietary supplements may not
contain anti-adhesive oligosaccharides. Most dietary supplement manufacturers do not disclose
the full product manufacturing processes. It is therefore difficult to determine whether certain
products may contain oligosaccharides without subjecting product samples to HPLC-ELSD,
NMR spectroscopy, and other analyses. It is likely, however, that many manufacturers are
enriching for flavonoid content based on the hypothesis that PACs are the target anti-adhesive
constituents, and the methods used for flavonoid enrichment may or may not also enrich for
oligosaccharides. Additional studies are needed to independently quantify the relative amounts
of cranberry oligosaccharides in different dietary supplements prior to the use or marketing of
such products for UTI prevention.
One survey of cranberry clinical trials compared the reported efficacy of cranberry juice
to that of dietary supplements and found that juice was more effective (Wang et al. 2012a). The
authors hypothesized that this may be due to improved patient hydration (Wang et al. 2012a),
but this observed result may also have been due to the presence of cranberry oligosaccharides
in juice products but not in dietary supplement products, as observed in the present studies.
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It is also possible that clinical studies using various cranberry products are showing that
certain cranberry preparations do or do not contain the active ingredients, rather than that
cranberry itself isn’t active. For example, in one of the clinical trials that reported a lack of
cranberry efficacy (Beerepoot et al. 2011), the cranberry product used was a dietary
supplement called Cran-Max® (Proprietary Nutritionals, Inc., Kearny, NJ) that contained a
standardized dose of A-type PACs. Based on published product literature, it appears that the
Cran-Max® extract had been enriched for anthocyanins and flavonoids and likely lacked
oligosaccharides (Proprietary Nutritionals 2007, Appendix C-5). A different study that
supported the effectiveness of cranberry products (Howell et al. 2010) used a cranberry dietary
supplement known as ElluraTM (Ellura, Trōphikōs Nutritive Health, Atlanta, GA) that
reportedly contained “cranberry powder.” The limited product literature that could be found on
the internet regarding ElluraTM (Appendix C-6) indicated that this material was derived from
cranberry juice and standardized with regards to PAC content, but provided minimal
information regarding other possible constituents. Another study that used whole cranberry
powder with standardized PAC content also showed efficacy for preventing UTIs (Sengupta et
al. 2011). Additional cranberry compounds, such as oligosaccharides, may have therefore been
present in cranberry products that have shown efficacy (Howell et al. 2010, Sengupta et al.
2011).
The most recent survey of cranberry clinical trials (Jepson et al. 2012) has concluded
that “cranberry products cannot be recommended for preventing UTIs” and that more studies
are needed that quantify the amount of active ingredient in source material. The results of the
studies presented in this report indicate that such quantification may now be possible for both
source material and patient samples.
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C. Occurrence & Potential Uses of Arabinoxyloglucan Oligosaccharides

1. Natural Sources of Arabinoxyloglucan Oligosaccharides
The oligosaccharides identified in both urine and cranberry are structurally related to
known hemicellulose polymers, specifically xyloglucans and arabinoxyloglucans.
Hemicelluloses are heterogeneous, branching polymers with a high degree of variety in
structural components and arrangements (Scheller & Ulvskov 2010). They typically contain
backbones composed of β-(1 → 4)-linked glucose units, but backbones may also be composed
of xylose, mannose, or galactose units. Branching patterns and side chain compositions vary
across plant families and species, and any given plant may produce a wide range of
hemicelluloses with common structural motifs. Monosaccharides commonly found in side
chains include galactose, mannose, arabinose, glucuronic acid, xylose, fucose, and rhamnose.
The xyloglucans, composed of cellulose-type β-(1 → 4)-linked glucose backbones and xylosecontaining side chains, are one of the most common classes of hemicelluloses (Figure 93).
Hemicelluloses are an essential component of plant primary cell walls, crosslinking cellulose
fibers to provide structure and strength (York et al. 1986, Scheller & Ulvskov 2010). Native
hemicellulose polymers are typically studied using enzymatic cleavage via fungal enzymes, and
it has been shown that hemicellulose polymers are naturally cleaved during fruit ripening
(Hisamatsu et al. 1992, York et al. 1996, Brummell et al. 2004, Goulão & Oliveira 2008).
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Figure 93. Structures of cellulose (a) and xyloglucan (b) segments showing the cellulose-type
backbone of xyloglucans and the preferred equatorial and boat conformations of the glucosyl
and xylosyl units, respectively.
Current research supports the potential for complex oligosaccharides to play a clinical
role in the prevention of UTIs, but the availability of such compounds has been limited,
delaying progress in this area. As oligosaccharides are relatively difficult and expensive to
synthesize de novo, there is a need for renewable natural sources of oligosaccharides that
possess anti-adhesion properties (Sharon & Ofek 2000, Larsson et al. 2003, Turner et al. 2005).
Hemicellulose-derived oligosaccharides may be able to meet this need, and cranberry
oligosaccharides could be used to guide investigations of similar compounds from other
possible human dietary sources.
Investigations to identify anti-adhesive hemicellulose-derived oligosaccharides could
begin with examinations of variations in oligosaccharide content for juice produced from
cranberry at different stages of fruit ripeness (Vvedenskaya & Vorsa 2004) or from different
cranberry cultivars. Additional studies may investigate other plants of the Vaccinium genus,
especially the closely related blueberry (V. corymbosum), using quantitative survey approaches
similar to those applied to characterize resveratrol and other stilbenes in Vaccinium species
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(Rimando et al. 2004, Rimando & Barney 2005, Rimando & Cody 2005). Plant species within
the same genus often share biosynthetic pathways, especially for the biosynthesis of “primary
metabolites” such as hemicellulose, and it is likely that other Vaccinium species produce
oligosaccharides with similar structures during fruit ripening.
Blueberry juice has been reported to possess an ability similar to that of cranberry juice
to prevent P-fimbriated E. coli adhesion (Ofek et al. 1991, Ofek et al. 1996). Similar, partially
characterized, high-MW inhibitors were reported to be present in both cranberry and blueberry
juices and the active fractions were initially characterized to contain a type of PAC. While
PACs were subsequently purified from cranberry and shown to have in vitro anti-adhesion
properties (Foo et al. 2000a,b), the active fractions described in the initial reports of cranberry
and blueberry anti-adhesion activity could also have contained oligosaccharides (Ofek et al.
1991, Ofek et al. 1996). The presence of oligosaccharide-type compounds in blueberry has,
however, yet to be confirmed. Additional studies involving the detection, quantification,
isolation and structural elucidation of oligosaccharides from multiple Vaccinium species will be
necessary to support or refute the hypothesis that the anti-adhesive oligosaccharides identified
in cranberry are present in other Vaccinium species.
Plants other than cranberry, such as tobacco, tomato, and flax, are known to produce
xyloglucan and arabinoxyloglucan containing polymers, but the structures of free, soluble
oligosaccharides derived from these polymers are unknown (York et al. 1990, York et al. 1996,
Naran et al. 2008). Free arabinoxyloglucan oligosaccharides produced by non-Vaccinium plants
may also possess anti-adhesive properties, but such compounds have yet to be identified. Many
studies regarding hemicellulose-derived oligosaccharides have focused on characterizing
biosynthesis pathways and structural variation and on genetic modifications to improve animal
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feedstock or biofuel production (Scheller & Ulvskov 2010). These studies often employ fungal
hemicellulases that cleave polymers to produce lower-MW compounds that can be more easily
studied, and studies that do exist typically have a botanical or agricultural focus rather than a
human medicine focus (Scheller & Ulvskov 2010). Neutral oligosaccharides are inherently
difficult to detect, isolate, and characterize structurally (York et al. 1996, Chai et al. 2002,
Yamagaki et al. 2006, LaMotte 2008). Studies of the biological properties of naturallyoccurring, plant-derived oligosaccharides as pure compounds or as native mixtures have
therefore been limited, and additional work is needed in this area.

2. Cranberry Oligosaccharides as Analytical Standards
To date, two cranberry oligosaccharides have been purified to the degree necessary for
full structural elucidation and identification as arabinoxyloglucans (Auker 2013). Evidence
from NMR and HPLC-ELSD data indicates the presence of a series of structurally related
compounds in cranberry, all of which are hypothesized to be arabinoxyloglucans based on the
presence of anomeric 1H NMR resonances characteristic of this chemical class. Current data
also supports the hypothesis that the absolute configurations of the primary monosaccharide
units will be D-Glc, D-Xyl, and L-Ara, consistent with the natural abundances of these
monosaccharides. An additional monosaccharide that may be present is galactose based on
preliminary chemical analysis of cranberry oligosaccharide fractions (CJA2, Auker 2013).
Further work to isolate individual cranberry oligosaccharides is still necessary and full
structural elucidation for each compound will require the application of multiple
complimentary techniques (Hisamatsu et al. 1992, York et al. 1996, Weiskopf et al. 1997, Chai
et al. 2002, Yamagaki et al. 2006, LaMotte 2008). Multiple structural features for each
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oligosaccharide must be determined before complete structures can be assigned, including (a)
molecular weight, (b) glycosyl composition, (c) glycosyl linkage positions, (d) glycosyl
configuration (D vs. L), (e) glycosyl anomeric configuration (α vs. β), and (f) glycosyl
sequence. Individual oligosaccharides within the series may differ by single structural
elements, such as a single change in linkage position or anomeric configuration between any
two compounds (York et al. 1990, Hisamatsu et al. 1992, York et al. 1996, Scheller & Ulvskov
2010). Any analytical methods used to detect individual compounds within the series must
therefore be appropriate for discriminating between such closely related compounds or must
consider this limitation when assigning putative structures (York et al. 1996, Weiskopf et al.
1997, Chai et al. 2002, Yamagaki et al. 2006, LaMotte 2008).
The present studies have yielded a large quantity (~20 g) of enriched cranberry
oligosaccharide fractions that can be used for further studies, and the methods presented here
provide simple, reproducible, low cost procedures for obtaining relatively large amounts of
oligosaccharides from renewable and readily available starting material. These cranberry
oligosaccharide mixtures will primarily be useful as starting material for further purification of
individual components. Once obtained, purified compounds will be useful for detailed
structural assignments, biological mechanism of action studies, and as analytical standards for
many applications. Individual cranberry oligosaccharides and oligosaccharide mixtures with
known composition have the potential to be used as analytical standards for (a) the
development of optimized methods suited to rapid detection of oligosaccharides, (b) the
detection of oligosaccharides in clinical biofluids, (c) the detection of oligosaccharides in
various plants and dietary sources, and (d) the standardization of cranberry-containing dietary
supplements. Additional applications will also likely be found by future researchers.
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3. Commercial Product Development
Preparations of cranberry-derived oligosaccharides, as mixtures or as pure compounds,
could potentially be developed into numerous products with commercial applications. These
include dietary supplements, botanical drugs (FDA CDER 2004), and anti-adhesion coatings
for medical devices (Nickel et al. 1994), among others. Cranberry is a common food item, and
cranberry-derived oligosaccharides would therefore be generally regarded as safe (GRAS) for
human consumption and medical use (McCaleb et al. 2000). As a botanical drug, or as
oligosaccharide-enriched dietary supplements, cranberry-derived oligosaccharides could be
used in place of whole cranberry products or cranberry juice for the prevention of UTIs.
Enrichments for anti-adhesive oligosaccharides and the removal of other cranberry
compounds may increase the potential marketability of cranberry-derived materials, providing
the benefits of cranberry anti-adhesion properties while avoiding the inclusion of unwanted
components. Common reasons given for patient withdrawal from clinical trials concerning
cranberry were the “unpalatable or intolerable nature of the cranberry product” (Jepson et al.
2012). The objectives of avoiding caloric intake (simple sugars) or cranberry flavor (tartness)
and the convenience of a pill form are common reasons consumers may choose cranberry
dietary supplements instead of the traditionally recommended cranberry juice (Jepson et al.
2012, Proprietary Nutritionals 2007). Cranberry compounds can also cause herbal-drug
interactions such as those reported for warfarin (Aston et al. 2006). Enriched preparations of
oligosaccharides could be prepared from cranberry materials to exclude simple sugars, flavor
components, and other compounds that cause interactions, while providing consumers with a
convenient product form.
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As the active anti-adhesive metabolites of cranberry that are excreted into urine have
remained unidentified prior to this report, the “concentrated” versions of cranberry currently
sold as dietary supplements are not necessarily enriched for the appropriate cranberry
components. The need for standardization of dietary supplement materials to appropriate
concentrations of active constituents is a well-recognized problem, but requires that the
constituents responsible for a given bioactivity have been suitably characterized. The
identification of oligosaccharides as anti-adhesive components of cranberry in this report will
enable researchers to identify, quantify, and standardize to target these active components in
various commercial products. The preliminary analyses presented here regarding the
oligosaccharide composition of commercially obtained cranberry products suggests that juice
products with a sufficient percentage of cranberry juice already contain the active components.
These studies also suggest that dietary supplement manufacturers may need to redesign their
cranberry processing protocols and implement new standardization procedures to ensure that
their products contain sufficient oligosaccharide content to provide the target biological
activity.

D. Summary of Future Directions
The above discussion addresses the results of the current study within the context of
existing research and highlights the need for additional research regarding both the chemistry
and biological properties of cranberry oligosaccharides. Future research will need to address
many different areas, especially with regards to clinical, agricultural, and basic science
applications.

220

The anti-adhesion properties of cranberry oligosaccharides, as both pure compounds
and as mixtures, need further study, especially with regards to the mechanism of action for the
prevention of UPEC adhesion and possible synergistic effects of oligosaccharide mixtures.
Further anti-adhesion studies will also be needed to determine if oligosaccharides contribute to
the reported abilities of cranberry to prevent the adhesion or biofilm formation of bacteria other
than E. coli. The inherent difficulties of oligosaccharide detection without specialized methods
suggests that these compounds may be present in many cranberry materials that have been
attributed with different biological activities. The possible bioactivities of cranberry
oligosaccharides will therefore need to be assessed in many different types of bioassays.
Additional cranberry oligosaccharides need to be purified and fully elucidated, and the
natural occurrence of these or similar compounds in cranberry, in related Vaccinium species,
and in other plants needs to be assessed. Purified oligosaccharides and oligosaccharide
mixtures can be used as analytical reference standards for any future study that aims to
investigate the presence of these compounds. Such studies may include investigations of
cranberry oligosaccharide content as a function of fruit ripeness, investigations of possible
dietary sources other than cranberry, mammalian ADME studies, and studies that aim to
establish clinical correlations between oligosaccharide intake, urinary excretion and UTI
occurrence, among others.
Cranberry oligosaccharides, as pure compounds or as mixtures, have potential for
development into a variety of commercial products, including anti-adhesive coatings for
medical devices, oligosaccharide-enriched dietary supplements, and even possibly a botanical
drug product. Such products would be useful as clinical therapies for the prevention of UTIs
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caused by P-fimbriated E. coli and may have other applications that have not yet been
identified.

E. Final Conclusions
These studies have identified mixtures of arabinoxyloglucan oligosaccharides as the
anti-adhesive components of both cranberry products and the urine of swine after the
consumption of cranberry products. The anti-adhesion activity of oligosaccharide mixtures has
been confirmed using two separate assays. The structure of a representative arabinoxyloglucan
octasaccharide from swine urine was fully elucidated and found to be similar in structure to two
arabinoxyloglucan oligosaccharides isolated from cranberry products. Similar HPLC-ELSD
profiles are present in both cranberry and urine materials, indicating direct absorption and
excretion of a complex mixture of structurally related oligosaccharides. The results of these
studies support the new hypothesis that cranberry-derived oligosaccharides are a major
constituent responsible for the anti-adhesion effects of urine produced after cranberry product
consumption. Overall, the hypotheses presented in this report provide a new guiding paradigm
for future research regarding the bioactive constituents of cranberry fruit and juice products.
The information presented here regarding the anti-adhesion properties of cranberry
oligosaccharides and their hypothesized role as urinary anti-adhesion metabolites will
significantly change how researchers and the general public view cranberry for the prevention
of UTIs.
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1. Overview of Appendix A
The images shown below are included here to show color characteristics in support of
the methods and materials described in Chapters 2 and 3. All photographs included as color
plates were taken by C. M. Coleman during the studies discussed in this report.

Figure 94. A cranberry bog located in northeastern U.S. with an inset that shows the cranberry
plant. This photograph was taken by C. M. Coleman on 2013-05-20.
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Figure 95. Sephadex LH-20 column for the FC urine separation.
The control urine material was similar in appearance to the active urine study materials, with an
apparent lack of pink color. This photograph was taken by C. M. Coleman on 2008-05-07.
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Figure 96. Sephadex LH-20 column for the F5 urine separation.
Compounds of interest eluted as the first fraction below the lowest visible band of yellow. The
darker bands visible on this column (redish, orange, and brown) constituted the bulk of the
collected material, and the dried fractions from these bands were hygroscopic. This photograph
was taken by C. M. Coleman on 2007-07-20.
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Figure 97. Sephadex LH-20 column for the IF2 urine separation showing elution progression
(2, 9.5 and 20 h) and the appearance of the resulting fractions in test tubes.
These photographs were taken by C. M. Coleman on 2009-06-23 and 2009-06-24.
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Figure 98. Cranberry dietary supplement products analyzed by HPLC-ELSC, showing
packaging, labeling, capsules, and samples in aqueous solution.
All four dietary supplement products resulted in aqueous solutions that had high amounts of
insoluble material. These solutions were not similar to that obtained from cranberry juice
powder (see Figure 99). These photographs were taken by C. M. Coleman on 2011-03-24.

Figure 99. Cranberry fruit (SN) and juice (CJ) powders in aqueous solution, showing the
differences in appearance. This photograph was taken by C. M. Coleman on 2011-03-24.
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Figure 100. Cranberry juice products analyzed by HPLC-ELSD (BCB, GVC, and GVNS),
showing packaging, label information, and juice appearance.
All juice products analyzed appeared similar in color in spite of the differences in primary
ingredient. These photographs were taken by C. M. Coleman on 2011-04-20.
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Figure 101. Cranberry juice products analyzed by HPLC-ELSD (OSC, LCP, and NL), showing
packaging, label information, and juice appearance.
All juice products analyzed appeared similar in color in spite of the differences in primary
ingredient. These photographs were taken by C. M. Coleman on 2011-04-20.
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Figure 102. Sephadex LH-20 column for the CJA1 cranberry separation showing elution
progression (10 min – 18 h) and the appearance of resulting fractions in test tubes.
Oligosaccharide components eluted early from this column, below the visible lavender band.
The pink/red material remaining on the column at 18 h produced a relatively low quantity of
material in spite of the visible color. These photographs were taken by C. M. Coleman on
2010-09-24 and 2010-09-25.
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Figure 103. Sephadex LH-20 column for the CCA2 cranberry separation showing elution
progression (3–35 h).
Distinct visible bands are apparent with this column (e.g. 6 h), corresponding to the higher
resolution of components into discrete fractions. These photographs were taken by C. M.
Coleman on 2013-09-03 and 2013-09-04.
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Figure 104. Overview of the configuration and equipment set-up for the CCA2 Sephadex LH20 column.
This photograph was taken by C. M. Coleman on 2010-09-25.
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1. Overview of Appendix B
The data in this appendix is provided in support of the discussion points presented in the
main text. This appendix contains additional discussion points in relation to the UPEC-HRBC
anti-agglutination assay and the raw data provided by this assay as discussed in Chapter 2;
Section C1, and Chapter 3; Sections C1 and C4a. This appendix also contains figures with
NMR spectra and chromatograms in support of the efforts made to isolate active urine
components, as discussed in Chapter 2; Sections C2 – C4.

2. Additional Discussion of the UPEC-HRBC Anti-agglutination Assay
Results were provided by RU to UM in the form of Excel spreadsheets that contained
dilution endpoint values (mg/mL) assigned by RU corresponding to the sample codes provided
by UM. These data were decoded at UM and interpreted using qualitative activity scores
assigned by UM (UM Scores) as discussed above (Chapter 2, Section B3, Table 3: reproduced
below). The results of a given data set were compared to those of previously obtained assay
data sets to evaluate relative data quality and interpretations. For some data sets (Tables 45, 47,
49, 51), the visual agglutination scores (VAS) determined for each dilution of each sample
were included by RU. Most result files did not include VAS values and the number of two-fold
dilutions used to obtain the reported dilution endpoint value was calculated based on the
methods reported by RU. The reported number of two-fold dilutions does not include the
starting concentration.
The initial dilution volume used for a given sample was arbitrarily determined by RU
based on the weight of the sample within a range. An example of a sample weight range to
dilution volume is as follows: sample mg > 80: 400 µL, 79 > mg > 40: 200 µL, 39 > mg > 10:
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150 µL, 9 > mg > 7: 100 µL. The dilution volumes used per sample weight range varied
between sample sets over time. An example of this variation is the use of 150 µL PBS for 24.5
mg (08/2006 sample; Table 43), 200 µL for 24.5 mg (06/2008 sample; Table 52), and 100 µL
for 27.0 mg (12/2008 sample; Table 56). Changes in sample initial dilution volumes combined
with the variety of submitted sample weights resulted in the testing of a range of sample
starting concentrations at any one time; e.g. 74–420 mg/mL; Table 44, and 26–740 mg/mL;
Table 54. Two-fold dilutions performed on these starting concentrations yielded yet another set
of varied concentrations and ultimately yielded the reported dilution endpoint values. These
variations in sample concentration throughout the performance of the assay may have affected
the overall assay sensitivity and contributed to issues with assay reproducibility.
Table 3. Description of the qualitative scoring system developed by UM to interpret the results
provided by the UPEC-HRBC anti-agglutination assay.
Samples were assessed within an individual sample set test date and then across test dates.
Scoring criteria were applied in the order shown to determine the probable activity of
individual samples and assign a UM Score. Replicates were not available for most samples.
Scoring Criteria:
First
Second
Third
Fourth
UM Assessment
Dilution
No. of
Sample
UM
Replicates
of Sample
Endpoint
Two-fold
Compared to
Score
(if available):
Activity
Range
Dilutions Parent Fraction:
++
+
+/–
–
––

active
probably active
may or may not
be active
probably not
active
not active

< 10 mg/mL

5+

more active

show activity

10–30 mg/mL

4

more active

show activity

30–60 mg/mL

3

about the same

may or may not
show activity

60–100 mg/mL

2

less active

show no activity

> 100 mg/mL

0, 1

less active

show no activity

Samples for which the dilution endpoint was equal to the starting concentration may
have had visual agglutination scores of ‘1’ or ‘2’ but the apparent activity for these samples
was not retained (VAS = ‘0’) after the first two-fold dilution. Single-concentration sample
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activity cannot be accurately assessed without VAS values, but most of these samples were
tested at starting concentrations of > 100 mg/mL and were therefore assigned as inactive.
Samples that were assigned a dilution endpoint of “Neg” (= negative) were found to have no
ability to inhibit HRBC agglutination at the highest (first) concentration tested.
Samples that were assigned a dilution endpoint of “Solv” (= solvent) were associated
with the bursting of HRBCs at the highest concentration tested. Although RU attributed this
bursting of HRBCs to the presence of solvent in the samples, most samples that could have
contained solvent had been dried completely, re-dissolved in water, lyophilized, and then
provided to RU as dry powders. These samples were therefore unlikely to have contained
sufficient solvent to have caused this effect. While samples may have contained other
components that could have contributed to the bursting of HRBCs, no sample-related pattern
could be discerned regarding the assignment of the “Solv” dilution endpoint. Replicates of
some samples that showed the “Solv” effect (e.g. FG; Table 44) were found to lack activity and
all samples for which this was the reported dilution endpoint were assigned a negative UM
score (‘– –’ Table 3). The “Solv” effect may have been related to issues with the HRBCs
themselves or other methodological factors unknown to UM.
When provided, the VAS values assigned to samples were predominantly ‘1’ or ‘2’.
The assay methods suggested that higher VAS values of ‘3’ or ‘4’ could be obtained, indicating
the inhibition of agglutination for 70-95 and 95-100% of HRBCs, respectively. Published
evidence could not be found in support of the ability of the assay to yield these VAS values
with positive controls, and VAS values or other information for positive control samples tested
with the samples from this study were not provided to UM.
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False negative results were more likely than false positive results for most samples, as
the reported dilution endpoints may have been higher than actual sample concentrations. Many
urine fractions were hygroscopic and the absorption of water from the atmosphere would have
resulted in higher than actual apparent weights for these samples, yielding lower actual solute
concentrations. Crude urine materials often had significant sample heterogeneity, containing
insoluble and soluble components within any give aliquot. Efforts were made to homogenize
these materials prior to assay submission, but only part of a given sample may have been
soluble in the PBS used for the assay. The low-volume drops used for the assay were also
reported to be affected by ambient humidity, absorbing water from the atmosphere on days
when it rained and further diluting test samples (A. B. Howell, personal communication).
Cumulative results indicate that samples did not lose activity when stored at –20 oC as dry
powders, and the apparent changes in sample activity (e.g. the FF aqueous fraction; Chapter 2,
Table 8) are likely to be false negative results due to some of the reasons presented here.
Additional assay variation can be attributed to the subjective nature of human judgment
and visual assessments, variations between collections of HRBCs, and variations in the
characteristics of the clinical strains of E. coli used. While E. coli were subcultured on
colonization factor agar to enhance the expression of P fimbriae (Evans et al. 1977) prior the
use of the bacteria for sample testing, the expression of P fimbriae was not quantified for each
sample set. Changes in P fimbriae expression or strain characteristics over time may therefore
have affected the assay results. Other unknown factors may also have contributed to the
inconsistencies that were observed in sample data.
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3. Supporting Data Tables for the UPEC-HRBC Anti-agglutination Assay
The raw data results for the UPEC-HRBC anti-agglutination assay are included in the
following tables (Tables 41–59). These tables are arranged in date order by test date. Samples
within a given test date were sent from UM to RU within a single shipment but were not
necessarily tested on the same day at RU. Individual samples within a test date were coded,
randomized, and not necessarily tested in the order shown. Sample descriptions contain sample
codes as well as brief descriptions of sample origins. Urine samples and fractions are discussed
in more detail in Chapter 2 while cranberry samples and fractions are discussed in Chapter 3.

Table 41. Urine fractions (D) tested in the anti-agglutination assay, 03/2006.
No. of
Amount Dilution Starting
Dilution
Sample
Test
UM
TwoConc.
Submitted Volume
Endpoint
fold
Description
Date
Score
(mg/mL)
(µL)
(mg/mL)
(mg)
Dilutions
D (crude urine)
03/2006
––
111.0
1
110.6
500
221.2
DE (D EtOAc
03/2006
––
Neg
0
16.1
150
107.3
fraction
DS (D secBuOH fraction)

03/2006

––

Solv

1

120.2

500

240.4

DA (D aqueous
fraction)

03/2006

+/–

87.4

1

87.4

500

174.8
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Table 42. Urine fractions (DA Sephadex LH-20 fractions) tested in the anti-agglutination assay,
05/2006.
No. of
Amount Dilution Starting
Dilution
TwoSample
Test
UM
Endpoint
Submitted Volume
Conc.
fold
Description
Date
Score
(mg/mL)
(mg)
(µL)
(mg/mL)
Dilutions
DA1
05/2006
–
52.2
2
52.2
250
208.8
DA2
05/2006
–
112.0
1
56.0
250
224.0
DA3
05/2006
+/–
43.1
2
86.1
500
172.2
DA4
05/2006
+/–
43.2
2
172.9
1000
172.9
DA5
05/2006
––
226.4
1
226.4
500
452.8
DA6
05/2006
––
Neg
2
57.6
250
230.4
DA7
05/2006
––
Neg
2
77.7
250
310.8
DA8
05/2006
––
Neg
1
91.7
500
183.4
DA9
05/2006
––
Neg
2
59.1
250
236.4
DA10
05/2006
––
202.4
0
50.6
250
202.4
DA11
05/2006
––
328.4
0
82.1
250
328.4
DA12
05/2006
––
106.0
0
53.0
250
212.0
DA13
05/2006
++
1.4
7
44.9
250
179.6
DA14
05/2006
++
5.3
4
21.3
250
85.2
DA15
05/2006
++
1.4
7
46.3
250
185.2
DA16
05/2006
++
1.6
7
51.4
250
205.6
DA17
05/2006
––
191.6
0
47.9
250
191.6
DA18
05/2006
++
7.7
4
30.9
250
123.6
DA19
05/2006
++
0.8
8
48.0
250
192.0
DA20
05/2006
––
Neg
0
50.6
250
202.4
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Table 43. Urine fractions (DA Sephadex LH-20 fractions) tested in the anti-agglutination assay,
08/2006.
No. of
Amount Dilution Starting
Dilution
TwoSample
Test
UM
Endpoint
Submitted Volume
Conc.
fold
Description
Date
Score
(mg/mL)
(mg)
(µL)
(mg/mL)
Dilutions
DA13
08/2006
++
2.5
5
14.4
150
96.0
DA14
08/2006
–
76.0
1
11.4
150
76.0
DA15
08/2006
–
74.6
2
37.3
250
149.2
DA16
08/2006
+/–
48.9
2
48.9
250
195.6
DA17
08/2006
++
5.0
5
24.5
150
163.3
DA18
08/2006
++
2.5
5
13.4
150
89.3
DA19
08/2006
++
2.5
6
19.1
150
127.3
DA20
08/2006
––
Neg
2
35.3
250
141.2
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Table 44. Urine fractions (F and Sephadex LH-20 fractions for DA and FF columns 1 & 2)
tested in the anti-agglutination assay, 03/2007.
No. of
Amount Dilution Starting
Dilution
TwoSample
Test
UM
Endpoint
Submitted Volume
Conc.
fold
Description
Date
Score
(mg/mL)
(mg)
(µL)
(mg/mL)
Dilutions
DA1

03/2007

++

2.6

5

12.2

150

81.3

DA2

03/2007

+

23.2

2

13.9

150

92.7

DA3

03/2007

+

10.0

3

8.0

100

80.0

DA4

03/2007

––

74.6

0

11.2

150

74.7

DA5

03/2007

––

Solv

0

14.6

150

97.3

DA6

03/2007

––

Solv

0

9.3

100

93.0

DA7

03/2007

––

186.0

0

37.2

200

186.0

DA8

03/2007

++

5.1

5

32.5

200

162.5

03/2007

+/–

35.8

3

114.5

400

286.3

03/2007

+/–

52.5

3

168.1

400

420.3

FG (F solids)

03/2007

––

Neg

0

62.7

200

313.5

FG (F solids)

03/2007

––

Solv

0

47.7

200

238.5

FG (F solids)

03/2007

––

Neg

0

42.1

200

210.5

FF1-1

03/2007

++

9.7

3

11.6

150

77.3

FF1-2

03/2007

++

6.2

4

9.9

100

99.0

FF1-3

03/2007

––

Neg

0

42.5

200

212.5

FF1-4

03/2007

––

Solv

0

53.5

200

267.5

FF1-5

03/2007

–

84.6

2

135.4

400

338.5

FF1-6

03/2007

+/–

31.4

3

50.3

200

251.5

FF1-7

03/2007

++

2.6

5

12.5

150

83.3

FF1-8

03/2007

––

Neg

0

11.6

150

77.3

FF1-9

03/2007

––

Neg

0

16.5

150

110.0

FF (aqueous
fraction)
FF (aqueous
fraction)
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Table 45. Urine fractions (F and Sephadex LH-20 fractions for DA and FF columns 1 & 2)
tested in the anti-agglutination assay, 03/2007, showing dilution concentrations tested and
visual agglutination scores (VAS).
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Table 46. Urine fractions (FF Sephadex LH-20 fractions, columns 2 & 3) tested in the antiagglutination assay, 05/2007.
No. of
Amount Dilution Starting
Dilution
TwoSample
Test
UM
Endpoint
Submitted Volume
Conc.
fold
Description
Date
Score
(mg/mL)
(mg)
(µL)
(mg/mL)
Dilutions
FF (aqueous
05/2007
++
11.8
5
75.2
200
376.0
fraction)
FF (aqueous
05/2007
+
19.9
3
79.9
500
159.8
fraction)
FF (aqueous
05/2007
–
105.8
2
84.7
200
423.5
fraction)
FF2-1

05/2007

++

2.5

5

11.9

150

79.3

FF2-2

05/2007

+

12.8

4

30.8

150

205.3

FF2-3

05/2007

+

14.3

4

135.8

600

226.3

FF2-4

05/2007

+

13.6

4

32.8

150

218.7

FF2-5

05/2007

––

Neg

0

55.6

200

278.0

FF2-6

05/2007

+/–

42.5

2

25.5

150

170.0

FF2-7

05/2007

+/–

34.3

2

20.6

150

137.3

FF2-8

05/2007

––

222.5

0

44.5

200

222.5

FF3-1

05/2007

++

9.3

3

11.2

150

74.7

FF3-2

05/2007

++

3.7

5

17.9

150

119.3

FF3-3

05/2007

––

119.6

1

35.9

150

239.3

FF3-4

05/2007

––

Neg

0

56.8

200

284.0

FF3-5

05/2007

––

Neg

0

23.3

150

155.3

FF3-6

05/2007

+/–

38.8

2

38.1

250

152.4
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Table 47. Urine fractions (FF Sephadex LH-20 fractions, columns 2 & 3) tested in the antiagglutination assay, 05/2007, showing dilution concentrations tested and visual agglutination
scores (VAS).
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Table 48. Urine fractions (FF Sephadex LH-20 fractions, columns 4 & 5) tested in the antiagglutination assay, 06/2007.
No. of
Amount Dilution Starting
Dilution
TwoSample
Test
UM
Endpoint
Submitted Volume
Conc.
fold
Description
Date
Score
(mg/mL)
(mg)
(µL)
(mg/mL)
Dilutions
FF (aqueous
06/2007
+/–
54.6
2
43.7
200
218.5
fraction)
FF (aqueous
06/2007
+/–
53.0
3
84.8
200
424.0
fraction)
FF (aqueous
06/2007
–
73.4
2
117.4
400
293.5
fraction)
FF4-1

06/2007

+

12.4

4

29.7

150

198.0

FF4-2

06/2007

+

25.5

2

15.3

150

102.0

FF4-3

06/2007

–

105.0

2

168.2

400

420.5

FF4-4

06/2007

––

120.6

2

193.0

400

482.5

FF4-5

06/2007

––

120.0

0

98.5

820

120.1

FF4-6

06/2007

––

300.0

0

60.1

200

300.5

FF4-7

06/2007

––

323.0

0

129.3

400

323.3

FF4-8

06/2007

––

116.0

0

17.5

150

116.7

FF5-1

06/2007

++

9.8

3

7.9

100

79.0

FF5-2

06/2007

––

204.6

0

30.7

150

204.7

FF5-3

06/2007

––

240.6

0

36.1

150

240.7

FF5-4

06/2007

––

371.0

0

148.4

400

371.0

FF5-5

06/2007

––

120.0

0

18.1

150

120.7

FF5-6

06/2007

––

374.0

0

149.6

400

374.0

FF5-7

06/2007

––

208.0

0

31.3

150

208.7

FF5-8

06/2007

–

62.3

2

49.9

200

249.5
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Table 49. Urine fractions (FF Sephadex LH-20 fractions, columns 4 & 5) tested in the antiagglutination assay, 06/2007, showing dilution concentrations tested and visual agglutination
scores (VAS).
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Table 50. Urine fractions (FF and FC fractions, and FA Sephadex LH-20 fractions) tested in the
anti-agglutination assay, 09/2007.
No. of
Amount Dilution Starting
Dilution
TwoSample
Test
UM
Endpoint
Submitted Volume
Conc.
fold
Description
Date
Score
(mg/mL)
(mg)
(µL)
(mg/mL)
Dilutions
FF (aqueous
09/2007
–
92.5
2
74.0
200
370.0
fraction)
FF (aqueous
09/2007
–
95.3
2
152.5
400
381.3
fraction)
FB (F EtOAc
09/2007
–
Neg
0
6.3
100
63.0
fraction)
FA (combined
active F
09/2007
+/–
35.2
2
21.1
150
140.7
fractions)
FA1 (Sep LH-20
09/2007
++
5.8
4
14.0
150
93.3
fraction)
FA2 (Sep LH-20
fraction)

09/2007

+

13.9

4

33.3

150

222.0

FA3 (Sep LH-20
fraction)

09/2007

––

204.0

0

30.6

150

204.0

FA4 (Sep LH-20
fraction)

09/2007

+/–

55.7

1

16.7

150

111.3

09/2007

––

Neg

0

27.5

150

183.3

09/2007

––

305.5

0

61.1

200

305.5

09/2007

+/–

35.0

2

21.0

150

140.0

FC1 (FC
aqueous fraction)

09/2007

–

106.8

2

170.8

400

427.0

FC1 (FC
aqueous fraction)

09/2007

–

99.9

2

159.8

400

399.5

FC1 (FC
aqueous fraction)

09/2007

–

82.6

2

132.1

400

330.3

FA5 (Sep LH-20
fraction)
FC (control
urine)
FCE (FC EtOAc
fraction)
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Table 51. Urine fractions (FF and FC fractions, and FA Sephadex LH-20 fractions) tested in the
anti-agglutination assay, 09/2007, showing dilution concentrations tested and visual
agglutination scores (VAS).
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Table 52. Cranberry juice powder fractions (CJ, and MW-filter and Acid/Base experiments)
tested in the anti-agglutination assay, 06/2008.
No. of
Amount Dilution Starting
Dilution
TwoSample
Test
UM
Endpoint
Submitted Volume
Conc.
fold
Description
Date
Score
(mg/mL)
(mg)
(µL)
(mg/mL)
Dilutions
CJ (cranberry
06/2008
++
3.8
6
49.2
200
246.0
juice powder)
CJ (cranberry
juice powder)

06/2008

++

3.4

6

44.3

200

221.5

CJ-MA3a (3 kDa
retentate)

06/2008

++

0.7

7

9.5

100

95.0

CJ-MB3a (10
kDa retentate)

06/2008

++

0.7

7

8.7

100

87.0

CJ-MC3a (30
kDa retentate)

06/2008

++

0.5

7

6.3

100

63.0

CJ-MA3b (3 kDa
06/2008
filtrate)

––

Neg

0

21.4

200

107.0

CJ-MB3b (10
kDa filtrate)

06/2008

––

Neg

0

23.7

200

118.5

CJ-MC3b (30
kDa filtrate)
CJ pH 2.0, 2 h
CJ pH 2.0, 4 h
CJ pH 2.1, 8 h
CJ pH 5.9, 2 h
CJ pH 6.0, 4 h
CJ pH 6.1, 8 h
CJ pH 7.9, 2 h
CJ pH 8.0, 4 h
CJ pH 8.2, 8 h
CJ Native pH
(2.7), 2 h

06/2008

––

Neg

0

19.1

200

95.5

06/2008
06/2008
06/2008
06/2008
06/2008
06/2008
06/2008
06/2008
06/2008

+
+
+
++
++
++
++
++
++

13.4
13.6
12.3
1.8
1.9
1.8
1.7
2.0
1.9

3
3
3
6
6
6
6
6
6

21.4
21.8
19.7
23.0
24.5
23.2
22.2
25.3
24.6

200
200
200
200
200
200
200
200
200

107.0
109.0
98.5
115.0
122.5
116.0
111.0
126.5
123.0

06/2008

++

1.6

6

20.1

200

100.5

CJ Native pH
(2.7), 4 h

06/2008

++

1.8

6

23.6

200

118.0

CJ Native pH
(2.7), 8 h

06/2008

++

3.6

5

23.1

200

115.5
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Table 53. Urine fractions (FA and FC Sephadex LH-20 column fractions) tested in the antiagglutination assay, 06/2008.
No. of
Amount Dilution Starting
Dilution
TwoSample
Test
UM
Endpoint
Submitted Volume
Conc.
fold
Description
Date
Score
(mg/mL)
(mg)
(µL)
(mg/mL)
Dilutions
FA (combined
active F
06/2008
+/–
45.2
1
18.1
200
90.5
fractions)
FA1 (Sep LH-20
06/2008
––
Neg
0
3.7
100
37.0
fraction)
FA2 (Sep LH-20
fraction)

06/2008

––

Neg

0

3.3

100

33.0

FA3 (Sep LH-20
fraction)

06/2008

––

Neg

0

6.9

100

69.0

FA4 (Sep LH-20
fraction)

06/2008

+/–

47.2

1

18.9

200

94.5

FA5 (Sep LH-20
fraction)

06/2008

+/–

34.0

1

8.5

125

68.0

FC1-1 (Sep LH20 fraction)

06/2008

––

182.5

1

73.0

200

365.0

FC1-2 (Sep LH20 fraction)

06/2008

––

Neg

0

46.5

200

232.5

FC1-3 (Sep LH20 fraction)

06/2008

––

118.2

1

47.3

200

236.5

271

Table 54. Urine fractions (H) tested in the anti-agglutination assay, 08/2008.
No. of
Dilution
Amount Dilution Starting
TwoSample
Test
UM
Submitted Volume
Conc.
Endpoint
Description
Date
Score
fold
(mg)
(µL)
(mg/mL)
(mg/mL)
Dilutions
H (crude urine)

08/2008

+/–

40.8

4

653.7

1000

653.7

HCE (H EtOAc
extract, water
soluble)

08/2008

+

13.1

3

20.9

200

104.5

HCM (H EtOAc
fraction, MeOH
soluble)

08/2008

––

Neg

0

1.3

50

26.0

HD (H EtOAc:
MeOH fraction,
water soluble)

08/2008

––

157.5

1

94.5

300

315.0

HF (H aqueous
fraction)

08/2008

+

23.1

5

369.8

500

739.6

HG (H solids)

08/2008

––

Neg

0

71.8

1000

71.8
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Table 55. Urine fractions (FC and I) tested in the anti-agglutination assay, 12/2008.
No. of
Dilution
Amount Dilution Starting
TwoSample
Test
UM
Submitted Volume
Conc.
Endpoint
Description
Date
Score
fold
(mg)
(µL)
(mg/mL)
(mg/mL)
Dilutions
FC1 (FC aqueous
12/2008
–
73.3
3
146.6
250
586.4
fraction)
FC1-1 (Sep LH20 fraction)

12/2008

–

102.8

2

82.2

200

411.0

I (crude urine)

12/2008

+/–

45.1

3

72.2

200

361.0

ICE (I EtOAc:
MeOH fraction,
water soluble)

12/2008

++

9.5

2

5.7

150

38.0

ICM (I EtOAc:
MeOH fraction,
EtOAc soluble)

12/2008

––

Neg

0

38.7

100

387.0

12/2008

––

Neg

0

100.7

200

503.5

12/2008

+/–

57.4

3

68.9

150

459.3

12/2008

+

14.1

3

16.9

150

112.7

ID (EtOAc:
MeOH fraction,
water soluble)
IF (I aqueous
fraction)
IZ (I stability
test)
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Table 56. Urine fractions (H and HF Sephadex LH-20 fractions) and reference compounds
tested in the anti-agglutination assay, 12/2008.
No. of
Amount Dilution Starting
Dilution
TwoSample
Test
UM
Endpoint
Submitted Volume
Conc.
fold
Description
Date
Score
(mg/mL)
(mg)
(µL)
(mg/mL)
Dilutions
H (crude urine)

12/2008

+/–

61.7

3

123.4

250

493.6

HD (H EtOAcMeOH fraction,
water soluble)

12/2008

––

120.8

2

96.7

200

483.5

HF (H aqueous
fraction)

12/2008

––

169.5

2

203.4

300

678.0

HF1-1 (Sep LH20 fraction)

12/2008

++

8.5

5

27.3

100

273.0

HF1-2 (Sep LH20 fraction)

12/2008

+/–

55.3

3

66.3

150

442.0

HF1-3 (Sep LH20 fraction)

12/2008

–

108.6

2

86.9

200

434.5

HF1-4 (Sep LH20 fraction)

12/2008

–

102.7

2

82.2

200

411.0

HF1-5 (Sep LH20 fraction)

12/2008

––

269.0

1

107.6

200

538.0

HF1-6 (Sep LH20 fraction)

12/2008

–

109.6

2

65.8

150

438.7

HF1-7 (Sep LH20 fraction)

12/2008

––

416.7

0

62.5

150

416.7

D-Glucose

12/2008

+/–

35.8

3

28.7

100

287.0

D-Glucuronic
Acid

12/2008

––

388.0

0

38.8

100

388.0

D-Galacturonic
Acid

12/2008

––

270.0

0

27.0

100

270.0

D-Sorbitol

12/2008

––

226.0

0

22.6

100

226.0

Sucrose (Great
Value Brand)

12/2008

––

224.0

0

22.4

100

224.0
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Table 57. Urine fractions (DA19, FC, FF, I, H and HI) tested in the anti-agglutination assay,
07/2011.
No. of
Amount Dilution Starting
Dilution
TwoSample
Test
UM
Endpoint
Submitted Volume
Conc.
fold
Description
Date
Score
(mg/mL)
(mg)
(µL)
(mg/mL)
Dilutions
DA19

07/2011

++

3.4

6

21.8

100

218.0

07/2011

–

87.5

2

52.5

150

350.0

07/2011

––

Neg

0

49.8

150

332.0

FC1-1 (Sep LH20 fraction)

07/2011

––

199.0

1

59.7

150

398.0

FC1-1 (Sep LH20 fraction)

07/2011

––

353-176

1

53.0

150

353.3

07/2011

––

338.0

0

50.7

150

338.0

07/2011

+

11.9

5

57.1

150

380.7

07/2011

+

28.6

4

68.6

150

457.3

07/2011

++

10.8

5

51.9

150

346.0

H (crude urine)

07/2011

+/–

47.7

3

57.3

150

382.0

HI1 (Combined
H & I Active
fractions, HF2-1
+ IF1-1)

07/2011

++

6.3

5

20.1

100

201.0

HI2 (Combined
H & I Active
07/2011
fractions, HF1-1
+ HF2-2 + IF1-2)

+

12.7

4

20.4

100

204.0

HI3 (Combined
H & I Active
07/2011
fractions, HF1-2
+ IF1-3 + HF2-3)

––

101.0

1

20.2

100

202.0

FC1 (aqueous
fraction)
FC1 (aqueous
fraction)

FC1-2 (Sep LH20 fraction)
FF (aqueous
fraction)
FF (aqueous
fraction)
IZA (IZ aqueous
fraction after
stability test)
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Table 58. Cranberry fractions (CJ, CJA, and CJA Sephadex LH-20 fractions) tested in the antiagglutination assay, 07/2011.
No. of
Amount Dilution Starting
Dilution
TwoSample
Test
UM
Endpoint
Submitted Volume
Conc.
fold
Description
Date
Score
(mg/mL)
(mg)
(µL)
(mg/mL)
Dilutions
CJ (cranberry
07/2011
+
21.3
4
51.2
150
341.3
juice powder)
CJA (aqueous
07/2011
++
7.1
6
51.2
150
341.3
fraction)
CJA (aqueous
07/2011
+/–
43.3
3
52.0
150
346.7
fraction)
CJA1-02B (Sep
07/2011
++
5.1
6
49.0
150
326.7
LH-20 fraction)
CJA2-02 (Sep
LH-20 fraction)

07/2011

++

10.5

5

50.7

150

338.0

CJA2-02 (Sep
LH-20 fraction)

07/2011

+

21.2

4

50.9

150

339.3

CJA2-03 (Sep
LH-20 fraction)

07/2011

+/–

42.7

3

51.3

150

342.0

CJA2-04 (Sep
LH-20 fraction)

07/2011

+/–

42.9

3

51.5

150

343.3

CJA2-05 (Sep
LH-20 fraction)

07/2011

+/–

41.2

3

49.5

150

330.0

CJA2-05 (Sep
LH-20 fraction)

07/2011

––

168.0

1

50.4

150

336.0
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Table 59. Reference compounds tested in the anti-agglutination assay, 07/2011.
No. of
Dilution
Amount Dilution Starting
TwoSample
Test
UM
Submitted Volume
Conc.
Endpoint
Description
Date
Score
fold
(mg)
(µL)
(mg/mL)
(mg/mL)
Dilutions
Glucose Tabs
(ReliOn Glucose
Tablets
07/2011
++
5.2
6
50.2
150
334.7
commercial
product,
powdered)
Glucose Tabs
(ReliOn Glucose
Tablets
07/2011
++
10.3
5
49.3
150
328.7
commercial
product,
powdered)
D-Glucose
(Sigma Aldrich
07/2011
++
10.7
5
51.4
150
342.7
99.5%)
D-Glucose
(Sigma Aldrich
07/2011
++
10.8
5
52.1
150
347.3
99.5%)
D-Fructose
07/2011
+/–
41.4
3
49.7
150
331.3
(CalBioChem)
D-Fructose
(CalBioChem)

07/2011

–

81.6

2

49.0

150

326.7

Sucrose (Great
Value Brand)

07/2011

–

82.6

2

49.6

150

330.7
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4. Overview of Principles for Evaporative Light-Scattering Detection
Evaporative light-scattering detection (ELSD) is a semi-quantitative, mass-sensitive
method (Mourey & Oppenheimer 1984). Solvent is introduced to the detector and nebulized
using a gas such as nitrogen to form a cloud of sample droplets. The resulting cloud of droplets
is carried into a flight/evaporator tube by the stream of nebulizing gas where heat is used to
evaporate solvent and produce dry solute particles. This cloud of dried particles moves past a
light source and scatters the incident light. The scattered light is collected by a photomultiplier
tube detector to generate an electronic signal (mV) that corresponds to the concentration of
sample present (more particles of solute = more signal). Adjustable parameters that affect
detector sensitivity and function include the nebulizor temp, the evaporator tube temp, and the
gas flow rate. The inlet solvent flow rate and the solvent used for a given separation dictate the
settings for these parameters. This type of detector is moderately compatible with gradient
separations as long as the solvents used for the gradient can be removed by relatively similar
evaporator temperatures.
Non-volatile and semi-volatile compounds can be detected by ELSD regardless of the
presence or absence of specific structural features such as chromophores. In contrast, UV
detection methods require that compounds contain chromophores with absorbances typically
above 210 nm (for MeOH as an eluting solvent).

Image reproduced from Polymer Laboratories PL-ELS 2100 Operator’s
Manual, Version 1.01, Revision August 2003, Document # 6/26069B
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5. Additional Chromatographic & Spectroscopic Data
The additional figures included below contain supporting information relevant to the
text of Chapters 2 and 3.

Figure 105. Analytical HPLC-ELSD of glucose, fructose, and sucrose standards (AtldC18)
showing the early elution (< 5 min) of these compounds.
Standards of the monosaccharides glucose and fructose, and the disaccharide, sucrose, were
analyzed via analytical HPLC-ELSD using the optimized method used for detecting the
oligosaccharides discussed in Chapters 2 and 3. All three standards eluted with 100% water at <
5 min, and were therefore not significantly retained by the C18 sorbent of the AtldC18 column.
Compounds such as these low-MW carbohydrates also elute at later retention times from gelfiltration chromatography sorbents such as Sephadex LH-20. In contrast, the oligosaccharide
mixtures of interest from both cranberry and urine samples eluted with the void volume from
the Sephadex LH-20 sorbent, indicating larger MW, and at ~20 min on the AtldC18 analytical
column with the method shown here.
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Figure 106. The 1H NMR spectrum of urine fraction DA18 showing the low quality of the data,
400 MHz, D2O.
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Figure 107. The 1H NMR spectrum of urine fraction DA19 showing the low quality of the data,
400 MHz, D2O.
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Figure 108. Analytical HPLC-UV (210 and 256 nm) chromatograms of fractions FA1 and FA2
(HILIC).
The material eluting at ~270 min appears to be a major component of the FA1 sample with the
scale used, but actually has a relatively low absorbance (0.07 AU), and would normally be
considered part of a baseline. A HILIC method similar to the one shows for these analytical
separations was used to isolate the detectable components from the FA2 sample, especially
those corresponding to the FA1 sample. The resulting fractions were tested in the antiagglutination assay but showed no detectable activity, possibly due to the low amounts of
sample submitted (< 10 mg each).
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Figure 109. Comparisons of the analytical HPLC-ELSD spectra for active urine fraction HF1-1
and control urine fractions (FC1-11, FC1-2, and FC1-3) (AtldC19).
These spectra were collected using the same HPLC-ELSD method as applied to HF1-1
previously. Additional baseline expansions of the region of interest (18-24 min) for Fraction
FC1-1 show no evidence of possible oligosaccharide components. The components visible in
this region for FC1-1 and FC1-3 both contain chromophores detectable by UV.
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Figure 110. Comparisons of the analytical HPLC-ELSD/UV spectra for active urine fraction
HF1-1 and crude urine fractions (HF and HD) (AtldC19).
The HF material was the parent fraction for the HF1-1 material and both showed activity in the
anti-agglutination assay. The oligosaccharide components of HF1-1 were not readily apparent
in the HF material via HPLC-ELSD at the concentration of sample used above, indicating that
enrichments or methods with increased sensitivity are necessary to detect oligosaccharide
components in mammalian urine samples. The HD fraction (the EtOAc fraction of H urine) did
now show anti-agglutination activity, did not contain detectable oligosaccharide components,
and the majority of this fraction eluted in the polar region between 0-10 min. The composition
of HF and HD appeared similar when examined with ELSD/UV, indicating the predominantly
polar nature of the urine material.
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APPENDIX C: EXAMPLES OF CRANBERRY
DIETARY SUPPLEMENT PRODUCT
LITERATURE
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1. Overview of Appendix C
Many consumers make decisions regarding their use of dietary supplements based on
the product literature that is most easily accessible to them. Most of this literature is,
unfortunately, inaccurate and often contains pseudo-scientific content that can be misleading to
consumers. The actual composition and method of preparation for many dietary supplement
products is often incompletely reported, making it impossible to propose possible compounds
that may be present in any given material. For example, a product label may specify that the
material contains an “extract” or “concentrate” but no information is given as to the method or
solvents used, thereby making it impossible to determine the types of compounds that may
have been enriched in the resulting material. Claims of equivalency (concentrate equivalent to
X g of fruit) are also specious as no information is given as to the basis for comparison between
the original material and the final dietary supplement product.
Many ‘supplement facts’ labels on products in the U.S. include an entry for ‘total
carbohydrate’ with sub-entries for ‘dietary fiber’ and ‘sugars.’ Current nutrition science
considers compounds with cellulose-type backbones to be a type of dietary fiber as such
compounds are not digested by mammalian enzymes (Haard & Chism 1996). The
oligosaccharides identified as active components of cranberry in these studies would therefore
most likely be represented as a component of the carbohydrate label fields currently on
products. Although detection and accurate measurement of oligosaccharide-specific content
would depend on the method used for assessment, products that currently claim to have no
sugars or carbohydrates are probably less likely to contain the active oligosaccharides identified
in these studies. Sensitive methods for the detection of soluble oligosaccharides would need to
be used to determine the presence or absence of these compounds in products.
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2. Sundown Naturals® Product Literature
Below is a reproduction of the label from the SN product used in Chapter 3, analyzed in
Section B6, and discussed in Section C3. No additional information was available on the
internet for this product during these studies.
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3. Nature’s BountyTM Product Literature
Below is a reproduction of the label from the NB product used in Chapter 3, analyzed in
Section B6 and discussed in Section C3. The information available for this product on the
internet during these studies is also included on the following page.
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4. Nature MadeTM Product Literature
A reproduction of the product label was not available for the NM product used in
Chapter 3, analyzed in Section B6, and discussed in Section C3. The limited information
available for this product on the internet during these studies is included in the following five
pages and includes a reproduction of the product label. The product shown here differs slightly
from that used by the added presence of vitamin C; the study product lacked vitamin C but was
otherwise the same in labeling and apparent composition.
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5. CranMax® Product Literature
A reproduction of the product label was not available for the CranMax® product
discussed in Chapter 4, Section B4, and used in the studies of Beerepoot and coworkers (2011).
Selected information for this product excerpted from the Proprietary Nutritionals 2007 White
Paper found on the internet during the writing of this report is included below for ease of future
reference. This literature is an excellent example of the pseudo-scientific content that ends up
in the advertisements for many dietary supplement products. Note the relatively large number
of nonsensical and contradictory statements.
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6. ElluraTM Product Literature
A reproduction of the product label was not available for the ElluraTM product discussed
in Chapter 4, Section B4, and used in the studies of Howell and coworkers (2010). An excerpt
of the information for this product found on the internet during the writing of this report is
included below for ease of reference. This literature is an excellent example of the pseudoscientific content that ends up in the advertisements for many dietary supplement products.
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Aug 2004 – Aug 2014
UM, Dept. of Pharmacognosy, Dr. Daneel Ferreira
- Isolation and identification of cranberry juice metabolites from porcine urine
- Isolation and identification of cranberry juice chemical constituents
- Electronic circular dichroism (ECD) of flavonoids and other small molecule natural
products
- Training & supervision of post-doctoral research associates, visiting scientists, and graduate
students
- General lab and equipment maintenance and supply ordering
Research Assistant/Personal Assistant
Dec 2006 – May 2008
UM, Office of Research & Sponsored Programs (Vice Chancellor), Dr. Alice Clark
- Literature searches, document summaries & reviews, PowerPoint slide preparation (see
below), fact finding, source verification
- Collaborated with the preparation of the following invited oral PowerPoint presentations
given by Dr. Alice Clark:
o “The Role of Natural Products in Drug Discovery and Development,” National
Institutes of Health Staff Training in Extramural Programs Symposium, Bethesda, MD,
January 17, 2008.
o “The Evolution of Antimicrobial Drug Discovery & Development,” University of GA,
Athens, GA, April 2007.
o “The Evolution of Antifungal Drug Discovery,” First Tennessee Chair of Excellence
Symposium, University of Tennessee Health Science Center, Memphis, TN, January
25, 2007.
Undergraduate Research Assistant
Oct 2001 – Dec 2003
AU, Dept. of Biological Sciences, Dr. Robert Boyd & AU, Dept. of Entomology & Plant
Pathology, Dr. Micky Eubanks
- Conducted experiments to determine the toxicity of heavy metals hyperaccumulated by
plants, using the diamondback moth, Plutella xylostella, as a bioassay herbivore
- Optimized colony maintenance protocols for maximal production of quality diamondback
moth eggs
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Undergraduate Research Assistant
Jan 2001 – Dec 2003
AU, Dept. of Biological Sciences, Dr. Robert Locy & José M. Barbosa
- Aseptic growth of Arabidopsis thaliana on modified agar media to determine the growth
effects of β-alanine and other amino acids
- Feeding of 13C-labeled L-alanine to A. thaliana and subsequent tissue preparation for GCMS and NMR analysis of metabolic pathway components
- Cultivation and selection of A. thaliana mutants for subsequent gene screening
Undergraduate Laboratory Assistant
May – Aug 2001
AU, USDA-ARS National Soil Dynamics Lab, Dr. Hugo Rogers & Dr. Michael Davis
Global Change Research Project (study of the effects of elevated CO2)
- Assisted with the collection and preparation of plant samples for TEM and SEM analysis
- Collection of Redheaded Pine Sawfly life cycle data
- Assisted with field sample plot harvesting and sample sorting
TEACHING EXPERIENCE
Instructor for PHCG 422: Natural Product Derived Pharmaceuticals
Jan – May 2013
UM, Dept. of Pharmacognosy, School of Pharmacy, Professional Curriculum Course
Full responsibility for all course material related to antimicrobial agents (70% of the course).
Dr. Jordan Zjawiony as the instructor of record.
Laboratory Technical Training Instructor
2007 – Present
UM, Dept. of Pharmacognosy & the UM School of Pharmacy, Research Institute of
Pharmaceutical Sciences
Instructed research scientists, postdoctoral scientists and graduate students regarding
background theory and correct equipment use and maintenance for the following instruments:
- OLIS DSM 20 Circular Dichroism Spectrophotometer
- JASCO 815 Circular Dichroism Spectrometer
- Various HPLC systems: Waters Prep 400, 600, and 2695 Separations Modules with PDA,
UV, and ELS Detectors
- 400 MHz Bruker NMR instrument with Topspin 2.1 software
Graduate Teaching Assistant
UM, Dept. of Pharmacognosy

Aug 2005 – Dec 2010

Courses Assisted: Pharmacognosy (PHCG):
- PHCG 321 – Dr. Marc Slattery: Pathogenesis of Infectious Diseases, Spring 2009, Fall
2009, Fall 2010
- PHCG 421 – Dr. Marc Slattery: Pathogenesis and Etiology of Infectious Diseases, Fall
2005 – 2008
- PHCG 422 – Dr. Dale G. Nagle & Dr. Jordan Zjawiony: Natural Product Derived
Pharmaceuticals, Spring 2006 – 2008, 2010
- PHCG 544 – Dr. Daneel Ferreira: Departmental Seminar Series, Spring 2007
- PHCG 627 – Dr. Daneel Ferreira: Natural Products Chemistry I, Fall 2005 – 2007
- PHCG 628 – Dr. Daneel Ferreira: Natural Products Chemistry II, Spring 2006, 2007
- PHCG 634 – Dr. Daneel Ferreira: Natural Product Biosynthesis, Spring 2006, 2007
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Duties:
PHCG 321/421/422: Exam preparation, proctoring & grading; student counseling, tutoring &
group study sessions; preparation and presentation of selected lectures for 20-40% of
course material (see below); management of Blackboard online student interface;
preparation of study guides and question sets for each lecture to aid students in learning
course material
PHCG 627/628, 634: guest lecturer; typing, formatting & copying of exams and homework
problem sets; preparation of lecture slides from book figures; hosting of student problem
solving sessions; exam proctor
Selected Lectures Given:
– PHCG 321: Pulmonary Infections; CNS Infections; Cardiovascular Infections;
Gastrointestinal Infections; HIV/AIDS, Group Book Exercises
– PHCG 421: Normal Flora and Gram (+) Bacteria Intro; Respiratory Acquired Gram (-)
Rods; STD/Genitourinary Tract Infections; Retroviridae & HIV/AIDS
– PHCG 422: Introduction to Antibiotics, Drug Selection Criteria & Management of
Antimicrobial Therapy; Broad Spectrum Agents & Principles of Combination Therapy;
Antimicrobial Drug Resistance – Types, Mechanisms, & Prevention; Tetracyclines;
Ribosomes Review & Antibiotics that Inhibit Protein Synthesis; Vitamins
– PHCG 627: Biosynthetic Construction Mechanisms; The Acetate Pathway: Prostaglandins,
Aromatic Polyketides
– PHCG 634: Guest lecturer & problem solving sessions
Undergraduate Teaching Assistant
Jan 2003 – May 2003
AU, Dept. of Biological Sciences
Biology (BIOL) 3101 – Dr. Joe Cherry: Plant Biology Laboratory
- Solely responsible for laboratory lecture preparation, student instruction and assessment,
laboratory set-up, and protocol revisions for assigned student experiments.
GENERAL WORK EXPERIENCE
Head Greenhouse Technician
Feb 2002 – Sept 2002
Flower Zone Nursery, Opelika, AL
- Transplanting, watering, fertilizing, pruning, general greenhouse maintenance
Assistant Manager, Designer, Decorator & Baker
Feb 1997 – June 2000
Ellen’s Creative Cakes, Huntsville, AL
- Custom client sales, managed and trained employees, coordinated deliveries
- Baking of cakes, pastries, and appetizers
- Assembly, sculpting, and decorating of cakes
- Catering of wedding receptions and other events
- Training & supervision of regular empolyees and temporary event employees
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AWARDS & HONORS
Scholarships & Awards
 NIH Common Fund Travel Fellowship to Attend the 2nd Annual Metabolomics Workshop
at the University of Alabama, Birmingham, AL, June 2014
 UM Graduate School Dissertation Fellowship, Spring 2012
 UM Dept. of Pharmacognosy, Outstanding Service Award, Dec 16, 2010
 UM Dept. of Pharmacognosy Retreat, Outstanding Podium Presentation Award, Dec 16,
2010
 UM Graduate School, Graduate Research Assistant Scholarship (full tuition), Fall 2004 –
Summer 2014
 Entomological Society of America and the Entomological Foundation, BioQuip
Scholarship (1 of 1 awarded), Fall 2003 – Spring 2004
 National Botanical Society of America Award for Best Student Poster in the Ecological
Section, July 31, 2003
 AU College of Sciences and Mathematics, Dean’s Undergraduate Research Fellowship (1
of 4 awarded), Fall 2002 – Summer 2003
 AU Dept. of Biological Sciences, Fund For Excellence Undergraduate Research Award (1
of 9 awarded), Fall 2002 & Spring 2003
 AU Honors College, Drummond Company Honors Scholarship, Fall 2002 & Fall 2003
 AU Freshman Academic Scholarship (full tuition), Fall 2000 – Spring 2004
 AU College of Sciences and Mathematics, Academic Scholarship, Fall 2000
 Padgett Business Services, Book Scholarship, Huntsville, AL, Fall 2000
Honors
 Graduate Achievement Award in Pharmacognosy, April 2012
 Who’s Who Among Students in American Universities and Colleges, Jan 2010
 Teaching Assistant of the Year, 2008–2009, Selected by the P4 Class (4th Year Pharmacy
Students), May 2009
 Young Botanist of the Year, American Botanical Society, 2004
 Student Spotlight in AU College of Sciences & Mathematics, Journey Newsletter (p. 38),
2004
 Dean’s List, AU College of Sciences & Mathematics, Fall 2000, Spring 2002 – Fall 2004
 Junior Honors Certificate, AU Honors College, Spring 2002
 Harry M. Rhett, Jr., Community Service Book Award, Randolph School, Huntsville, AL,
May 26, 2000
 National Merit Scholarship Program Letter of Commendation, Spring 2000
Honor Societies
Rho Chi (Spring 2009), Phi Kappa Phi (Spring 2004), Beta Beta Beta (Spring 2003), Alpha
Lambda Delta (Spring 2001), Phi Eta Sigma (Spring 2001), National Society of Collegiate
Scholars (Spring 2001)
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PROFESSIONAL SERVICE & INVOLVEMENT
Peer Review
 NIH-NCRR COBRE CORE-NPN Predoctoral Fellowship ad hoc Study Section 2009,
Oxford, MS, Oct – Nov 2009
- Mentored review of scientific research proposals submitted by UM graduate students.
Mentor: Dr. David Pasco, UM National Center for Natural Products Research.
 Peer Reviewer for Scientific Journals, May 2012 – Present
- Journal of Natural Products
- Molecular Nutrition and Food Research
Professional Committee Positions
 Department of Pharmacognosy Graduate Student Committee for Graduate Program
Revision, May – Dec 2011
- Revised Departmental published degree requirements for MS and PhD students
 MALTO-PharmForum Joint Meeting, Executive Organizing Committee, Jan – May 2010
- Participated in all aspects of planning necessary for meeting organization
- Focused on recreational event planning, design and purchase of give-away items,
volunteer coordination, and on-site operations
 American Society of Pharmacognosy, Young Members Committee, July 2007 – July 2010
- Contributed two biographies of previous ASP presidents for the 50th anniversary
commemorative book
 Phytochemical Society of North America, Young Members Committee, July 2007 – July
2009
- Organized & implemented conference activities, wrote newsletter articles, membership
drive participation
- Hosted: “Ask the Editor, A Panel Discussion on Common Manuscript Errors and Ways
to Avoid Them.” Panel Members: Dr. Daneel Ferreira, Dr. John Pezzuto, Dr. John
Romeo, and Dr. Norman Lewis. Hosts: Coleman, Christina M.; Kutrzeba, Lukasz;
Mazourek, Michael. Phytochemical Soc. N. America Annual Meeting, Pullman, WA,
June 25–30, 2008.
 Historian – AU Beta Beta Beta Biological Honor Society
Fall 2003 – Spring 2004
 Social Committee Planner – AU Honors Congress
Fall 2000 – Fall 2002
 Assistant Director, Outdoor Recreation – AU Program Council Spring 2001 – Spring 2002
 President & Founder – AU Hiking Club
Spring 2001 – Summer 2002
 Committee Member, Outdoor Recreation – AU Program Council
Fall 2000 – Spring 2001
 Secretary and Assistant Event Organizer – Residence Hall Council Fall 2000 – Spring 2001
Professional Organizations
American Society for Microbiology
American Society of Pharmacognosy
American Chemical Society
Phytochemical Society of North America
American Botanical Society
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Volunteer Education & Outreach
 Department of Pharmacognosy Representative, Fall 2007 – Spring 2014
- Host and tour guide for prospective graduate students.
- Poster: Ferreira, Daneel; Coleman, Christina M. “The Department of Pharmacognosy:
An Overview” UM School of Pharmacy, National Center for Natural Products Research
Annual Poster Session, Oxford, MS, Nov 8, 2012 & October 11, 2013
 Science Fair Judge – North Mississippi Regional Science Fair; Grades 4–12, Botany
Division, UM Tad Smith Coliseum, Oxford, MS, March of 2007, 2009 – 2012, 2014
 Science Fair Judge – Local Science Fair; Grades 4–7, Oxford University School, Oxford,
MS, Feb 5, 2008; Feb 5, 2009
 Chemistry lab tour & career counseling for high school students attending a BISC 102
summer course with the UM Department of Biology, June 2009
 Adult GED Tutor – Algebra, vocabulary, reading skills; Lafayette County Literacy
Coalition, Susan Nicholas, Managing Director, Oxford, MS, July 2005 – Mar 2006
 Adult GED Tutor – Algebra, grammar, reading skills; Lee County Literacy Coalition,
Opelika, AL, Aug 2003 – July 2004
PROFESSIONAL DEVELOPMENT & ADVANCED TRAINING
Professional Development
 “Grants Workshop Series: (1) Proposal & Award Lifecycle, (2) Budgeting for Proposals,
(3) Data Security, (4) Obtaining a Patent.” UM, Office of Research and Sponsored
Programs, Oxford, MS, Sept 2013
 UM, School of Pharmacy, Interdepartmental Faculty Retreat, June 6–7, 2013
 UM, Dept. of Pharmacognosy Annual Retreat, Oxford, MS, Dec 16, 2010; Aug 26, 2011
 Graduate Student/Post-doc Summer Institute, American Chemical Society Publications
Division, Organizer: David Martinsen. ACS Headquarters Building, Washington, DC, Aug
8–12, 2011
 Objective of the Institute: “To bring together creative graduate students and
postdocs to help [the ACS Publications Division] redefine how science is published,
distributed, and incorporated into the research and learning workflow.”
 Competitively selected from a pool of applicants nominated by ACS Journal
Editors.
 UM Women in STEM Dinner Program, Follow Up Round Table Discussion of recent
attendees to the National Conference for College Women Student Leaders, Oxford, MS,
Oct 26, 2010
 UM Women in STEM Roundtable Series: “What Women Need to Know to Survive and
Succeed in STEM Careers,” Hosted by the Sarah Isom Center for Women and Gender
Studies, Spring 2010
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Advanced Technical Training
 University of Alabama at Birmingham, 2nd Annual Workshop on Metabolomics, Sponsored
by the National Institute of General Medical Sciences as part of the NIH Common Fund
Metabolomics Initiative, and by the Departments of Chemistry and Pharmacology and
Toxicology at UAB, Birmingham, AL, June 2–5, 2014
 University of Florida Metabolomics Workshop & Symposium, Sponsored by the Southeast
Center for Integrated Metabolomics (SECIM), and the Clinical and Translational Science
Institute, University of Florida, Gainesville, FL, May 20–23, 2014
 Metabolomics Afternoon Workshop. Presenters: Dr. Paul Shiply, Dr. Susan Murch, & Dr.
Christina Turi from the University of British Columbia. American Society of
Pharmacognosy Annual Meeting, St. Louis, MO, July 13, 2013
 Electronic and Vibrational Circular Dichroism Afternoon Workshop. Presenters: Dr. Nina
Berova, Professor & Senior Research Scientist, Columbia University, and Dr. Ana Petrovic,
Assistant Professor, New York Institute of Technology. American Society of
Pharmacognosy Annual Meeting, New York, NY, July 28, 2012
 X-Ray Crystallography Introductory Short Course, Dr. Frank Fronczek, Director of X-Ray
Crystallography Facility, Dept. of Chemistry, Louisiana State University, Held at UM, June
1–5, 2009
 Bruker NMR Training Seminar Series. Mike Brown, Application Scientist for the Southern
Region, Bruker South Training Center, Held at UM, Jan 2006
Communications & Education Training
 “Best Practices in Teaching Online” Workshop Series, Mark Yacovone, UM Graduate
School, Oxford, MS, Spring 2013
 “Introduction and Overview of the Wimba Classroom” Workshop, Randall Uncapher, IT
Designer, UM Division of Outreach & Continuing Education, UM Faculty Technology
Development Center, Oxford, MS, Sept 16, 2011
 “Science: Becoming the Messenger” Full Day Workshop. Presenters: Dan Agan, President,
Panthera Group LLC; Chris Mooney, Science Journalist; Joe Schreiber, President, Mattmar
Productions. National Science Foundation EPSCoR Workshop, Mississippi State
University, Starkville, MS, Aug 29, 2011
 “The Use of Technology for Teaching,” iLearning Event Workshop for UM Faculty and
TAs, UM Faculty Technology Development Center, Oxford, MS, Nov 18, 2010
 “Elevator Talks,” Bringing Scientists to the People Workshop, Carolyn Gayle, Clear
Communication Group, UM Graduate School, Oxford, MS, Nov 25, 2008
 “School of Pharmacy Graduate Teaching Assistant Seminar Series” (Monthly meetings
each fall). Dr. Alicia Bouldin, Professor & Teaching Assistant Mentor for the School of
Pharmacy, UM, Fall 2006 – 2010
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 “Using PRS RF-Clickers in Classrooms Workshop” (beginning & advanced sessions). Julie
Weiss, InterWrite Inc., and Penny Rice, UM Faculty Technology Development Center,
Oxford, MS, Jan 14, 2008
 “Teaching Assistant Orientation & Training” (3 day workshop). Dr. Johnny Lott, UM
Center for Excellence in Teaching and Learning, Oxford, MS, Aug 2007, 2008
University of Mississippi: Selected Elective Courses
 BISC 502: Mycology – Instructor: Dr. Jason Hoeksema, Fall 2008; Included laboratory
work studying gross anatomy and microscopy of macro-fungi of the southeast U.S.
 PHAD 692: Drug Development & Marketing – Instructor: Ms. Allyson Best, Spring 2006;
Participated in the research and design of a development and marketing plan for a
compound possessing antitumor activity. Acted as the group director with eight people in
the group.
 BISC 522: Microbial Ecology – Instructor: Dr. Clifford Ochs, Fall 2005
 PHCL 381: Introduction to Toxicology (Audit) – Instructor: Dr. Kristie Willett, Fall 2005
Auburn University: Selected Elective Courses
 NUFS 643: Food Chemistry – Instructor: Dr. Leonard Bell, Spring 2004
 HORT 622: Greenhouse Management Science – Instructor: Dr. Raymond Kessler, Fall
2003; Developed a business plan for the foundation and management of a greenhouse
business
 BIOL 497 Special Topics: Plant Anatomy & Development – Instructor: Dr. Roland Dute,
Spring 2003; Special Project: TEM sample preparation and TEM & confocal microscopy of
wood tissue segments
 ENTM 304: General Entomology – Instructor: Dr. Wayne Clark, Fall 2002; Special Project:
Insect collection and preservation
RESEARCH SUPPORT
Ongoing Research Support
Ocean Spray Cranberries, Inc.
Ferreira (PI)
10/01/2011 – 03/15/2014
Human Urinary Metabolites Produced as a Result of Cranberry Juice Consumption
The goal of this study was to isolate and identify the anti-adhesive metabolites of human urine
produced as a result of cranberry consumption. Role: Investigator & proposal co-author
Completed Research Support
1R21AT002076-01 NIH/NCCAM
Howell (PI)
04/05/2004 – 04/04/2009
Identification of Bioactive Cranberry Metabolites
The goal of this study was to isolate and identify the anti-adhesive metabolites of swine urine
produced as a result of cranberry consumption. Role: Investigator
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PUBLICATIONS
Refereed Original Research and Scholarly Review Articles
1. Coleman, Christina M.; Boyd, Robert S.; Eubanks, Micky D. Extending the Elemental
Defense Hypothesis: Dietary Metal Concentrations Below Hyperaccumulator Levels
Could Harm Herbivores. Journal of Chemical Ecology, 2005, 31 (8), 1669-1681.
PMID: 16222801.
2. Coleman, Christina M.; Prather, Brian L.; Valente, Matthew J.; Dute, Roland R.; Miller,
Michael E.; Torus Lignification in Hardwoods. International Association of Wood
Anatomists (IAWA) Journal, 2004, 25 (4), 435-447.
3. Ferreira, Daneel; Marais, Jannie P. J.; Coleman, Christina M.; Slade, Desmond.
“Proanthocyanidins: Chemistry and Biology” In: Comprehensive Natural Products
Chemistry II, Pergamon Press (Elsevier), New York, 2009, Chapter 6.15.
4. Ferreira, Daneel; Coleman, Christina M. Towards the Synthesis of Proanthocyanidins:
Half a Century of Innovation, Invited Review Publication, Planta Medica, 2011, 77
(11), 1071-85. doi: 10.1055/s-0030-1270908. PMID: 21412691.
5. Xu, Yong-Jiang; Foubert, Kenn; Dhooghe, Liene; Lemière, Filip; Maregesi, Sheila;
Coleman, Christina M.; Zou, Yike; Ferreira, Daneel; Apers, Sandra; Pieters, Luc.
Rapid Isolation and Identification of Minor Natural Products by LC-MS, LC-SPENMR, and ECD: Isoflavanones, Biflavanones, and Bisdihydrocoumarins from
Ormocarpum kirkii, Phytochemistry, 2012, 79, 121-128. doi:
10.1016/j.phytochem.2012.04.004. PMID: 22575670.
6. Belofsky, Gil; Kolaczkowski, Marcin; Adams, Earle; Schreiber, John; Eisenberg, Victoria;
Coleman, Christina M.; Zou, Yike; Ferreira, Daneel. Fungal ABC TransporterAssociated Activity of Isoflavonoids from the Root Extract of Dalea formosa
(Fabaceae). Journal of Natural Products, 2013, 76 (5), 915-925. doi:
10.1021/np4000763. PMID: 23631483. Accepted without change by two independent
reviewers.
7. Li, Jun; Coleman, Christina M.; Wu, Hankui; Burandt, Charles L.; Ferreira, Daneel;
Zjawiony, Jordan K., Triterpenoids and Flavonoids from Cecropia schreberiana Miq.
(Urticaceae). Biochemical Systematics and Ecology, 2013, 48 (June), 96-99. PMID:
23459662.
8. Campana, Priscilla R. V.; Coleman, Christina M.; Teixeira, Mauro M.; Ferreira, Daneel;
Braga Fernão C., TNF-α Inhibition Elicited by Mansoins A and B, Heterotrimeric
Flavonoids Isolated from Mansoa hirsuta. Journal of Natural Products, 2014, 77 (4),
824-830. PMID: 24576254.
9. Canuto, Kirley M.; Leal, Luzia K. A. M.; Lopes, Amanda A.; Coleman, Christina M.;
Ferreira, D.; Silveira, Edilberto R. Amburanins A and B from Amburana cearensis:
Daphnodorin-Type Biflavonoids That Modulate Human Neutrophil Degranulation.
Journal of the Brazilian Chemical Society, 2014, 25 (4), 639-647. doi: 10.5935/01035053.20140011.
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10. Villinski, Jacquelyn R.; Bergeron, Chantal; Cannistra, Joseph C.; Gloer, James B.;
Coleman, Christina M.; Ferreira, Daneel; Azelmat, Jabrane; Grenier, Daniel; Gafner,
Stefan. Pyrano-Isoflavans from Glycyrrhiza uralensis with Antibacterial Activity
Against Streptococcus mutans and Porphyromonas gingivalis. Journal of Natural
Products, 2014, 77 (3), 521-526. PMID: 24479468.
11. Belofsky, Gil; Aronica, Mario; Foss, Eric; Diamond, Jane; Santana, Felipe; Darley, Jacob;
Dowd, Patrick; Coleman, Christina M.; Ferreira, Daneel. Antimicrobial and
Antiinsectan Phenolic Metabolites of Dalea searlsiae (Fabaceae). Journal of Natural
Products, 2014, 77 (5), 1140–1149.
12. Du, Kun; Coleman, Christina M.; Van Vuuren, Sandy F.; Van Zyl, Robyn L.; Zietsman,
Pieter C.; Ferreira, Daneel; Marston, Andrew; Van Der Westhuizen, Jan H. Flavonol
Acyl Glucosides from the Aril of Schotia brachypetala Sond. and Their Antioxidant,
Antibacterial and Antimalarial Activities. Phytochemistry Letters, Available online,
June 2014.
In Preparation for Refereed Journals
Coleman, Christina M.; Howell, Amy B.; Krueger, Christian G.; Auker, Kimberly M.; Reed,
Jess D.; Ferreira, Daneel. Porcine Anti-Adhesive Urinary Metabolites Produced as a Result
of Cranberry Consumption. Journal of Agricultural and Food Chemistry, 2014, In
Preparation.
Auker, Kimberly M.; Coleman, Christina M.; Wang, Mei; Avula, Bharathi; Khan, Ikhlas;
Ferreira, Daneel. Structural Characterization of Cranberry Oligosaccharides. Journal of the
American Chemical Society, 2014, In Preparation.
Auker, Kimberly M.; Coleman, Christina M.; Kimble, Lindsey; Mathison, Bridget; Chew,
Boon P.; Howell, Amy B.; Ferreira, Daneel. Human Anti-Adhesive Urinary Metabolites
Produced as a Result of Cranberry Juice Consumption. In Preparation.
Coleman, Christina M.; Akgul, Yurdanur; Auker, Kimberly M.; Kimble, Lindsey; Mathison,
Bridget; Wang, Mei; Avula, Bharathi; Khan, Ikhlas; Chew, Boon P.; Ferreira, Daneel. AntiAdhesive Oligosaccharides from Cranberry Products. In Preparation.
Coleman, Christina M.; Nael, Manal A.; Zou, Yike; Eisenberg, Victoria; Belofsky, Gil;
Doerksen, Robert J.; Ferreira, Daneel. The Absolute Configuration of 3Hydroxyisoflavanones Through Experimental and Calculated Electronic Circular
Dichroism. In Preparation.
Coleman, Christina M.; Zou, Yike; Ferreira, Daneel. How to Study Small Molecule Natural
Products by Electronic Circular Dichroism. In Preparation.
Peddikotla, Prabhakar; Coleman, Christina M.; Adelli, Vijender R.; Marais, Johannes P. J.;
Ferreira, Daneel, Synthesis of A-Type Proanthocyanidins. In Preparation.
Radhakrishnan, Sri Vedavyasa Sri; Sharma, Vimal K.; Ankisetty, Sridevi; Coleman, Christina
M.; Ferreira, Daneel; Zjawiony, Jordan K. 12a-Hydroxyrotenoids from Mirabilis
multiflora. In Preparation.
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Professional Newsletter Publications
Clark, Alice M. & Coleman, Christina M. “The Changing Face of ASP: The Role of
Women.” American Society of Pharmacognosy Newsletter, December 2007, 43(4), p 4, 9.
Coleman, Christina M.; Mazourek, Michael; Biedrzycki, Meredith; Kutrzeba, Lukasz.
“Potential Conference Activities for Young Members for PSNA 2008 General Scientific
Meeting.” Phytochemical Society of North America Newsletter, December 2007, 46(2), p
18-21.
Technical Writing & Reports
Coleman, Christina M. “Operational Instructions for the JASCO J-815 Circular Dichroism
Spectrometer,” May 2013, Instrument Operation Manual.
Coleman, Christina M. "Operational Instructions for the OLIS DSM-20 Circular Dichroism
Spectrophotometer," May 2012, Instrument Operation Manual.
Coleman, Christina M., “Toosendanin – Structure, Sourcing, Uses & General Notes.”
Technical Report prepared for Dr. Alice Clark, March 03, 2007.
PROFESSIONAL MEETINGS ATTENDED
 American Society of Pharmacognosy Annual Meeting, St. Louis, MO, July 13–17, 2013
 International Congress on Natural Products Research (Joint with ASP), New York, NY,
July 28 – Aug 1, 2012
 Joint Meeting of the American Society of Pharmacognosy and the Phytochemical Society
of North America, St. Petersburg, FL, July 10–14, 2010
 Joint Meeting of MALTO and PharmForum, Oxford, MS, May 23–26, 2010
 American Society for Microbiology National Meeting, Philadelphia, PA, May 17–21, 2009
 Phytochemical Society of North America Annual Meeting, Pullman, WA, June 25–30,
2008
 Phytochemical Society of North America Annual Meeting, St. Louis, MO, July 21–25,
2007
 American Society of Pharmacognosy Annual Meeting, Portland, ME, July 14–18, 2007
 MALTO Medicinal Chemistry & Pharmacognosy Annual Meeting, Monroe, LA, May 20–
22, 2007
 American Chemical Society National Meeting (Fifth Tannin Conference), San Francisco,
CA, Sept 10–14, 2006
 Phytochemical Society of North America Annual Meeting, Oxford, MS, July 8–12, 2006
 MALTO Medicinal Chemistry & Pharmacognosy Annual Meeting, Houston, TX, May 21–
23, 2006
 MALTO Medicinal Chemistry & Pharmacognosy Annual Meeting, Oxford, MS, May 22–
24, 2005
 Botanical Society of America National Meeting, Mobile, AL, July 26–31, 2003
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PRESENTATIONS
Scientific Meetings – Presenting Author
Coleman, Christina M.; Auker, Kimberly M.; Ferreira, Daneel. “Anti-adhesion Properties of
Cranberry Products: Current Status and New Directions.” American Society of
Pharmacognosy Annual Meeting, St. Louis, MO, July 17, 2013. Oral.
Auker, Kimberly M.; Coleman, Christina M.; Wang, Mei; Avula, Bharathi; Kimble, Lindsey;
Mathison, Bridget; Khan, Ikhlas; Chew, Boon P.; Ferreira, Daneel. “Structural
Characterization and Bioactivity of Cranberry Oligosaccharides.” American Society of
Pharmacognosy Annual Meeting, St. Louis, MO, July 15, 2013. Poster.
Coleman, Christina M.; Zou, Yike; Eisenberg, Victoria; Belofsky, Gil; Ferreira, Daneel.
“Absolute configuration of 3-hydroxyisoflavanones and conjugated 2-(5H)-furanones
through electronic circular dichroism.” ICNPR/ASP Joint Meeting, New York, NY, July 28
– Aug 1, 2012. Poster.
Coleman, Christina M.; Ferreira, Daneel; Howell, Amy B.; Reed, Jess D.; Krueger, Christian
G.; Marais, Jannie P. J. “Anti-Adhesive Urinary Metabolites Produced as a Result of
Cranberry Juice Consumption.” UM Department of Pharmacognosy Annual Retreat,
Oxford, MS, Dec 16, 2010. Oral.
Coleman, Christina M.; Ferreira, Daneel; Howell, Amy B.; Reed, Jess D.; Krueger, Christian
G.; Marais, Jannie P. J. “Anti-Adhesive Urinary Metabolites Produced as a Result of
Cranberry Juice Consumption.” ASP/PSNA Joint Meeting, St. Petersburg, FL, July 13,
2010. Oral.
Coleman, Christina M.; Ferreira, Daneel; Howell, Amy B.; Reed, Jess D.; Krueger, Christian
G.; Marais, Jannie P. J. “Isolation and Identification of Anti-Adhesive Urinary Metabolites
from Cranberry Juice.” Phytochemical Society of North America Annual Meeting,
Pullman, WA, June 25–30, 2008. Poster.
Coleman, Christina M.; Ferreira, Daneel; Marais, Jannie P. J.; Howell, Amy B.; Cihlar,
Ronald; Cohen, Jesse. “Cranberry Juice Compounds with Anti-Adhesive Properties in
Urine.” Phytochemical Society of North America Annual Meeting, Pullman, WA, June 25–
30, 2008. Poster.
Coleman, Christina M.; Ferreira, Daneel; Howell, Amy B.; Reed, Jess D.; Krueger, Christian
G.; Marais, Jannie P.J. “Isolation and Identification of Anti-Adhesive Urinary Metabolites
from Cranberry Juice.” Phytochemical Society of North America Annual Meeting, St.
Louis, MO, July 21–25, 2007. Poster.
Coleman, Christina M.; Ferreira, Daneel; Howell, Amy B.; Reed, Jess D.; Krueger, Christian
G.; Marais, Jannie P. J. “Bioactive Metabolites of Cranberry Juice.” American Society of
Pharmacognosy Annual Meeting, Portland, ME, July 14–18, 2007. Poster
Coleman, Christina M.; Ferreira, Daneel; Howell, Amy B.; Reed, Jess D.; Krueger, Christian
G.; Marais, Jannie P. J. “Bioactive Metabolites of Cranberry Juice.” MALTO Medicinal
Chemistry & Pharmacognosy Annual Meeting, Monroe, LA, May 20–22, 2007. Poster.
Coleman, Christina M.; Ferreira, Daneel; Howell, Amy B.; Reed, Jess D.; Krueger, Christian
G.; Marais, Jannie P. J. “Bioactive Metabolites of Cranberry Juice.” American Chemical
Society National Meeting, CELL Division – Fifth Tannin Conference, San Francisco, CA,
Sept 10–14, 2006. Poster.
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Coleman, Christina M.; Ferreira, Daneel; Howell, Amy B.; Reed, Jess D.; Krueger, Christian
G.; Marais, Jannie P. J. “Bioactive Metabolites of Cranberry Juice.” Phytochemical Society
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